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Abstract 
 
The conversion of phosphatidic acid (PA) to cytidine diphosphate-diacylglycerol 
(CDP-DAG) by CDP-DAG synthase (Cds) is the rate-limiting step for the 
biosynthesis of the mitochondrial lipid, cardiolipin (CL) and phosphatidylinositol (PI), 
the precursor for many signalling phosphoinositides. There are two Cds isoforms in 
mammals, Cds1 and Cds2. During cardiomyocyte growth and development, 
mitochondrial biogenesis is increased under the control of the transcription factor, 
PGC-1α which also regulates Cds1 expression. Mitochondria have limited capacity 
to synthesise their own lipids and are dependent on the endo/sarcoplasmic 
reticulum for many of their lipids, including PI and PA. RdgBβ (Retinal degeneration 
B beta) is a phosphatidylinositol transfer protein (PITP), recently found to be 
enriched in cardiac tissue, able to transfer both PI and PA. This investigation 
attempts to identify the residues within the PITP domain that are required for PA 
transfer and it focuses on the characterisation of the expression and distribution of 
RdgBβ and Cds1 in rat hearts and H9c2 cells which are derived from embryonic rat 
ventricles. Withdrawal of serum and the addition of retinoic acid induces 
differentiation of H9c2 cells towards a cardiomyocyte-like phenotype. At the protein 
level, proliferating H9c2 cells have low RdgBβ expression which increases 
dramatically following differentiation with retinoic acid.  The increase in RdgBβ 
expression occurred in parallel with an elevation in mitochondrial content. In 
addition to the cytosol, RdgBβ was also located at membrane fractions, suggesting 
that RdgBβ may facilitate PI and PA transport between the ER and the 
mitochondria. The regulation of mRNA expression of Cds1 was not associated with 
cellular differentiation but with vasopressin stimulation of H9c2 cells. Both myoblasts 
and differentiated H9c2 cells showed an increase of Cds1 mRNA suggesting that 
Cds1 is involved in the PI cycle.                                                        
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CHAPTER 1: Introduction 
 
Biological membranes are fundamental cellular constituents that rely on the 
diversity of their structures and biophysical properties given by the mixture of their 
specific lipid and protein composition to function. Phospholipids are the major 
component of cellular membranes and each cellular organelle presents a specific 
lipid composition. For instance, although phosphatidylcholine (PC) and 
phosphatidylethanolamine (PE) are the most abundant cellular phospholipids, 
mitochondria are enriched in cardiolipin (CL) and the plasma membranes are 
enriched in phosphatidylserine (PS). Structurally phospholipids are composed of a 
molecule of glycerol connected to two fatty acids that may differ in length (Figure 
1.1.). Phosphatidic acid (PA) is a key intermediate for phospholipid synthesis via its 
consecutive modification including the dephosphorylation to diacylglycerol (DAG) or 
the conversion into cytidine-diphosphate diacylglycerol (CDP-DAG). 34,111,112 
  
The endoplasmic reticulum (sarcoplasmic reticulum in muscle and cardiac 
cells) is the main site of phospholipid synthesis, but other organelles such as the 
Golgi apparatus and the mitochondria are capable of producing limited quantities of 
lipids. Mitochondria have the capacity to synthesise PE, PG and cardiolipin but not 
PC, PI and PS. The mechanisms of intracellular transport of lipids include general 
vesicular traffic or the use of specific transporters111. Mitochondria do not interact 
with vesicles and depend entirely on alternative routes to obtain many of their 
lipids55. Generally, mitochondria co-purify experimentally with a sub-region of the 
SR known as mitochondria-associated endoplasmic reticulum membranes (MAM). 
This fraction has being shown to possess PS, PE and PC synthesis capability52,111. 
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Figure 1.1: Structure of Phospholipids 
Membrane phospholipids are made of two fatty acids (R1 and R2), which may differ 
in length, linked to glycerol (CH2-CHO- -CH2O-). The third carbon of glycerol is joined 
to a phosphate group (PO42-) to form PA, the precursor of other phospholipids 
including PC, PS, PE, PI, or PG, the precursor of cardiolipin (CL). 
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1.1: Phosphatidic Acid (PA). 
 
1.1.1: PA biosynthesis. 
 
PA can be generated through different mechanisms: firstly, the de 
novo synthesis pathway consist of sequential acylations from glycerol-3-phosphate 
(G3P) by distinctive G3P and lyso-PA acyltransferases localised to both 
endoplasmic reticulum (ER) and mitochondrial membranes within mammalian cells. 
G3P acyltransferases (GPAT enzymes, EC 2.3.1.15) catalyse the conversion of 
G3P and acyl-CoA into lyso-PA. In mammals, there are four isoforms of GPAT 
enzymes that have been identified to date. GPAT1 and GPAT2 are found in the 
outer mitochondrial membranes while GPAT3 and GPAT4 are associated with the 
ER. PA is finally produced by the action of the lyso-PA acyltransferases (LPAAT, 
EC 2.3.1.51), which convert lyso-PA and acyl-CoA into phosphatidic acid (Figure 
1.2.A). There are eleven LPAAT family members in mouse and human reported in 
the literature but only four isoforms of LPAAT display acyl donor specificity for PA 
(LPAAT 1-4) which in mammalian cells localise to the ER.105,126 To date is still 
unclear whether PA is synthesised in mitochondria.   
 
In addition to the G3P pathway, PA is also generated during cellular signalling 
during activation of G-protein coupled receptors as well as receptor tyrosine 
kinases. Hydrolysis of phosphatidylcholine (PC) by phospholipase PLD activity 
results in PA formation whilst hydrolysis of phosphatidylinositol bisphosphate (PIP2) 
results in DAG formation which is converted into PA by the action of DAG kinases., 
116,130 (Figure 1.2.B-C) 
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Figure 1.2: Phosphatidic acid biosynthesis. 
[A]: PA is synthesised by the addition of an acyl group to Glycerol-3-Phosphate by a 
G3P acyltransferase (GPAT) to form Lyso-PA, followed by acylation of Lyso-PA by 
LPAAT.  
[B]: PA is formed from PC hydrolysis by phospholipase D. 
[C]: PA generation results from phosphorylation of DAG produced from the 
phospholipase C signalling pathway.   
 
 
1.1.2: PA is the key intermediate of phospholipid biosynthesis. 
 
The metabolic outcomes of synthesised PA include its deacylation back to 
lyso-PA by phospholipase PLA1 (EC 3.1.1.32). Newly synthesised PA is also rapidly 
dephosphorylated by members of the Lipin family (EC 3.1.3.4) to produce 
diacylglycerol (DAG) which can be involved in either cell signalling or the synthesis 
of triacylglycerol (TAG) and the phospholipids PC, PE, and PS (Figure 1.3.A). 
Alternatively, PA can react with CTP to produce CDP-DAG catalysed by Cds 
enzymes. CDP-DAG is the precursor for PI biosynthesis in the ER by PI synthase 
(PIS, EC 2.7.8.11) 74. There is a single gene for PIS in mammalian cells and it does 
not exhibit acyl chain specificity28. Sequential phosphorylation of PI at the plasma 
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membrane produces phosphoinositides which are central for signalling and 
membrane traffic8. In mammals, the fatty acid chains of the phosphoinositides are 
enriched with 1-stearoyl-2-arachidonoyl species33 (Figure 1.3.B and Figure 1.6). 
 
Phosphatidylglycerol phosphate (PGP) is synthesised from glycerol-3-P and 
CDP-DG by PGP synthase, an enzyme located in the inner mitochondria 
membrane.112 PG is formed through PGP dephosphorylation by PG 
phosphatase79,112 (Figure 1.3.C).  
 
a: Cardiolipin biosynthesis 
Biosynthesis of cardiolipin, also known as diphosphatidylglycerol, takes 
place in the inner mitochondrial membrane. Cardiolipin (CL) is formed from the 
condensation of PG and CDP-DAG catalysed by cardiolipin synthase (CLS, EC 
2.7.8.41.) in eukaryotic cells (Figure 1.2). Nascent CL in the mitochondrial 
membranes requires acyl chain remodelling which occurs either by deacylation–
reacylation or by transacylation. The deacylation–reacylation reaction forms a 
monolyso-CL (MNCL) intermediate catalysed by several acyl-CoA dependent 
phospholipases, while CoA-independent transacylation of CL occurs by the transfer 
of an acyl chain from PC by the enzyme to form a functional mature CL molecule 
rich in linoleic acid127. For CL synthesis to occur, PA is required to be transferred 
from the outer mitochondrial membrane to the inner mitochondrial membrane. This 
is achieved by the PA transporter Ups1/Mdm35 complex in yeast,26 and their 
homologues in humans, the TRIAP1/PRELI complex.91  
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Figure 1.3: PA is the key intermediate on phospholipid biosynthesis. 
[A]: Synthesis of triglycerides (TAG), PC, PS and PE via DAG following PA 
dephosphorylation by members of the Lipin family. 
[B]: Synthesis of PI by PI synthase action on CDP-DAG formed by CDS enzymes 
from PA. PI is sequentially phosphorylated by kinases to produce phosphoinositides 
(PI4P, PI (4,5)P2 and PI(3,4,5)P3).   
[C]: Cardiolipin synthesis results from the condensation of CDP-DAG and PG by 
Cardiolipin synthase.  
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1.1.3: CDP-DAG synthases (Cds)  
 
The activity of the Cds enzymes is the rate limiting step for PI and Cardiolipin 
biosynthesis in the ER and the mitochondria respectively.46,50,119 The Cds enzyme 
was first cloned from E.Coli 57 followed by S. cerevisae Cds, 99 and later in 
Drosophila melanogaster 124. These species present one Cds gene. In mammals, 
cloning of human Cds enzymes was achieved, 46 and studies in mice 58 were able to 
characterise two Cds homologues Cds1 and Cds2. Early studies using rat liver 
reported that Cds was responsible to produce the CDP-DAG precursor of PI in the 
ER and CL in mitochondria 81. However, studies in yeast (Saccharomyces 
cerevisae) revealed that Tam41 is the mitochondrial Cds while endogenous Cds1 
was present in both ER and crude mitochondria but absent from purified 
mitochondrial fractions, 106 suggesting that Cds1 could be present in mitochondrial 
associated ER membranes known as MAMs.  
 
The genes of mouse and human Cds1 encode a 461 a.a. protein (52.9 kDa) 
while Cds2 encode a 444a.a./445a.a. (51 kDa). The sequences of murine Cds1 and 
Cds2 are 56% and 57% identical, respectively, to the Drosophila Cds sequence58. 
Alignment of the amino acid sequences encoded by Rattus Norvegicus Cds1 and 
Cds2 showed that they are 69.5% identical and 81% similar (Figure 1.4). It was 
recently suggested that Cds2 provides CDP-DAG for the PI-cycle due to its 
selectivity for the acyl chains 1-stearoyl, 2-arachidonoyl species of the precursor 
PA. Cds1 showed no particular substrate specificity 29.  
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Initially, it was predicted that Cds were tightly membrane-bound enzymes  
with different number of trans-membrane domains between Cds1 and Cds2, with 
nine trans-membrane segments in Cds1 and eight in Cds258. Indeed, the crystal 
structure of the Cds enzyme from the thermophilic bacterium Thermotoga maritima 
revealed the existence of a homodimer and each monomer is composed of nine 
transmembrane helices (Figure 1.5.A), exhibiting a funnel-shaped structural feature 
which enables Cds to simultaneously interact with membrane-associated PA and 
cytosolic CTP molecules to catalyse their condensation to form CDP-DAG with a 
hetero-di-metal centre for the cofactors Mg2+ and K1+. The proposed catalytic 
mechanism of Cds is that the Mg2+ ion might serve as the metal responsible for 
activating the phosphate group of PA molecule, whereas K1+ promotes binding to 
the β- and γ-phosphates of CTP and facilitates the dissociation of pyrophosphate 
from the active site. (Figure 1.5.B).71 Structurally, Cds1 and Cds2 differ mainly in 
their cytosolic N-terminal (residues 1-99; Figure 1.4).  
 
Expression studies indicated that Cds1 and Cds2 mRNA exhibit different 
tissue specificity. In mouse, Cds2 is ubiquitously expressed whilst Cds1 has an 
expression pattern restricted to the brain, eye, smooth muscle and testis 46.  
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Figure 1.4: Sequence alignment of Rat Cds1 and Cds2. 
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Figure 1.5 Structure and mechanism of Thermotoga maritime CdsA. 
[A.] Overall structure of Thermotoga maritime CdsA homodimer location along the 
membrane in the substrate free form.   
[B.] Proposed model for the catalytic mechanism of CDP-DAG synthesis. (Taken 
from Liu, et al. 2014) 
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1.1.4: PA is involved in cell signalling 
In addition to its critical role as a metabolite at the heart of membrane 
phospholipid biosynthesis, PA has also been involved in cell signalling as a lipid 
second messenger that regulates several proteins implicated in the control of cell 
cycle progression and cell growth. While the LPAAT pathway is integral to de novo 
membrane PA biosynthesis, the activation of the signalling pathways of 
phospholipase C and phospholipase D (PLC and PLD) in response to growth 
factors and stress also produce PA. Both pathways are stimulated by the activation 
of their respective receptors at the plasma membrane. The PLD pathway produces 
PA from phosphatidylcholine (PC) hydrolysis and it is also responsive to nutrients. 
Two mammalian PLDs, PLD1 and PLD2 have been characterised and are regulated 
by small GTPases as well as protein kinase C 83. The PA produced from this 
pathway mainly contains mono-unsaturated fatty acids and is readily distinguished 
from the PA generated from the PLC pathway.116 
 
PA has been studied as a key target for the lipid second messenger of 
mTOR signalling, which integrates both nutrient and growth factor stimulation to 
control cell growth and proliferation. PLD-generated PA has been widely implicated 
in mTOR activation, however PA generated via the LPAAT and PLC pathways has 
also been described as playing a role in the regulation of mTOR specially in period 
of stress.37 
 
The mammalian PLC family consists of at least 13 separate isoforms in 6 sub-
families (β, γ, δ, ε, ζ and η) that differ in their structural organisation, mode of 
activation, cellular and tissue distribution, membrane-binding and catalytic 
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properties.44 Phospholipase C beta Cβ (PLCβ) hydrolyses PI(4,5)P2 into DAG and 
inositol 1,4,5-trisphosphate (IP3). IP3 regulates intracellular Ca2+ release from 
intracellular stores by binding to the IP3 receptor (IP3R) localised in the ER (Figure 
1.6). DAG is the physiological activator of some isoforms of protein kinase C (PKC) 
and is rapidly phosphorylated by DAG kinases to form PA18. The PA which derives 
from the PLC pathway has a distinctive fatty acid composition in most mammalian 
cells. It is highly enriched in stearic acid (C18:0) and arachidonic acid (C20:4).116 
 
Figure 1.6: Phospholipase C signalling and PITPs involvement in PI and PA 
transport across cellular compartments. 
The PLC pathway starts when agonists stimulate specific isoforms of PLC through 
their receptors. PLC catalyses the hydrolysis of phosphatidylinositol bisphosphate 
[PI(4,5)P2] into the second messengers diacylglycerol (DAG) and inositol 
triphosphate (IP3). PA is converted to DAG at the plasma membrane. All the 
members of the phosphatidylinositol transfer protein (PITPs) family function as non-
vesicular transporters of phosphatidylinositol (PI). Class II PITPs (RdgBs) 
exclusively transfer PI and PA. 
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The limiting factor for PLC signalling is the amount of substrate available. 
PI(4,5)P2 levels are maintained through the sequential phosphorylation of PI by lipid 
kinases present at the plasma membrane. However, PI and its precursor PA are 
synthesised at the ER and the mechanisms of PI and PA transfer between 
organelles has not been elucidated. In fact all organelles contain some lipids that 
were synthesised elsewhere. Lipid transport can occur by various mechanisms 
including diffusion, vesicular traffic and the recruitment of transport proteins.   
 
a. Diffusion 
Cellular lipids can diffuse laterally through membrane continuities, such as 
those that exist between the ER and the outer and inner nuclear membrane. 
Tubular connections have been observed between Golgi cisternae. The major 
membrane transport pathway between cellular organelles in the secretory and 
endocytic pathways is through the budding and fusion of membrane vesicles. In 
contrast, organelles such as mitochondria and peroxisomes are not connected to 
the vesicular transport system and lipids are most likely to enter and leave these 
organelles as monomers, assisted by both soluble and membrane proteins. 
 
b. Vesicular trafficking of membrane components 
Secretory and endocytic organelles are connected by bidirectional vesicular 
transport. The lipid raft hypothesis proposes that preferential interactions between 
lipids generate domains of specific lipid compositions to drive the sorting of 
membrane proteins8,58. Vesicle-independent movement has been demonstrated for 
PC, PE and PS between the ER, mitochondria, Golgi and the plasma 
membrane57,64–69  
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c. Recruitment of cytosolic proteins 
Recruitment of cytosolic proteins by membrane phospholipid has also been 
found to facilitate lipid transfer. The lipid components include PI, PC and PA while 
the protein components include various domains including START and PITP. The 
phosphatidylinositol transfer proteins (PITP) family was identified and characterised 
by the ability of binding and transferring PI between different membrane 
compartments in vitro 23 Recently, it was reported that a subclass of the PITPs was 
able to bind and transfer PA in vitro40,125.(Figure 1.6 and Figure 1.8).  
 
 
1.2: Phosphatidylinositol Transfer Proteins (PITPs). 
 
 The PITP family has five members in the mammalian genome subdivided 
into two classes based on sequence analysis. The PITP domain is ∼260 amino 
acids whose sequence is highly conserved in all species. The sequences can be 
found in electronic databases under the Pfam IDs PF02121.23 There are several 
reports studying the suppression or downregulation of specific isoforms in vivo have 
implicating PITPs in a diverse range of effects such as defects in signal transduction 
via phospholipase C and phosphoinositide 3-kinase, membrane trafficking, stem cell 
viability, neurite outgrowth, and cytokinesis (Reviewed in Cockcroft and Garner 
2011; Figure 1.8.B)21 
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Figure 1.7. Structural organisation of the human PITP family.  
Human PITP proteins are divided into Class I and II. Class II is subdivided into IIA 
and IIB. The splice variants of RdgBβ are shown. The number of amino acids of the 
entire protein is indicated. The different C-terminal tails are indicated by different 
colours. The domains are colour-coded: green, PITP domain; red, FFAT motif; 
yellow, DDHD domain; blue, LNS2 domain  
 
 
1.2.1: Class I PITPs. 
The class I PITPs includes the two highly homologous PITP and PITPβ 
proteins of approximately 35kDa 23. Based on the crystal structure of PITP and 
PITPβ, the N- terminal PITP domain forms a hydrophobic cavity where a single 
molecule of either PI or PC binds; while their C-terminal extension forms the ‘lid’ that 
regulates the entry and exit of lipids to and from the cavity.  Four amino acid 
residues (T59, K61, E86 and N90 using mouse PITPα numbering) were found to be 
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essential for binding to the inositol ring 109 (Figure 3.7). Conversely, the residues 
responsible for PC binding have not been identified. However, it has been reported 
that the mutation C95T which localises in the binding pocket, causes loss of PC 
transfer in PITPβ 15. The residues within the PITP domain that make contact with 
both PI and PC are those in proximity to the phosphate group and the acyl chains 
(T97, K195, E218 and Y63)109.The PI and PC molecular species bound by PITPα 
have been examined using tandem electrospray ionisation mass spectrometry (ESI-
MS/MS), and compared with the profile of PI and PC molecular species in HL60 
cells. PITPα showed selectivity towards two mono-unsaturated PC species in 
particular, 16:0/16:1 and 16:1/18:1. 56  
 
Several studies have shown that the PI transfer activity of PITP and PITPβ 
can reconstitute PLC signalling in cytosol depleted cells23. For instance, PLC 
signalling gets disrupted when PITPα is phosphorylated at residues S166 and T59 
in cells treated with the PKC activator phorbol myristate acetate (PMA)82. Mice 
lacking a functional copy or expressing a mutant PITP unable to bind PI showed 
neurological defects.47 On the other hand, PITPβ is required for retrograde traffic 
from the Golgi to the ER and for maintenance of the nuclear morphology of HeLa 
cells.15 PITPβ deficiency is lethal in mice.3 (Figure 1.8.B) 
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1.2.2: Class II PITPs. 
 
Unlike Class I PITPs, all members of Class II PITPs bind and transfer PI and 
PA 40,125 (Figure 1.8). Class II PITPs (also known as RdgBs) are subdivided into IIA 
and IIB (Figure 1.7). The founding member of Class IIA is the Drosophila 
melanogaster Retinal Degeneration protein (Dm-RdgB). In photoreceptor cells, 
Dm-RdgB is considered to transfer the PI required to replenish the PLC pathway 
which generates electrical responses to light.115 RdgB are multi-domain 
membrane-associated proteins. They contain the PITP domain, a FFAT motif that 
binds to VAMP-associated proteins (VAP), where VAMP stands for vesicle-
associated membrane proteins, and two additional domains, DDHD and LNS2. The 
DDHD domain is 195 amino acids and is also present in proteins with PA-PLA1 
activity. The LNS2 domain is 130 amino acids also found in lipins and has been 
shown to bind PA. There are two RdgB isoforms, RdgBI (alt. name: PITPNM1, 
Nir2) and RdgBII (alt. name: PITPNM2, Nir3) (Figure 1.7). 4,21-24Recently, it was 
reported that Hu-RdgbαI translocates from the Golgi complex to the plasma 
membrane in response to growth factor stimulation in HeLa cells where it binds PA 
at its C-terminal region.61 On the other hand, the N-terminal PITP domain of Hu-
RdgbαI and Dm-Rdgbα bound mostly PI and some  PA which increased upon 
GTPγS stimulation in HL60 cells40. Most recently, it was proposed that RdgBα 
proteins facilitate the reciprocal transport of PA and PI at ER-PM membrane contact 
sites to maintain PI(4,5)P2 metabolism after PLC activation24. The Class IIB PITP 
RdgBβ, consists of the PITP domain followed by an unstructured eighty amino acid 
N-terminal tail which is phosphorylated at two sites to form a 14-3-3 binding site. 41  
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Figure 1.8: PI, PC and PA transfer activity and known functions of PITPs. [A.] 
The PI, PC and PA transfer activities of the PITP domains of class I and class II 
were measured by the amount of labelled lipid transferred to an acceptor 
compartment as a percentage of the total input present in the donor compartment. 
PITPα transfers PI and PC whereas RdgB proteins transfer PI and PA. The figure 
was taken from Cockcroft et al 201624. [B.] PITPs reported functions in mammalian 
cells. The function of the individual PITPs in mammals is indicated. The PITPs that 
are highlighted in yellow are those which absence causes embryonic lethality. 
Figure taken from Cockcroft and Garner 201121 
 
A. 
B. 
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1.2.3: RdgBβ 
 
RdgBβ is also known as Cytoplasmic phosphatidylinositol transfer protein 1 
(PITPNC1). Although it was identified in 1999, 39 studies of its characteristics have 
only been reported recently 40,41. There are two splice variants of RdgBβ, sp1 and 
sp2, which differ at their carboxyl-terminal104 (Figure 1.7). RdgBβ sp1 (38kDa) 
contains an amino terminal PITP domain and a specific 80 amino acid long C-
terminal disordered (unstructured) region with two PEST sequences 41 (Figure 1.7). 
Disordered regions are found in proteins with signalling and regulatory functions 
frequently subject to tight regulation 6. PEST sequences are often found in proteins 
subject to rapid turnover in cells 92.  
 
The endogenous protein expression of RdgBβ has been investigated in a 
previous study.41 Fractionation of concentrated rat heart cytosol by gel filtration 
showed immunoreactivity for a protein of the expected size suggesting that rat heart 
does contain endogenous RdgBβ. Its elution on gel filtration partially overlapped 
with 14-3-3 proteins which suggested that cytosolic RdgBβ is likely to be associated 
with 14-3-3. Indeed, transfection of Cos7 cells with FLAG-RdgBβ was found to 
directly bind to 14-3-3 proteins at the phosphorylated residues S274 and S299 
which are located at the C-terminal (Figure 1.9). The phosphorylation was studied 
with the use of inhibitors of protein kinases (PK) A, B and C and it was suggested 
that RdgBβ phosphorylation is probably mediated by PKC.41 The treatment of COS-
7 cells with phorbol 12-myristate 13-acetate (PMA), increased the expression of 
FLAG-RdgBβ and mildly increased binding to 14-3-3 41. PMA is an analogue of DAG 
and a potent activator of PKC. In addition, independent from 14-3-3 binding, FLAG-
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RdgBβ binds HA-tagged ATRAP in Cos-7 cells. This was found only after treatment 
with PMA for 16 hours. The binding site is located at the N-terminal PITP domain of 
RdgBβ, possibly at the regulatory loop (Figure 1.9). 
 
RdgBβ mRNA expression has been found in different tissues, but it was 
found enriched in the heart [23;24]. The expression regulation of RdgBβ mRNA has 
not been directly studied but it was recently associated with the microRNA miR-126 
in a cell-type specific manner. For instance, loss of miR-126 expression was related 
to an increased expression of RdgBβ in breast cancer cells, 90  whilst 
overexpression of miR-126 in leukaemic cells did not reduce the expression levels 
of RdgBβ.2 
 
The lipid binding properties of RdgBβ have also been investigated. RdgBβ 
binds and transfers a specific species of PI, one enriched in stearic (C18:0) and 
arachidonic (C20:4) acids. It was the first protein to be reported to bind and transfer 
PA species derived from phosphatidylcholine (PC) hydrolysis by phospholipase D 
(PLD) which are rich in palmitic (C16:0), palmitoleic (C16:1) and oleic (C18:1) acids. 
RdgBβ binds either PI or PA in similar proportions although with higher affinity for 
PA 40. However, the normal levels of cellular PA are very low (<1% of all lipids), due 
to its rapid conversion into other metabolites 101. This specific interaction could 
potentially be the clue to the functional role of RdgBβ. For instance, the transfer 
activity of RdgBβ could facilitate the reciprocal transfer of PI and PA between the 
ER and the plasma membrane and therefore maintain the PI(4,5)P2 recycling 
pathway (Figure 1.3). Very recently, RdgBβ was found to bind the phosphoinositide 
PI4P in order to recruit the RAB1B to the Golgi in order to promote secretion of 
malignant pro-metastatic factors in human cells45 
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Figure 1.9. Predicted structure of RdgBβ.  
Modelled structure of RdgBβ bound to 14-3-3. In the cytosol, RdgBβ directly binds 
with 14-3-3 dimer proteins at the phosphorylated sites indicated in the 80 amino acid 
C-terminal region (red). RSXXXSXP and RXXSXP are the phosphorylated motif 
sequences where ‘X’ is any amino acid and ‘pS’ represents the phosphorylated 
serine residue. The PITP domain (yellow) of RdgBβ binds and transfers PI and PA 
and also interacts with ATRAP possibly at the regulatory loop (blue). Figure taken 
from Cockcroft and Garner, 201222. 
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1.3: Cardiac function, growth and development in health and disease 
 
The mammalian heart is a complex organ whose function is to pump blood 
through the circulatory system to carry essential molecules across the body. This is 
achieved by a highly coordinated series of events within cardiomyocytes. For 
instance, the excitation-contraction coupling of cardiomyocytes is regulated by 
intracellular calcium ions (Ca2+) levels. The prompt release of Ca2+ is facilitated by 
the close physical proximity between mitochondria, endoplasmic (sarcoplasmic) 
reticulum (ER; SR), and plasma membrane (sarcolemma). All of these cellular 
compartments play a role in calcium homeostasis.114  
 
Following cell growth and terminal differentiation, mature cardiomyocytes 
can undergo an adaptive hypertrophic response as a result of pressure or volume 
overload, damage, or genetic factors. Cellular hypertrophy is accompanied by 
expression of several foetal genes, abnormal Ca2+ homeostasis, oxidative stress, 
increased protein synthesis, and mitochondrial DNA damage. Physiological heart 
enlargement is beneficial in order to increase cardiac output to compensate for the 
demands of normal development and growth but also transient stress. However, in 
the case of hypertension, valvular insufficiency, ischemia, infections, or genetic 
mutations, when the stress to the heart persists, pathological cardiac hypertrophy 
occurs. Pathological hypertrophy is characterised by reduced contractile function 
and plays a significant role in the development of heart failure. Cardiac hypertrophy 
is caused by a complex interaction of signal transduction pathways. The insulin-like 
growth factor (IGF-I) signalling (IGF-I–PI3K–AKT/PKB–mTOR) regulates 
physiological cardiac hypertrophy, whereas G-protein coupled signalling is a 
necessary event in the induction of pathological cardiac hypertrophy.94 
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1.3.1 Cardiac mitochondria 
Mitochondria comprise approximately 30% of cardiac mass, where they are 
essential for providing the ATP that is required to meet the high energy demand for 
cardiac function 60,95. The highly dense mitochondria in cardiomyocytes are arranged 
in a regular pattern around the nucleus, between the myofibrils and beneath the 
sarcolemma and occupy nearly a third of a volume of a cardiomyocyte.54 In the adult 
cardiomyocyte, there are three distinct populations of mitochondria with unique 
spatial organisation: peri-nuclear mitochondria which are arranged in an area 
adjacent to the nucleus; interfibrillar mitochondria which are arranged along the 
myofibrils alongside the sarcomere; and subsarcolemmal mitochondria which are 
present in an area located just beneath the subsarcolemma as seen in Figure 1.10. 
 
Figure 1.10: Distribution of mitochondria in the adult heart. Electron 
micrograph of adult murine heart indicating the subpopulations of cardiac 
mitochondria: perinuclear (PN), interfibrillar (IF) and subsarcolemmal mitochondria 
(SSM). Image taken from Ong and Hausenloy (2010)85 
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Cellular growth and development is associated with an increase in protein, lipid 
and mitochondrial biosynthesis. For instance the peroxisome proliferator-activated 
receptor _ coactivator-1 (PGC-1) family of proteins play a critical role in cardiac 
mitochondrial biogenesis69,114 and PGC-1β transcript and protein were increased as 
a result of differentiation of H9c2 myoblasts11. In the adult heart, PGC-1 maintains 
high-level, coordinated expression of nuclear and mitochondrial genes encoding 
mitochondrial machinery. Mitochondrial function and energy production is 
compromised in the failing heart alongside decreased estrogen-related receptor 
(ERR)/PPAR/PGC-1 signalling114. Limited myocardial mitochondrial biogenesis 
occurs early in response to pathological stimuli and dilated cardiomyopathy but 
ultimately proliferation of mitochondria contributes to the eventual heart failure1 The 
dynamic changes in cardiac mitochondrial number, structure, and function during 
developmental stages and in the failing heart are depicted in Figure 1.11.  
 
 
Figure 1.11: Cellular dynamics of cardiac hypertrophy. These electron 
micrographs of cardiac myocytes show the increase in mitochondrial number and 
organisation during the transition from the foetal period to the adult. In addition the 
cellular changes observed during the development of cardiac hypertrophy as a 
result of PGC-1/PPPAR/ERR signalling are paired with the corresponding 
mitochondrial alterations. Image taken from the review of Vega, Horton and Kelly 
(2015)114  
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 1.3.2: Phospholipid metabolism in cardiac physiology and pathology.   
 
In addition to their role in sarcolemma formation and structure, phospholipids 
are involved in the modulation of membrane bound enzymes and are functional 
components of cardiomyocyte membranes. The enzymology of the biosynthesis and 
the characteristics of the phospholipids related to this thesis (PA and CL) were 
described in section 1.1. This section will highlight some of the evidence of 
phospholipid metabolism associated with cardiac health and disease. 
   
 
a. Phospholipid biosynthesis - CDP-DAG synthase (Cds)  
 
Cds are key enzymes involved in the production of PI and CL from PA 
through CDP-DAG (Section 1.1.3). Loss of Cds function in Drosophila caused 
significant accumulation of neutral lipids in many tissues along with reduced cellular 
size. In addition there were reduced PI levels which generated low PIP3, a regulator 
of the insulin pathway72. Mammalian Cds1 has been shown to be highly expressed 
in the heart 51 and in spontaneously hypertensive rats (SHHF), an increase in Cds1 
mRNA was observed with increasing age whilst Cds2 mRNA decreased during 
heart failure development.93. Interestingly, Cds1 mRNA transcription was found to 
be directly regulated by the PGC-1 in adult mice however no other enzymes in the 
CL biosynthesis pathway were regulated by PGC-1. Gene expression profiling of 
PGC-1α-/β- hearts revealed a mitochondrial phenotype similar to the one found in 
Barth syndrome associated with reduced levels of CL, PC, and PE68.   
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b. Phospholipid remodelling – Phospholipases 
 
Pressure overload during early heart development influences postnatal 
growth and other physiological characteristics including the remodelling of 
membrane phospholipids. Neonatal rats subjected to abdominal aorta constriction 
showed changes in ventricular mass concomitant to a reduction in the 
concentrations of PC, PE, CL and PI.84  
 
The fatty acid distribution of membrane phospholipids in the heart is 
continually in flux producing continuous degradation and remodelling through the 
action of phospholipases. For instance, there are several forms of phospholipase A2 
identified in the mammalian heart playing critical roles in the maintenance of 
membrane structure and function. PLAs differ in primary structure, subcellular 
localisation, and requirement for Ca+2 for activity16. Calcium independent PLA2 
modulates PLD activity in the heart under physiological and pathological conditions 
via hormonal stimulation of the plasma membrane.70  Phospholipase A2b (iPLA2b) 
is the primary mediator of arachidonic acid release from cellular phospholipids 
during ischaemia.59 In addition to PLA, both in vivo and in vitro studies have 
demonstrated that prolonged stimulation of PLC and PLD by agonists such as Ang II 
can induce cardiac pathologies including hypertrophy78,131.   
 
c. Phosphatidylinositol (PI) 
Phosphatidylinositol constitutes 4-6 % of total myocardial phospholipids and 
during rat heart development, maximum PI concentration was found early in 
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neonatal stages.84 Although a minor component, PI plays important roles as a 
glycolipid (glycoPI) anchoring proteins to membrane but especially as the precursor 
of phosphoinositides. The metabolism of phosphatidylinositol-4,5-bisphosphate 
(PIP2), which is hydrolysed by PLC to the second messengers IP3 and DAG 
following G-protein-coupled receptor stimulation (Figure 1.6) has been studied 
extensively in many types of tissues including the heart. For example, PIP2 
homeostasis may regulate arrhythmias caused by electrophysiological imbalance123.  
In isolated myocytes from stroke-prone spontaneously hypertensive rats (SHRSP), 
the Ca2+ influx as result of increased IP3 and DAG levels was higher than in 
normotensive WKY rats which correlated to increased protein synthesis suggesting 
a contribution to the development of pressure-overloaded cardiac hypertrophy89. In 
addition, cardiac ischaemia has been reported to cause a reduction of inositol 
phosphates, including IP3 in both intact heart and cardiomyocyte models due to 
degradation. Nevertheless activation of the PI cycle can also aggravate myocardial 
damage upon re-oxygenation following an ischemic period after agonist 
stimulation.123 
 
 
d. Phosphatidic acid (PA) 
PA is a versatile phospholipid which is a key intermediate of phospholipid 
biosynthesis and signalling (Sections 1.1.2 and Section 1.1.4). As a result, the levels 
of cellular PA are very low and represent a challenge for experimentation design. In 
addition, the literature directly linking PA levels and heart physiology or pathology is 
scarce and there are no studies published in the past 20 years (personal 
observation). The associations of PA with cardiac metabolism are described and 
discussed throughout this thesis. 
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e.  Cardiolipin (CL). 
 
CL is highly enriched in cardiac tissues making up 15–20% of the total 
phospholipid phosphorus mass of the heart. The concentration of CL increases 
markedly with cardiomyocyte development suggesting that mitochondrial 
membranes are predominant structures accounting for the growth of total 
phospholipids concentration during the first five weeks of rat postnatal life. In fact, 
the rate of CL biosynthesis is higher in mitochondria isolated from neonatal rat 
hearts than in those from adults. CL is known to be associated with several inner 
mitochondrial membrane proteins, the most characterised being cytochrome c 
oxidase activity in adult rat myocardium79,84,100 
  
Detrimental metabolism or function of mitochondrial cardiolipin leads to 
several cardiomyopathies and it has been subject of various reviews. Barth 
syndrome is an X-linked genetic disorder of CL remodelling caused by tafazzin 
mutations (160 found to date). As a result of the mutation, the levels of CL decrease 
to about 80% in platelets and skeletal muscle and 20% in cardiac tissue. In addition 
to reduced CL levels, the fatty acyl composition is altered. Tetralinoleoyl-CL, the 
most abundant species in the heart and most tissues are absent. The clinical 
manifestations include cardiomyopathy, skeletal myopathy, neutropenia, and growth 
retardation. Diabetic cardiomyopathy is characterised by altered lipid composition 
and mitochondrial dysfunction in the diabetic myocardium. In the early stages of 
pathological development in the type II diabetic mouse model, a sharp decrease in 
total cardiac CL and a shift to longer and polyunsaturated fatty acid species is 
observed. During the development of myocardial ischemia, there is an increase in 
reactive oxygen species (ROS) and after ischemia-reperfusion, ROS is thought to 
trigger lipid peroxidation as well as damage to cellular macromolecules and the 
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electron transport chain which, together, lead to apoptosis, necrosis, and tissue 
damage. Unsaturated CL acyl species in the mitochondrial inner membrane are 
vulnerable to ROS oxidative damage. Study of ischemia-reperfusion in rat and rabbit 
hearts reported a significant decrease in CL in the subsarcolemmal mitochondria, 
whereas CL in the interfibrillar mitochondria was unchanged as well as the levels of 
all other phospholipids. Exogenously added cardiolipin and no other phospholipids 
rescued the phenotype to mitochondria from reperfused hearts79,100,127.  
 
  
f. Phospholipid associated proteins - RdgBβ 
RdgBβ, a protein with the capability of interact with PA, PI40 and PI4P45, is 
expressed with particularly strong expression in the heart39,41,104 RdgBβ also 
interacts with membrane associated proteins such as the  GTPase RAB1B45 which 
promotes cell growth of primary cultures of neonatal cardiomyocytes in vitro and 
induces cardiac hypertrophy in mouse hearts35 and the angiotensin receptor 
associated protein ATRAP41 which may facilitate cardiovascular pathologies 
including hypertrophy and hypertension86,107 The functional significance of RdgBβ in 
the heart has not been elucidated but it is possible that RdgBβ functions thorugh its 
ability to link phospholipids and proteins.  
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1.3.3: Biological systems to study cardiac physiology 
 
In order to study the heart, the models used include cultured neonatal/adult 
cardiomyocytes, mouse atrial HL-1 cells and rat ventricular H9c2 cells (myoblasts). 
Neonatal rat cardiomyocytes (NRC) can be considered as a very useful model for 
cardiac ventricular cells, in particular to study various adaptive mechanisms. This 
model represents a homogeneous population of cardiac cells offering numerous 
experiments to simulate cardiac pathologies. However, their use involves a high 
number of animals and their isolation, culture and maintenance are expensive and 
their usage time is limited.89 H9c2 and HL-1 cell lines are immortalised cells with a 
cardiac origin and both are widely used for the analysis of cardiac hypertrophy, 
injury and ischemic preconditioning 67. Currently, the experimental outcomes of 
studies using these cell lines and their interpretations suggest significant differences 
between them. H9c2 myoblasts demonstrate high ATP levels, mitochondrial mass 
and respiratory activity, as well as a higher vulnerability to hypoxia and oxidative 
stress than HL-1 cells.67,89 Kuznetsov and colleagues67 show that H9c2 cells are 
more similar to primary cardiomyocytes than HL-1 cells with regard to energy 
metabolism patterns, such as cellular ATP levels, bioenergetics, metabolism, 
function and morphology of mitochondria. In contrast to HL-1, H9c2 cells were 
significantly more sensitive to hypoxia-reoxygenation injury in terms of loss of cell 
viability and mitochondrial respiration, whereas HL-1 cells were more resistant to 
hypoxia as evidenced by their relative stability. H9c2 cells exhibit a higher 
phosphorylation of AMP-activated protein kinase, but lower PGC1 alpha levels, 
suggesting that each cell type is characterized by distinct regulation of mitochondrial 
biogenesis67.  
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a. H9c2 cells  
 
The H9c2 myoblast cell line, isolated from the ventricular part of a BDIX rat 
heart, is currently used for skeletal and cardiac muscle studies due its biochemical, 
morphological and electrical/hormonal signalling properties25,53,80. In the myoblast 
stage, cells are still not fully differentiated into adult cardiomyocytes. However they 
are programed to develop the appearance of several cardiomyocyte-specific 
markers from mono-nucleated myoblasts to myotubes. Differentiation is achieved 
after the cells are cultured in a low serum concentration media,80 which produces 
mostly cells with a skeletal muscle phenotype.53 Furthermore, providing constant 
addition of all-trans retinoic acid (RA) to a 1% serum media induces a predominant 
presence of cells presenting an adult cardiac muscle phenotype. Cardiomyocyte-like 
structural features are normally evident in the presence of retinoic acid only and 
require 7-14 days25. Although, H9c2 differentiated cells do not present contractile 
activity, they are characterised by the increased expression of cardiac markers and 
the alpha-1 subunit of L-type calcium channels80. 
  
Retinoic acid treatment of H9C2 cells leads to an increase in mitochondrial 
biogenesis; both increases in mitochondrial mass and in changes in mitochondrial 
morphology are observed11,25. Indeed the levels of the transcriptional coactivator 
PGC-1α levels also increase upon retinoic acid treatment.25. H9C2 cells can be 
stimulated with vasopressin to induce hypertrophy. Stimulation of AVP1 receptors at 
pM–nM concentrations of AVP promotes the accumulation of IP3, mobilization of SR 
calcium stores, elevation of calcium, and activations of phospholipases, PKC and 
ERK2. AVP stimulation was found to protect H9c2 cells against hypoxia/re-
oxygenation–induced cell death via a GRK2/b2 arrestin1/ERK1/2–dependent 
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mechanism that leads to decreased caspase 3/7 activity and enhanced survival 
under conditions of ischemic stress132. Translational up-regulation and protein 
accumulation in response to vasopressin was preserved after retinoic acid treatment 
to maintain the cardiac phenotype.14,118  These observations were also 
demonstrated in transgenic mice with inducible cardiac-restricted overexpression of 
V1AR which led to the development of left ventricular hypertrophy, dilatation, 
diminished contractile performance, and reprogramming of the HF gene profile in a 
G couple receptor–dependent manner132  Therefore H9c2 cells are an excellent 
model system in which to directly test the effects of V1AR signalling during in vitro 
stress. However H9c2 myocytes do not appear suitable for studying various other 
forms of cardiomyocyte hypertrophy induced by angiotensin II, phenylephrine, and 
endothelin-1.14 
 
Some of the modifications reported for H9c2 cells differentiation are 
summarised in Table 1.1.11,12,25,80,88 13,43,65 H9c2 cells and isolated neonatal 
cardiomyocytes respond similarly to several stimuli, this includes the developing of 
hypertrophic responses118. Recently, a comprehensive characterisation of 
transcriptome alterations during H9c2 differentiation towards a cardiac-like 
phenotype was reported 11. H9c2 cells appear to be a useful model to study cardiac 
phospholipid metabolism and physiology. 
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Table 1.1: Modifications upon H9c2 cells differentiation 
Feature Proliferating Differentiated Reference 
Cell morphology Isolated 
myoblasts 
Fused 
myotubes 
Menard et al 1999 
Cell Proliferation Increase Decrease Comelli et al 2011 
Branco et al 2012 
Branco et al 2015 
Cell growth rate Decrease Increase Comelli et al 2011 
Branco et al 2012 
Branco et al 2015 
Mitochondrial size and 
normal function 
Decrease Increase Comelli et al 2011 
Branco et al 2015 
Stress response 
 adrenegic mediated 
Protected Increased Branco et al 2013 
G subunit,  
Endothelin A receptor 
n/a Increase Giusti et al 2004 
Pro-survival proteins Increase Decrease Branco et al 2015 
Cardiotoxicity and 
Apoptosis 
High 
Decrease 
High 
Increase 
Konorev et al 2008 
Branco et al 2012 
Branco et al 2012 
Metabolism Glycolysis Oxidative 
respiration 
Pereira et al 2011 
Branco et al 2015 
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1.4: Hypothesis 
  
The research hypothesis is that the physiological function of RdgBβ in 
cardiac tissue is to facilitate phospholipid signalling and metabolism during cell 
development due to its association with phosphatidic acid. The null hypothesis is 
that RdgBβ does not play any role in the metabolism of cardiomyocytes. 
 
 
1.4.1: Aims of the Thesis 
 
 To test the hypothesis this study was designed with three strategies as 
follows: 
  Phosphatidic acid is involved in the synthesis of phospholipids and in cell 
signalling in different cellular organelles. Recently the Class II PITPs were found to 
bind and transfer PA in vitro40,125. The first aim of this study was to examine whether 
residues that are essential for PI transfer affected the PA transfer activity of RdgB 
proteins. In addition, I examined potential residues that were responsible for PA 
transfer. For this analysis, mutational analysis was carried using the PITP domain of 
Drosophila RdgBα. This work was part of a collaboration with Dr Raghu’s Laboratory 
who analysed these mutants in Drosophila phototransduction125.  
 
RdgBβ is capable of binding and transferring PA,40 but our understanding of 
its physiologic functions remain to be fully elucidated. RdgBβ transcripts are highly 
expressed in the heart39,104 and RdgB protein has been identified exclusively in the 
heart.41 The second aim of this thesis was to characterise the protein and mRNA 
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expression of RdgBβ using Immunoblotting and qRT-PCR respectively in the H9c2 
cell line and primary neonatal rat cardiomyocytes in order to examine its biological 
function. 
 
Finally, H9c2 cells have been used extensively as a cardiac model and their 
ability to differentiate into a cardiomyocyte-like cell line has also been studied (Table 
1.1). The third aim of this thesis was to examine whether retinoic acid treatment of 
H9c2 cells leads to increased levels of the enzyme Cds1 due to its upregulation with 
cardiac mitochondrial biogenesis and its involvement in phospholipid metabolism.
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CHAPTER 2: Materials and Methods 
 
2.1:  Bioinformatics 
 
Multiple sequence alignments of proteins and nucleic acids were carried out 
using the Clustal Omega online tool (http://www.ebi.ac.uk/Tools/msa/clustalo/) 
which generated alignments between three or more sequences. In addition, the 
EMBOSS Needle online tool (http://www.ebi.ac.uk/Tools/psa/) created alignment of 
two sequences. For primer design and sequence analysis, the Basic Local 
Alignment Search Tool (BLAST; http://www.ebi.ac.uk/Tools/sss/) was used for 
comparing primary biological sequence information with a database of sequences 
and identify library sequences that resemble the query sequence above a certain 
threshold. The ExPasy Translate tool (http://web.expasy.org/translate/) allowed the 
translation of a nucleotide (DNA/RNA) sequence to a protein sequence. Reverse 
complement of nucleotide sequences was obtained using the Translate tool. To 
obtain the reverse complement of sequences the tool at http://reverse-
complement.com/ was used.  
2.2:  Molecular biology 
2.2.1:  Plasmids  
The plasmids used for expression of the recombinant PITP proteins in E. coli 
(Table 2.1.), and transfection of RdgB-sp1 and Cds proteins in mammalian cells 
have been previously described (Table 2.2)40,41,62,98. The human Cds1 and Cds2 
plasmids were a gift from Dr. Tamas Balla (NICHD Bethesda, MD, USA)62. These 
plasmids were sent on filter paper and reconstituted by immersing them in Tris-
EDTA Buffer.  
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Table 2.1: Plasmids for expression of the recombinant PITP proteins used in 
this study. 
 
Table 2.2: Plasmids used in this study for mammalian expression of RdgBβ, 
Cds1 and Cds2. 
Protein Organism 
Accession 
number 
Expression 
Plasmid (Tag) 
Plasmid Ab 
resistance 
Ref. 
RdgBβ-sp1 
Homo 
sapiens 
Q9UKF7 pcDNA3.1(FLAG) Ampicillin [41] 
RdgBβ-sp1 
Homo 
sapiens Q9UKF7 pIRES2-EGFP Kanamycin [41] 
Cds1 
Homo 
sapiens BC074881 pEGFP-N1 (GFP) 
Kanamycin 
[62] 
Cds2 
Homo 
sapiens BC025751 pEGFP-N1 (GFP) 
Kanamycin 
[62] 
Cds1 
Homo 
sapiens BC074881 pcDNA3.1 (Myc) 
Ampicillin 
[62] 
Cds2 
Homo 
sapiens BC025751 pcDNA3.1 (Myc) 
Ampicillin 
[62] 
 
 
PITP Protein Organism 
Accession 
number 
Expression 
Plasmid-Tag 
Plasmid Ab 
resistance 
Ref. 
PITPα Homo sapiens P48739 pRSETC-His Ampicillin [40] 
PITPβ Homo sapiens Q00169 pRSETC-His Ampicillin [98] 
Hu-RdgBα 
(a.a. 1-277) 
Homo sapiens O00562 pET14b-His Ampicillin [40] 
Hu-RdgBβ Homo sapiens Q9UKF7 pRSETC-His Ampicillin [40] 
Dm-RdgBα 
(a.a. 1-281) 
Drosophila 
melanogaster 
NP_511149 pRSETC-His Ampicillin [40] 
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2.2.2:  Transformation and growth of bacterial cultures. 
 
XL1-blue super-competent E. coli cells were transformed to obtain plasmid 
stocks for mammalian cell expression, whereas the bacteria BL21 (DE3) pLysS 
competent strain (Stratagene) was transformed for recombinant protein expression 
in E. coli with the appropriate plasmid. The BL21 strain carries a chloramphenicol 
resistance gene, allowing for their selection in culture. The process of transformation 
was the same for either type of bacterial cells. For each transformation, 10μL of 
reconstituted or 2μL of stored plasmid was placed into an Eppendorf tube containing 
100μL of bacteria. The tubes were flicked briefly, to ensure the contents were 
properly mixed and incubated on ice for 30 minutes. The mixtures were then placed 
into a water bath at 42°C for 45 seconds to allow the plasmids to enter the bacterial 
walls (‘heat shock’). The tubes were immediately returned to ice for 2 minutes after 
which 800μL of autoclaved Miller’s Luria broth (LB) was added to each tube. To 
ensure adequate mixing, the tubes were inverted several times and then placed at 
37°C for 1 hour in an incubator. The LB (25g/L) was prepared with sterile water in 
Duran bottles, autoclaved and stored at 4°C. 
To prepare agar for bacterial inoculation on 10 cm-diameter Petri dishes, 
Luria agar (25g/L) was prepared with sterile water in Duran bottles, autoclaved and 
stored at room temperature. Antibiotics were added to melted Luria agar depending 
on the plasmid according to Tables 2.1 and Table 2.2. Final concentration of either 
Ampicillin or Kanamycyn in Luria agar was 100μg/mL. Approximately 10 mL of warm 
mixture of agar supplemented with antibiotic was poured into each dish and left to 
set at RT. 
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Under aseptic conditions (with a Bunsen flame close by), 200μL of 
transformed cells were transferred onto the agar plates (two per transformation) and 
spread using a sterilised glass cell spreader. Plates were left to dry for a few 
minutes then left overnight upside down in the incubator at 37°C.  Next day, using a 
sterile tip, one bacterial colony was picked and dropped into a falcon tube containing 
5mL of LB plus antibiotic (100µg/mL ampicillin for XL1-blues) and, in the case of 
BL21 colonies, four falcon tubes were set up for culture in LB plus antibiotics 
(100µg/mL ampicillin plus 40µg/ml chloramphenicol for BL21s). These starter 
cultures were used as described in the following sections. 
 
2.2.3:  Maxi/Miniprep and DNA sequencing 
 
The PureLink HiPure Plasmid DNA Maxiprep or Miniprep Kits (Invitrogen) 
allowed the purification of plasmid DNA from the culture of transformed XL1-blue 
cells described above. The choice of kit (Mini or Maxiprep) was made depending on 
the amount of plasmid required. Under aseptic conditions, the falcon tubes 
containing the 5mL starter cultures described in Section 2.2.2 were grown for ~16 
hours in an incubator shaker at 37°C for Mini preps. Alternatively the starter cultures 
were incubated for ~8 hours; and then transferred into 250mL of Luria Broth plus 
ampicillin (100 μg/mL) overnight in an incubator shaker at 37°C for Maxipreps. The 
cells were harvested by centrifuging the overnight LB cultures at 4000g for 10 
minutes. The LB media was discarded and the kit’s buffers were added following the 
manufacturer’s instructions. The final elution was carried out in 50 μL molecular 
grade water. The DNA concentration and quality of the obtained DNA was 
measured using the Nanodrop spectrophotometer. 1.5 μg of each plasmid 
preparation at a concentration of100 ng/μL was sent to Eurofins MG Operon for 
sequencing when plasmids were obtained as gifts to verify their sequence; finally 
the plasmids were stored at -20°C. 
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2.2.4:  Production of PITP Recombinant Proteins 
 
Recombinant PITP proteins were produced by transforming 
BL21(DE3)pLysS competent cells with plasmids (pET14b or prSETC), all encoding 
His6-tagged PITP proteins (Table 2.1). Transformation and bacterial growth 
procedures are detailed on Section 2.2.2. 
 
The starter cultures (Four Falcon tubes containing the transformed bacteria 
described in Section 2.2.2) were placed at 37°C in an incubator shaker at 200rpm 
for ~8 hours. One starter culture was then transferred into each of four 1L glass 
flasks containing 200mL LB including ampicillin (100 μg/mL) and chloramphenicol 
(40 μg/mL). The cultures were placed back into the incubator shaker overnight at 
37°C. Next day, the 200mL cultures were transferred to each of four flasks 
containing 900 mL LB with 100 μg/mL ampicillin and 40 μg/mL chloramphenicol. 
These large flasks were then placed into the incubator shaker at 37°C for 2 hours. 
Bacterial synthesis of the recombinant protein was induced by the addition of 0.5mM 
IPTG (Isopropyl β-D-1-Thiogalactopyranoside) to each large culture flask. The flasks 
were returned to the incubator shaker at the lower temperature of 28°C for 6 hours. 
 
Bacteria were harvested by centrifugation at 6000rpm for 10 minutes, in a 
Sorvall RC 5B Plus centrifuge using a GS-3 rotor. The supernatants were discarded, 
and the cell pellets were re-suspended in 20 mL Sonication buffer (50mM 
phosphate buffer pH 8.0 [11.65 mL 1M Na2HPO4, 0.85 mL 1M NaH2PO4], 300mM 
NaCl and 1%Triton X-100). When preparing recombinant RdgBβ, Triton-X was 
excluded from the buffer.  Bacterial suspensions were then transferred into a single 
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labelled 50 mL falcon tube with 20μL DNase (Sigma-Aldrich). The tube was placed 
at -20°C overnight.  
 
2.2.5:  Purification of recombinant protein 
 
The bacterial pellet frozen overnight was thawed at room temperature, 
divided into two equal parts in 20 mL ultracentrifuge tubes, and centrifuged at 
100,000g for 30 minutes at 4°C in a Kontron ultracentrifuge. The recombinant 
protein in the supernatant was captured using its His tag on an equilibrated nickel 
column of HIS-Select Nickel Affinity Gel (P6611, Sigma) in a PD-10 column 
(Disposable Chromatography Column, Bio-Rad Laboratories). The column was 
equilibrated with sonication buffer at room temperature, then filled with the 
supernatant and placed into a rotating wheel for 60 minutes at 4°C so the beads 
could capture the recombinant protein by their His tag. 
 
Following capture of the protein, all the liquid was drained from the column. 
The resin was first washed with Low Salt buffer (50 mM phosphate buffer pH 6.0 
[23.3 mL 1 M Na2HPO4, 1.70 mL 1M NaH2PO4], 300 mM NaCl and 10% glycerol), 
followed by 25 mL High Salt buffer (50 mM phosphate buffer pH 6.0 [23.3 mL 1M 
Na2HPO4, 1.70 mL 1M NaH2PO4], 525 mM NaCl and 10% glycerol). The 
recombinant protein was eluted from the resin by adding 3mL Imidazole (250mM) in 
High Salt Buffer and transferred into a desalting column (PD10) previously 
equilibrated with PIPES buffer pH 6.8 (20 mM PIPES, 137 mM NaCl, 2.7 mM KCl). 
(PIPES, 1,4-Piperazinediethanesulfonic acid, P6757, Sigma-Aldrich.). This elution 
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was allowed to drain from the desalting column. The purified recombinant protein 
was finally eluted with 4mL of PIPES buffer. 
 
The concentration of the purified recombinant protein was assessed initially 
using the bicinchoninic acid (BCA) assay (Section 2.2.6.). Subsequently 1.0, 2.0 and 
4.0 μg of the protein were run on a SDS-PAGE gel alongside 1.0, 2.0 and 4.0 μg 
BSA (Bovine Serum Albumin) and stained with Coomassie dye to visualise and 
evaluate protein purity (Figure 2.1). Imaging was done using a LAS-3000 system 
(Fuji). The protein concentration was adjusted accordingly using AIDA software by 
quantification of the bands relative to 1, 2 and 4g BSA. The purity and yield of the 
recombinant proteins varied between plasmids and batches.  
 
2.2.6:  BCA assay for protein concentration 
 
The Bicinchoninic Acid (BCA) kit was used to assess protein concentration. 
The BCA assay relies on the detection of a Cu2+-protein complex which, under an 
alkaline environment, reduces Cu2+ to Cu1+ and turns the mixture from green/blue to 
purple/blue. The intensity of the colouration is proportional to the amount of protein 
present (BCA1, Sigma-Aldrich). As controls, BSA protein standard solutions of 0.05, 
0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.8 and 1 mg/mL were made up in distilled water and 
stored at -20°C. The assay was performed in a 96-well plate. 10μL of each standard 
was pipetted into plate wells in duplicate including a negative control. Purified 
recombinant protein or lysates of unknown concentration were diluted (regularly two 
dilutions, 1:10 and 1:20), and 10μL of the diluted sample pipetted also in duplicate 
into the wells alongside the standards. 
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A BCA/Copper (II) sulphate solution was made in a 50:1 ratio. 200μL of this 
mixture was pipetted into each well of the 96-well plate containing diluted sample or 
protein standard. The plate was then covered with cling film and placed into the 
incubator for 30 min at 37°Cto allow the colour to develop. The relative intensity of 
the coloured mixtures was read using a plate reader at λ=540nm. Only readings of 
the standards with regression coefficient of >0.95 were considered for calculations. 
The final concentration was an average of the two dilutions of the unknown samples 
concentration. 
 
 
 
2.3: In vitro Phospholipid transfer activity assays 
 
2.3.1: PI transfer activity. 
 
PI transfer was assessed for all recombinant protein preparations to verify 
the activity status of each batch following a procedure reported previously108. 
Labelled [3H]-Inositol rat liver microsomes were the donors and unlabelled 
liposomes made of PC and PI from egg yolk (98:2 molar ratio) were the acceptors. 
The buffer used for all preparations was SET buffer (0.25M sucrose, 1mM EDTA, 
and 10mM Tris-HCl pH 7.4). The total volume per assay was 250μL from which 
100μL were the recombinant protein sample at different concentrations; 100μL of 
liposomes and 50μL of [3H] microsomes. 
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The mixtures were incubated in a 25°C water-bath for 20minutes after which 
the reactions were quenched with 50μL ice cold STOP buffer (0.2M Sodium acetate, 
0.25M Sucrose pH 5.0). Each tube was capped and vortex followed by 
centrifugation at 9500g for 15 minutes at 4°C to pellet the microsomes. 150μL of the 
supernatant were then transferred into scintillation vials for radioactivity counting in 
a Packard Tri-carb liquid scintillation analyser (TR2500). PI transfer was calculated 
by taking the amount of radioactivity measured per sample (x2), as a percentage of 
the total radioactivity input after subtraction of background activity. Each protein 
concentration was monitored in duplicate samples. 
 
 
 
2.3.2: PA transfer assay 
 
PA transfer activity of recombinant PITPs was assayed using an adaptation 
of a previously published protocol20. The donor compartment were liposomes made 
from egg PC and PA at a molar ratio of 98:2 plus radiolabelled PA (L-a-dipalmitoyl 
[2-palmitoyl-9, 10-3H] Phosphatidic acid, Cat # 2063, ARC UK), and the acceptors 
were rat liver mitochondria at a concentration of 8mg/mL. SET buffer (0.25M 
sucrose, 1mM EDTA and 10mM Tris-HCl pH 7.4) was used for all dilutions.  
 
Different concentrations of protein were mixed with donor and acceptor in a 
final volume of 200µL and then incubated at 37oC for 30 minutes. The mitochondria 
were pelleted by centrifugation at 9500g for 10 minutes at 4oC. The supernatant was 
discarded and the pellets resuspended in 500μL of SET buffer then transferred to a 
new tube containing 500μL of ice cold Sucrose buffer (14.33% w/v sucrose in 
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ddH2O) and pelleted again by centrifugation. The mitochondria were resuspended 
in 50μL of 10% SDS and boiled at 95oC for 5 minutes. The entire content of each 
tube was transferred to scintillation vials, Ultima-GOLD was added and radioactivity 
was counted using a liquid scintillation analyser (TR2500). Samples were analysed 
in duplicate. PA transfer was calculated as an average percentage of the total 
radioactivity input after subtraction of background activity.  
 
2.3:  Quantification of mRNA by polymerase chain reaction (PCR)  
 
2.3.1: RNA extraction 
RNA extraction of H9c2 cell lysates and rat heart tissue was achieved using 
the RNA Miniprep Kit (NBS Biologicals) first by lysing and homogenising the 
samples in 350μL guanidine thiocyanate and 2-mercaptoethanol to release RNA 
and inactivate RNases. Lysates were centrifuged through the filtration column to 
remove cellular debris and DNA. The filtrate is then applied to a Spin Column to 
bind total RNA, followed by washing and elution as per manufacturer instructions. 
Elution volume was 30μL in RNase free water. RNA concentration and quality was 
measured using Nanodrop. Samples with concentrations over 100ng/l and 260/280 
and 260/230 ratios close to 2.00 were used for all experiments.  
 
2.3.2: cDNA Synthesis  
One microgram of RNA from each sample was used to produce cDNA by 
Reverse Transcription (RT)-PCR following the First-Strand cDNA Synthesis protocol 
given by the manufacturer using SuperScript III Reverse Transcriptase (Invitrogen). 
In every experiment a sample containing no reverse transcriptase (-RT) was 
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included to use as negative control. A volume of 20μL of concentrated cDNA was 
obtained per sample which was diluted 1:5 in molecular grade water. 
 
2.3.3: Design and validation of primers for PCR 
Specific Rattus norvegicus primers were designed using the website Primer 
3 (http://bioinfo.ut.ee/primer3/) based on the NCBI sequence references on Table 
2.3. The requirements included:  
1. CG (guanine and cytosine nucleotides) content of minimum 50%, with an 
even distribution of all four bases along the length of the primer. 
2. Maximum size of 20 base pairs. 
3. Difference of annealing temperatures (Tm) between forward and reverse 
primers of below 1 degree Celsius. 
 
Primers were manufactured by Sigma-Aldrich Custom Oligos service and sent in 
tubes to be reconstituted with TE buffer at 100μM. Once the set of primers was 
validated, 25μL aliquots at 10μM were made and stored at -20°C. 
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Table 2.3: Validated primers used for PCR experiments. *Housekeeping genes. 
 
Protein 
NCBI Reference 
Name Forward primer Reverse primer 
Product 
Size (bp) 
ANP 
X00665.1 
Atrial natriuretic 
factor 
ATACAGTGCGGTGT
CCAACA 
CGAGAGCACCTCCAT
CTCTC 
209 
BNP  
NM_031545 
Natriuretic peptide B 
GGAAATGGCTCAGA
GACAGC 
CGATCCGGTCTATCTT
CTGC 
164 
Cds1  
NM_031242 
CDP-diacylglycerol 
synthase 1 
TACGACCTCCCGTG
GTTTAG 
CTCAGGACGAACATG
CAGAA 
194 
Cds2 
NM_053643 
CDP-diacylglycerol 
synthase 2 
GAGCCTTTGCGCAT
TCTCAG 
ACATGGGTCCAGCCA
AACAT 
137 
CLS  
NM_001014258 
Cardiolipin synthase  
(CLS) 
CGGTGTTGGGCTAT
CTGATT 
CAGCAAGTGGATCAA
GAGCA 
153 
PIS 
NM_138899.2 
CDP-diacylglycerol-
inositol 3-
phosphatidyltransfer
ase (Cdipt) 
AGTGTCATCCACCT
CGTCAC 
AGACATGACACTGGG
ACCTC 
164 
GAPDH * 
NM_017008.4 
Glyceraldehyde-3-
phosphate 
dehydrogenase 
AGACAGCCGCATCT
TCTTGT 
CTTGCCGTGGGTAGA
GTCAT 
207 
PGK1 * 
NM_0532913 
Phosphoglycerate 
kinase 1 
GAAGGGAAGGGAA
AAGATGC 
AAATCCACCAGCCTT
CTGTG 
180 
RdgBβ  
XM_573213 
Phosphatidylinositol 
transfer protein  
cytoplasmic 1 
 
GAAGCGCGTGTATC
TCAACA 
 
TCGAGGTCTTTGGCT
TCACT 
 
219 
RdgBα  
NM_001008369 
Phosphatidylinositol 
transfer protein, 
membrane-
associated 1 
(Pitpnm1) 
TGTTGGCAGGATGA
GTGGAT 
CAAAGCTGGCATCTG
GTGAG 
235 
Tam41 
NM_001108642 
Mitochondrial 
translocator 
assembly and 
maintenance protein 
CATGTGAAGCCCAA
CGTAG 
GCTGCTGTAACGTTC
TAGGC 
136 
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2.3.4: Polymerase Chain Reaction (PCR) 
To validate the designed primers (Table 2.4), 5μL diluted cDNA prepared 
from H9c2 cells and rat heart tissue was used as a template for amplification in PCR 
using the enzyme Platinum Taq Polymerase (Invitrogen). The protocol given in the 
kit was followed with the difference that only 0.2μL of Taq was added per sample. 
The thermocycler program used for all primers is shown on Table 2.5. 
 
Table 2.4: Overview of thermal cycler program for PCR. 
Activity Temperature Time Programme 
Enzyme activation 94° 2min  
Denaturation 94° 30sec  
30 cycles Annealing 60° 30sec 
Extension 72° 1min 
Final extension 72° 5min  
 
 
2.3.5: DNA gel electrophoresis 
To test the specificity of all the designed primers, their PCR products were 
analysed by electrophoresis in agarose NA gels in triplicate alongside a negative 
control (Figure 2.1.). DNA gel electrophoresis separates the PCR products based on 
their size and charge (the expected product sizes for each set of primers are given 
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in Table 2.4). A 1.6% agarose gel was prepared in a microwave by dissolving 0.65 g 
Agarose NA in 65mL Tris-acetate-EDTA buffer (0.8 mM Tris-HCl pH 8.0, 0.4 mM 
acetic acid, 0.02 mM EDTA). 5μL ethidium bromide (10 mg/mL) was added to the 
warm agarose solution and mixed by swirling. The mixture was then poured into a 
Bio-Rad gel caster tray and a comb was placed into the designated slots at one end 
of the gel. Setting was achieved at room temperature for ~30 minutes. 
 
The set gel was transferred from the caster tray to the Bio-Rad Mini-Sub Cell 
GT Cell for submerged horizontal electrophoresis with the comb end (sample wells) 
placed at the black (negative electrode) end. The comb was then removed and TAE 
buffer was poured into the apparatus allowing buffer to fill the wells. 5 μL ethidium 
bromide (10 mg/mL) was pipetted directly onto the buffer at the positive electrode 
end of the apparatus to prevent the ethidium bromide travelling faster than the DNA 
sample which could have affected the visibility under UV light. Each well was loaded 
with a mixture of 5μL PCR product + 1μL 6X DNA loading dye (Blue #R0611, 
Fermentas) including a negative control (-RT), alongside 3μL Fermentas GeneRuler 
1 kb DNA ladder (0.1 μg/μL, #SM0313, Fermentas). The lid was then placed onto 
the apparatus in the correct orientation, and electrical leads plugged into the Bio-
Rad Power-Pac 3000. Agarose NA gels were run at 100 V for ~40 mins or until the 
dye front had travelled ⅔ along the gel.  
 
The result was checked under UV light and imaged using a LAS-3000 
system. If any set of primers produced more than one clear band; primer dimer 
(band of 100bp or lower) or no visible band, the primers were discarded and a new 
set was designed and tested.  
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Figure 2.1: DNA gel electrophoresis testing PGK1 and RdgBβ primer 
specificity. 
H9c2 cells were harvested in RNA lysis buffer and 1μg of extracted RNA was used 
to make cDNA by Reverse transcription PCR. 5μL of H9c2 cDNA was used to 
amplify the expression of the reference gene Phosphoglycerate kinase 1 (PGK1) 
and RdgBβ to test the specificity of designed primers. Three separate preparations 
(1, 2 and 3) of cells alongside a negative sample made without reverse transcriptase 
(-RT), and a DNA 1Kb ladder (bp) were separated by DNA gel electrophoresis 
(1.6% agarose NA gel). The images were taken on a LAS3000 imaging system. All 
primers were analysed in a similar manner. 
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2.3.6: PCR product purification and sequencing 
 
Further primer validation for quantitative PCR included purification and 
sequencing of the positive PCR products. 30μL of purified DNA was obtained by 
using the QIAquick PCR Purification Kit (QIAGEN) and following the manufacturer 
instructions. The concentration of purified DNA was measured using Nanodrop. 
 
For sequencing, the purified PCR products (~10ng) were cloned into pGEM-
T easy vector (Promega) following the manufacturer protocol. Ligation mixtures 
were incubated overnight at 4°C. Transformation of XL1-blue cells was performed 
as described in Section 2.2.2. Duplicate LB plates containing 0.5mM IPTG, 80μg/mL 
X-Gal and 100μg/mL ampicillin were inoculated with the transformed bacteria. A 
positive bacterial colony (blue) was cultured in LB media overnight and the plasmid 
DNA was purified using the QIAprep Spin Miniprep Kit (QIAGEN). Final 
concentration was measured with Nanodrop and quality was evaluated by DNA gel 
electrophoresis in 1% Agarose NA gel. 15μL of purified DNA plasmid (100ng/μL) 
were then sent to Eurofins MWG Operon for sequencing. Sequences were 
confirmed by sequence alignment.  
 
2.3.7: Real Time Quantitative PCR (qRT-PCR) 
 
To quantitate mRNA from cDNA samples, qRT-PCR was performed in one 
step using a KAPA SYBR FAST qPCR Universal Master Mix (KAPA Biosystems) 
containing all components for qPCR except primers and template. Individual 15μL 
reactions (5μL cDNA +10μL Master mix with primers included) were set up on a 96 
well plate. Housekeeping gene (PGK1) was added at a final concentration of 200nM 
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while all other primers were added at 300nM. In addition each set of primer included 
a No Template Control (NTC) and No RT Control (NRT) reactions. The NTC 
enabled detection of contamination in the reaction components, while the NRT 
enabled detection of contaminating gDNA. The plate was sealed, shaken and 
centrifuged briefly before it was placed in the BIORAD CFX96 machine following the 
protocol on Table 2.5. Reaction optimisation was achieved by testing different 
annealing temperatures and primer concentrations. 
 
qPCR data obtained from the CFX96 machine was analysed in triplicate 
using the comparative ΔΔCT method73 which compares the Ct value of one target 
against the reference target ‘Housekeeping gene’ (PGK1). Primers efficiency and 
sensitivity was analysed by producing qPCR standard curves testing H9c2 cDNA 
serial dilutions with 200nM PGK1 (Figure 2.2: A) and 300nM RdgBβ (2.3: B) primer 
sets. Optimal values obtained from the standard curves data were considered as: 
Efficiency (E): 90-110%; Slope: -3.6 to -3.1; and Regression (R2) >0.98 which is an 
indication of reproducibility (Figure 2.2). 
Table 2.5: Overview of BIORAD CFX96 program for qRT-PCR experiments. 
Activity Temperature Time Programme 
Initial denaturation 95° 3min  
Denaturation 95° 15sec  
39 cycles Annealing 60° 30sec 
Extension 72° 30sec 
Melt curve 65°to 95°   
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Figure 2.2: qPCR Standard Curves testing of PGK1 and RdgBβ primers 
efficiency and sensitivity. 
Real Time Quantitative PCR (qRT-PCR) of H9c2 cDNA serial dilutions with 200nM 
PGK1 [A] and 300nM RdgBβ [B] designed primers using a KAPA SYBR FAST 
qPCR Universal Master Mix at 60°C annealing temperature on a BIORAD CFX 
machine. Sensitivity was the lowest concentration of H9c2 cDNA that produced 
amplification at these conditions. Print screen images from CFX96 report. 
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2.4:  Cell-based assays 
 
2.4.1:  Cos-7 cells 
 
Cos-7 cells (derived from African green monkey kidney cells), were used to 
confirm previous observations41 and as controls for validating RdgBβ and Cds1 
antibodies.   
 
a. Cell culture 
Cos-7 cells were grown in Dulbecco’s Modified Eagle Medium (DMEM) cell 
culture medium supplemented with 10% heat-inactivated Foetal Calf Serum (FCS), 
4 mM L-glutamine, 0.5 iu/mL penicillin and 50μg/mL streptomycin, in a T75 cell 
culture flask. Heat-inactivation of FCS was carried out by placing the unopened 
500mL bottle in a water bath at 56°C for 1 hour. Cells were passaged 1:3 every 48 
hours or 1:5 when left for 72 hours, in a class II laminar flow cabinet.  
 
b. Transient transfection of DNA plasmids by electroporation 
Cos-7 cells were seeded onto 10 cm cell culture plates (one per condition, 
10 mL media per plate), at a concentration of 1.0-2.0 x 105 cells/mL, 24 hours prior 
to transfection to allow the cells to adhere to the plastic and reach a 70-80% 
confluency. On the day of the transfection, cell harvest was achieved by incubating 
cells for 5 min with Trypsin-EDTA Phenol red (0.25%; Gibco). The mixture was 
placed in a falcon tube and centrifuged at 12000 rpm for 5 minutes, then washed 
once in PBS. 
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Transfection was carried out by electroporation using a Bio-Rad Gene 
Pulser. Sterile 0.4cm electroporation cuvettes were prepared in the flow cabinet as 
follows: 10μg of plasmid DNA was pipetted at the bottom of the cuvette followed by 
400μL of Cos-7 cells suspended in DMEM. The covered cuvettes were flicked gently 
to mix the contents and left at room temperature for 5 minutes. The Gene Pulser 
was set up at a 0.220kV Voltage; 950 μF High Capacitance and the Resistor (Pulse 
Controller) in the infinity position (). Two pulses were given to each cuvette before 
transferring it onto ice for 10 minutes. The cells were removed and re-suspended in 
fresh growth medium at room temperature. Cells were transferred to a T175 cell 
culture flask and grown for 24 to 48 hours depending on confluency before 
harvesting. 
 
2.4.2: H9c2 cells 
 
 Vials of H9C2 cells (ATCC number CRL-1446) derived from embryonic 
BD1X rat ventricular tissue 63 were a gift from Dr. Stuart Nicklin from the Institute of 
Cardiovascular and Medical Sciences, BHF, University of Glasgow, UK. H9c2 
myoblasts are able to differentiate into skeletal or cardiac muscle cells depending on 
the culture media. 
 
a. Cell culture 
H9c2 cells were seeded at around 2x105 cells/mL and cultured in Dulbecco’s 
modified Eagle’s medium (DMEM) 1X w/GlutaMAX + High Glucose +NaPyr (Cat # 
31966-021) supplemented with 10% heat inactivated foetal calf serum (FCS) and 
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1% Penicillin/Streptomycin (Pen/Strep) under standard culture conditions (37 °C, 
5% CO2). Before 70% confluence, cells were passaged at a ratio of 1:3. H9c2 cells 
took a few days (about 3 to 4) after thawing before they started replicating. Cells 
were not passaged until they reached confluency and the media was replaced every 
two days. Cultured cells were not used for experiments beyond passage 30. 
 
b. Transient transfection of DNA plasmids using Lipofectamine 2000. 
Transfection of Tagged RdgBβ DNA into H9c2 cells was achieved using 
lipofection. Cells were seeded at 2x105 cells/mL in 6 well plates containing 2mL 
complete media and cultured to ~80% confluency. One day prior to transfection the 
media was replaced by culture media without antibiotics. FLAG-tagged pcDNA and 
pIRES-RdgBβ plasmids (1g/ml) were transfected using Lipofectamine 2000 
(Invitrogen) following the manufacturer’s protocol. Optimum conditions of 
transfection were obtained at a ratio of 6:2 for 24 hours after which the media was 
replaced for 24hours further incubation. Optimisation of Lipofectamine 2000 and 
DNA together with period of incubation was evaluated by SDS-PAGE (Figure 2.3). 
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Figure 2.3: Optimisation of Lipofectamine 2000: DNA ratio. 
H9c2 cells were cultured to ~80% confluency prior to transfection with Lipofectamine 
2000 at different ratios (μL Lipofectamine: μg DNA) and left in culture with no 
antibiotics for 24 [A.] or 48 [B.] hours. 50μg of protein per sample separated by 
SDS-PAGE and probed with polyclonal Ab:Rb59 at a dilution of 1:200 for 2 hours in 
5% milk in PBS as blocking buffer. Image obtained with LAS3000. 
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c. Preparation of lysates for SDS-PAGE 
For SDS-PAGE analysis, the media was removed from the culture flask and 
cells were washed with PBS. To detach cells from the base of the culture vessel, 
0.25% Trypsin-EDTA was added and left for 5 minutes at 37oC. Complete media 
was added to quench Trypsin action and cells were transferred to a falcon tube and 
centrifuged at 350g for 5 minutes at 4oC. Following a wash with PBS, H9c2 cells 
were pelleted and resuspended in RIPA buffer (50mM Tris-HCl pH 7.5, 150mM 
NaCl, 1% Triton X-100 (v/v), 0.5% sodium deoxycholate (w/v), 0.1% SDS (w/v), 
protease inhibitor cocktail) and either put on ice for 30 minutes or at -20°C for 5 
minutes. The samples were sonicated and centrifuged at 12000g for 15 minutes at 
4°C to pellet unbroken cells and debris.  The supernatant was transferred to a fresh 
tube. The BCA assay was used to assess the protein concentration of the lysates. 
Typically, 50μg protein was mixed with enough 4X SDS-PAGE sample buffer and 
boiled at 95oC for 3 minutes before loading the gel wells.  
 
 
d. Cell differentiation 
H9c2 myoblasts cell line retain the ability to differentiate into skeletal muscle 
or cardiac cells depending on the culture media80. To differentiate cells into skeletal 
muscle in which myoblasts fuse to form mature multinucleated myotubes, H9c2 cells 
cultured in full media (10% FCS) were washed with PBS and the media was 
replaced for differentiation media (DMEM 1X w/GlutaMAX + NaPyr. (Cat # 31966-
021) supplemented with heat inactivated 1% foetal calf serum and 1% pen/strep). 
Media was replaced every 48 hours and cells started to fuse after 6 days of culture. 
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To differentiate H9C2 myoblasts towards a cardiomyocyte-like phenotype, 
cells were cultured in differentiation media with the daily addition of 1μM All-trans 
Retinoic acid (RA; Sigma: Cat# R2625). RA was dissolved in DMSO at 1mM in 50μL 
aliquots at 1mM and kept at -20ºC. Due to light sensitivity it was kept covered. 
Cardiomyocyte-like features were found after 8 days of differentiation and cells were 
viable up to 14 days of differentiation. 
 
2.4.3: Neonatal rat cardiomyocytes 
Primary culture of neonatal rat cardiomyocytes (NRVC) were used for 
comparison of the results obtained with the cell-line H9c2.  
 
a. Isolation and culture. 
The isolation of cardiomyocytes from Sprague-Dawley rat neonates (1-2 
days old) was performed as described previously76. Heart dissection was achieved 
after euthanasia of the pups according to code of practice under Schedule 1 
procedures approved by ASPA (Animals Scientific Procedures Act 1986) performed 
at the Biological Services Unit facilities.  The hearts were finely minced and placed 
into warm (37˚C) Digestion buffer (116mM NaCl, 20mM HEPES, 0.8mM Na2HPO4, 
5.6mM glucose, 5.4mM KCl and 0.8mM MgSO4, pH 7.35) containing 0.4 mg/ml 
collagenase type2 (Willington), 0.6 mg/ml pancreatin (Sigma), 100 units/ml penicillin 
and streptomycin and universal protease/phosphatase inhibitor (EZ block). 
 
The first digestion occurred for 20 minutes at 37°C in a shaker (160 
cycles/minute). The first supernatant was removed and discarded. Cell suspensions 
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from 7-8 subsequent digestions (15 minutes; 37°C; 136 cycles/minute) were 
recovered in FCS by centrifugation (5 minutes; 350g; RT). Cell viability was 
evaluated under the microscope with 10μl 0.5% Trypan blue after each digestion. 
The cell pellet was then either resuspended in RIPA or RNA lysis buffer for 
immediate analysis or resuspended in Plating Medium (Dulbecco's modified Eagle's 
medium (DMEM)/medium 199 [4:1 (v/v)], 15% (v/v) FCS, 100 units/ml penicillin and 
streptomycin) for culture. The cells were pre-plated on 60mm Primaria tissue culture 
dishes (30 minutes) to remove non-cardiomyocytes. Non- adherent cardiomyocytes 
were transferred to 60mm Primaria dishes pre-coated with sterile 1% (w/v) gelatine 
(Sigma-Aldrich UK) at a density of 4×106 cells/dish. After 24 hours, myocytes were 
confluent and beating spontaneously. Plating media was replaced for maintenance 
media (DMEM, 100 units/ml penicillin and streptomycin, 0%FCS). Viable cells were 
only seen for up to three days of culture. 
 
 
2.4.4: Rat Heart cells treatments 
 
a. Treatment with agonists 
H9c2 cells were evaluated for G-coupled receptor stimulation using [Asn1, 
Val5]-Angiotensin II (Sigma-Aldrich; A6402) and [Arg8]-Vasopressin (Sigma-Aldrich; 
V9879) at different concentrations. For treatment with chemical compounds, the cell 
culture media was aspirated and replaced with fresh media containing the 
compound at the appropriate time prior to cell harvest. 
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b. RNA interference by siRNA transfection 
The down-regulation of the expression of RdgBβ and Cds1 mRNA in H9c2 
differentiated cells and NRVC was achieved by siRNA transfection using 12nM 
siRNA oligonucleotides with HiPerFect Transfection Reagent following the 
manufacturer instructions. Rat specific siRNA oligos for mRNA downregulation of 
RdgBβ and Cds1 were purchased from QIAGEN (Table 2.6). Three siRNA Oligos 
were acquired for each protein and they were tested for mRNA reduction efficiency 
by qRT-PCR in combinations of pairs and all three together (Figure 2.4). For 
experiments in this study, RdgBβ mRNA was downregulated by transfection of 
Oligonucleotides 2+3 and Cds1 mRNA downregulation was achieved by transfection 
of Oligonucleotides 1+3. 
 
The application of RNA interference (RNAi) was usually performed on the 8th 
day of differentiation with retinoic acid and incubated for further 72 hours. 
Alternatively, three rounds of siRNA transfection were performed every 72 hours for 
the duration of cell differentiation until day 9. Media was removed and cells were 
washed with PBS before detachment of the flask by Trypsin-EDTA action. After cells 
were pellet and washed with PBS, cell were divided into 70% for lysis in RIPA buffer 
for SDS-PAGE as described on Section 2.4.2.c, and 30% of the cells were 
harvested in RNA lysis buffer for RNA extraction as described on Section 2.3.1. 
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Table 2.6: siRNA Oligos purchased for RNA interference of H9c2 cells. 
 
Name/ 
Gene Accession 
QIAGEN 
Catalogue code 
Sequences 
Negative control SI03650325 
Sense: 
UUCUCCGAACGUGUCACGUdTdT  
Antisense: 
ACGUGACACGUUCGGAGAAdTdT  
 
RdgBβ_1 
XM001081613, 
XM002724573, 
XM_573213 
SI05429753 
Rn_Pitpnc1_1 
Sense: 
5’GACUGCAUGUGGUUAGAUATT-3’ 
Antisense: 5’ 
UAUCUAACCACAUGCAGUCTG-3’  
 
RdgBβ_2 
XM001081613, 
XM002724573, 
XM_573213 
SI05429753 
Rn_Pitpnc1_2 
Sense: 
5’GCAUGGAAUUAUUACCCAUTT-3’ 
Antisense: 5’ 
AUGGGUAAUAAUUCCAUGCCT-3’  
 
RdgBβ_3 
XM001081613, 
XM002724573, 
XM_573213 
SI02937872 
Rn_LOC498015_3 
Sense: 
5’CGAUAUCGCCUGUGACGAATT-3’ 
Antisense: 5’ 
UUCGUCACAGGCGAUAUCGAT-3’  
 
Cds1_1 
NM 3142 
 
SI01497811  
Rn_Cds1_1 
 
Sense: 
5’AGAUAUUGAUGACAGGUAUTT-3’ 
Antisense: 
5’AUACCUGUCAUCAAUAUCUGT-3’  
 
Cds1_3 
NM 3142 
SI01497825  
Rn_Cds1_3 
Sense: 
5’GGUUCGAUUGUCAGUAUUUTT3’ 
Antisense:  
5’ AAAUACUGACAAUCGAACCTG-3’  
 
Cds1_4 
NM 3142 
SI01497832 
Rn_Cds1_4 
Sense 
5’CCCGUGGUUUAGAACACUATT-3’ 
Antisense:   
5’UAGUGUUCUAAACCACGGGAG3’  
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Figure 2.4: Test of efficiency of siRNA Oligonucleotides 
H9c2 cells were differentiated for 8 days prior to transfection with 12nM total siRNA 
Negative control compared to combination of rat oligonucleotides RdgBβ (1,2,3) [A.] 
and siRNA oligonucleotides Cds1 (1,3,4) [B.] After 72 hours incubation, the cells 
were harvested in RNA lysis buffer and 1μg of extracted RNA was used to make 
cDNA by RT-PCR. 5μL of H9c2 cDNA was used to amplify the expression of the 
reference gene PGK1 and RdgBβ by qRT-PCR using SYBR I on a BioradCFX96. 
The graph shows the fold change of mRNA normalised to PGK1 using the Ct values 
from the CFX96 equipment applying the ΔΔCt formula. N=3 from one experiment. 
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c. Cell fractionation 
To obtain the mitochondria, microsomes and cytosol from H9c2 cells, lysates 
in SET buffer (0.25M sucrose, 1mM EDTA, 10mM Tris-HCl pH 7.4) were sonicated 
on ice (50μm, 3×15 seconds) and centrifuged for 10 minutes (850g, 4oC) to pellet 
the nuclei and unbroken cells. Some of the homogenate was retained as whole cell 
extract (WCE). The homogenate was centrifuged for 15 minutes (9500rpm, 4oC) to 
sediment the mitochondria which were then washed with SET buffer twice. The 
supernatant containing the microsomes was centrifuged for 60 minutes (100,000 g, 
4oC) to pellet the membranes. The membranes were resuspended in SET buffer 
and re-centrifuged twice. The supernatant (cytosolic fraction) was also retained.   
 
2.5: Rat tissue isolation and differential fractionation 
Animals of the species Rattus norvegicus, strain Sprague-Dawley were used 
for this study. Rats were bred and cared for at the UCL Biological Services Unit 
where rats were euthanised following the code of practice under Schedule 1 
procedures approved by ASPA (Animals Scientific Procedures Act 1986). 
 
2.5.1:  Rat Heart 
 a. Neonatal rat hearts 
The isolation of rat hearts was performed as follows: hearts of neonatal (1-3 
days old) Sprague-Dawley rats were dissected and briefly washed in PBS. The 
hearts were finely minced and immediately transferred into either cold SET buffer 
(0.25M sucrose, 1mM EDTA, 10mM Tris-HCl pH 7.4) for differential fractionation, 
RIPA buffer [150mM NaCl, 1%(v/v) Triton X-100, 0.5% sodium deoxycholate, 
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0.1%SDS and 50mM Tris/HCl (pH 7.5)] for western blot analysis or RNA lysis buffer 
(NBS Biologicals) for RNA extraction. 
 
 b. Adult rat hearts 
The procedure of differential fractionation of rat hearts was adapted from 
previous studies77,121. Adult rat hearts (~6 months old) were removed and placed 
onto a weighing boat with cold (4°C) isolation medium TSE buffer ( 220mM 
Mannitol, 70mM Sucrose, 5mM Tris-HCl pH7.4, 2mM EGTA) (+/-) subtisilin (0.4 
mg/mL Sigma protease XXVII, P5380 previously referred to as nagarse) 10mL per 
gram of heart. Subtisilin is a protease which allows the release of the embedded 
mitochondria. Usually, each heart weighed about 1.25g. Using tweezers, hearts 
were squeezed gently to remove blood then perfused through the aorta briefly with 
x2 5mL of cold TSE to remove any residual blood. This was followed by perfusion 
with 5ml of TSE (+/-) subtilisin.  Hearts were washed on weighing boats with clean 
TSE then dried by gentle pressing against filter paper. All non-ventricular tissue was 
trimmed off and clean hearts were transferred into a falcon tube filled with TSE and 
taken to the lab. 
 
The ventricular pieces were homogenised thoroughly in TSE (0.4 mg/mL +/- 
10mL/g subtilisin) in the motor driven pestle homogeniser. The homogenate was 
centrifuged at 850g for 5minutes at 4ºC. The supernatant was carefully decanted 
into a clean cold tube. This was the whole cell extract (WCE) (Figure 2.5.A). An 
aliquot (1-3 mL) of WCE was kept with the addition of protease inhibitors (1:100) at -
80 ºC.The crude mitochondria were obtained by centrifugation of the WCE at 9500 g 
for 15 minutes at 4ºC. The supernatant (Microsomes + Cytosol) were kept aside on 
ice while the pellet was gently washed twice by swirling with 2 mL of TSE (+prot. 
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inh.) to remove a variable fluffy layer. The mitochondrial pellet was resuspended 
and homogenised in a glass tube diluted to 40mL of TSE and centrifuged again to 
obtain clean crude mitochondria (Figure 2.5.B).  
 
The supernatant obtained after centrifugation of the WCE (Microsomes + 
Cytosol) was centrifuged once more on a separate tube to pellet any residual 
mitochondria. The supernatant was recovered and centrifuged at 100000g for 1hour 
at 4oC. The microsomal fraction composed mainly by endoplasmic reticulum (ER) 
was the pellet which was resuspended in TSE buffer while the cytosolic fraction was 
the supernatant (Figure 2.5.C). 
 
To separate crude mitochondria into Pure Mitochondria and Membrane 
Associated Membranes (MAM), a Percol gradient was prepared following a previous 
study121. First, crude mitochondrial pellets were resuspended and homogenised in 
12mL of TSE buffer. Two identical tubes were prepared with 8mL Percol buffer 
(11.2mL TSE and 4.8mL Percol) and slowly added 5 mL homogenised Crude 
Mitochondria. Tubes containing the Percol gradients were centrifuged at 95000g for 
30 minutes in a swing out Kontron rotor TF41. The top fraction obtained after 
centrifugation corresponded to the MAM fractions which were removed first and 
transferred to a clean centrifugation tube followed by the bottom fraction 
corresponding to the pure mitochondrial fraction. Both fractions were centrifuged at 
9500g for 15 minutes to pellet mitochondria. The MAM fraction was further 
centrifuged at 100000g for 1 hour (Figure 2.5.D). The protein content of all fractions 
was measured by BCA assay. 
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Figure 2.5: Flow chart of differential fractionation of rat tissue as described in 
Section 2.5.1.b.  
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2.5.2 Rat Brain and Liver 
Rat Brain and Liver tissue was isolated alongside the heart dissection of rats 
and cellular fractions were obtained as exactly as described in section 2.5.1.b 
without any proteases in the isolation buffer (TSE). 
 
2.6: SDS-PAGE Gel Electrophoresis and Western Blotting 
 
2.6.1: Principle 
The technique used for analysis of protein expression on the different 
samples was Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE) which separated proteins according to their molecular weight. Protein 
samples were boiled in SDS/PAGE sample buffer containing 10% (v/v) glycerol, 
62.5 mM Tris-HCl pH 6.8, 2% SDS, 80 μg.mL-1 bromophenol blue and 5% β-
mercaptoethanol to denature proteins. SDS binds tightly and evenly to the uncoiled 
polypeptide chain so that the charge-density along its length is approximately equal. 
The reducing agent β-mercaptoethanol breaks disulphide bonds, disrupting protein 
tertiary structure. SDS was also present throughout the acrylamide gel and running 
buffer, ensuring the proteins remain as denatured monomers. The negatively 
charged proteins travelled down the acrylamide gel towards the positive electrode 
induced by electric voltage. 
 
Western blotting was the technique used for transferring the electrophoresed 
proteins by SDS-PAGE to a polyvinylidene difluoride (PDVF) membrane for 
immuno-detection and autoradiography.  
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2.6.2: Procedure overview 
After cell harvesting (Section 2.4.2.d.) and tissue isolation (Section 2.4.), 
50µg of sample mixed with SDS sample buffer was denatured at 95oC and loaded 
into 1.5mm Tris-glycine gels (12% acrylamide-bis) for electrophoresis at 130V for 90 
min in Running buffer (25mM Tris, 0.2M Glycine, 0.1% SDS). Protein separation in 
the gel was wet transferred on to PVDF membranes overnight at 30V in Blotting 
buffer (25mM Tris, 0.2M Glycine, 1% Methanol). Non-specific protein binding was 
blocked with 5% milk in PBS-Tween for 1 hour at RT. PVDF membranes were then 
probed with specific antibodies diluted in blocking buffer (as indicated in the figure 
legends), for 3 hours at RT or at 4°C overnight. Chemiluminescent detection was 
accomplished with Western Blotting reagent ECL (GE Healthcare). Membranes 
were exposed using a LAS3000 Luminescent Image Analyser and the images were 
analysed using AIDA software. 
 
a. SDS-PAGE gels 
Most of the protein expression analysis was done using casted gels in a Bio-Rad 
mini-gel casting apparatuses. The percentage of acrylamide in the resolving gel 
depended on the size of protein that needed to be analysed. The larger the protein 
of interest, the lower the percentage of acrylamide in the resolving gel. In this study, 
12% resolving gels were mostly used. However, gels with other acrylamide 
percentage were sometimes used and they are annotated in the figure legends. To 
make up resolving gels, a mixture of distilled water, 40% Acrylamide/Bis solution 
(BP14021, Fisher Scientific), 1.5M Tris pH 8.8 and 10% SDS was made in a glass 
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conical flask then, immediately prior to cast the gel, 10% w/v APS (Ammonium 
persulphate) and 1% TEMED (N,N,N',N'- tetramethyl ethylenediamine) were added 
to the mixture to allow the gels to set. Using a disposable pastette, the gel mixture 
was poured between two glass plates (one smaller than the other) separated by 
1.5mm to about 1cm below the edge of the smaller plate. The gel mixture was 
overlaid with 500μL water-saturated 1-isobutanol to exclude oxygen and allow 
acrylamide polymerisation. 
 
Once the resolving gels set at room temperature or in an incubator, the 
isobutanol was removed from the apparatus, and the top of the gel dried by tapping 
with blotting paper. The stacking gel was a 4% Acrylamide mixture prepared 
alongside the resolving gel mixture (Distilled water, 40% Acrylamide/Bis solution 
(BP14021, Fisher Scientific), 1M Tris pH 6.8 and 10% SDS) and 10% w/v APS 
(Ammonium persulphate) and 1% TEMED were added just before pouring. Next, the 
stacking gel mixture was poured on top of the resolving gel. A 10 or 15-well comb 
was then positioned in the stacking gel and set at room temperature. 
 
Gradient gels 
NuPAGE Novex 4-12% Bis-Tris Gel 1.5mm, 10 well (Invitrogen, NP0335), 
were used in an XCell SureLock MiniCell for resolution of proteins of a range of 
molecular weights. The apparatus was assembled following the manufacturer’s 
instructions. The gel was run at 200 V for 35 mins, in NuPAGE MES SDS Running 
Buffer (Invitrogen NP0002). 
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Samples were prepared using NuPAGE® LDS Sample Buffer (4X) (NP0007) 
was used to prepare protein samples for denaturing gel electrophoresis with 
NuPAGE® Novex® gels. NuPAGE® LDS Sample Buffer contains lithium dodecyl 
sulphate, pH 8.4, which allows for maximum activity of the reducing agent. 
 
b. SDS-PAGE running conditions 
Samples were loaded in the well of the acrylamide gels alongside 8μL molecular 
weight markers to allow the determination of protein molecular weight, 
PageRulerTM Plus Prestained Protein Ladder (SM1811 or SM1812, Fermentas).  
After sample loading, the gel was run at 130 V for 90-95 mins or until the dye 
front reached the bottom edge of the gel. The apparatus was then dismantled and 
the stacking gel was carefully cut from the rest of the gel then placed into either 
distilled water for Coomassie staining or blotting buffer for western blotting. 
 
c. Coomassie staining of gels 
To visualise the purity of recombinant proteins or protein separation efficiency, 
electrophoresed gels were stained in Coomassie blue stain (0.1% (w/v) Coomassie 
blue R250, 40% methanol, 10% acetic acid, 50% distilled water) and destained with 
a mixture of 40% methanol, 10% acetic acid and 50% distilled water. Usually, the 
stain and destain mixtures were made up in 2 L amber bottles and stored at room 
temperature.  
 
Prior to staining, the gel was washed briefly in distilled water in a small plastic 
box  covered with cling film then the Coomassie stain was poured into the box to 
completely submerge the gel into it. There were two methods of staining: one 
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involved overnight incubation in the stain at room temperature on a rocker; the other 
one used a microwave to warm up the gel in stain for ~60 seconds to encourage the 
gel to take up the solution and then incubated in the stain at room temperature for 
20 minutes on the rocker. For destaining, the gel was briefly washed in distilled 
water, then incubated in destaining mixture with a small piece of sponge which took 
up the excess stain. The destaining mixture was replaced several times until the 
protein bands were clearly visible.  
 
Once the destaining was complete by either method, the gel was washed in 
distilled water and the protein bands imaged using a Fujifilm LAS-3000 imaging 
device, and quantified using AIDA software.  
 
d. Western Blotting and antibody probing 
PVDF membranes were prepared and equilibrated while electrophoresis was 
under way. To activate the membranes, they were soaked in 100% methanol until 
they turned translucent followed by a wash with distilled water. To equilibrate the 
PVDF membranes, they were left in blotting buffer at 4ºC until required together with 
pieces of blotting paper and filter sponges (2 per membrane). 
 
The blotting sandwich was assembled in blotting buffer in the following order: 
sponge, blotting paper, gel, PVDF, blotting paper and sponge. The sandwich was 
placed inside the Bio-Rad Mini Protean tank. A small magnetic stirrer was placed 
into the tank, and an ice block placed alongside the blot transfer unit in the tank. The 
tank was then placed onto a magnetic stirring device and filled up with Blotting 
buffer. The lid was placed in the tank, with the electrodes appropriately aligned and 
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connected to the power pack. Blot transfer was carried out at 30 V overnight or 60 V 
for 4 hours. 
 
e. PVDF Membrane Blocking 
After the blot transfer had finished, the blotting apparatus was dismantled and 
the PVDF membrane was submerged in phosphate-buffered saline- tween (PBS-T; 
PBS: 20mM phosphate buffer pH 7.0 [10 mM Na2HPO4, 2mM KH2PO4], 300mM 
NaCl and 0.05% Tween20). The detergent Tween20 was added to the buffer to help 
remove non-specifically bound material. The membrane was then stained in 
Ponceau solution until the protein bands were visible to asses transfer efficiency 
and immediately washed in PBS-T. The blocking buffer (5% non-fat milk-PBS-T) 
was used to improve the sensitivity of the assay by reducing background 
interference and improving the signal to noise ratio. The membrane was then 
blocked by incubation at room temperature in for 1 hour.  
 
f. Primary antibody incubation 
Once blocking was completed, the appropriate primary antibody (Table 2.7 and 
Table 3.1) was diluted in blocking buffer and the membrane incubated in the mixture 
on a tube roller for 2 hours at room temperature or overnight at 4°C. 
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Table 2.7: Primary antibodies used for Western blotting.  
Antigen 
(Name) 
Function 
In the study 
Manufacturer; 
Cat. No. or 
Reference 
Species 
Dilution 
for WB 
Expected 
Molecular 
weight 
(kDA) 
14-3-3 pan 
 
Cytosolic 
marker 
Santa Cruz 
Biotech; sc-629 
Rabbit 
 
1:1000 28 
c-Myc-Cds1/2 
Transfection 
efficiency 
Santa Cruz 
Biotech; (C19) sc-
788 
Rabbit 1:1000 55 
Calnexin ER marker 
ENZO; ADI-SPA-
865-D  
Rabbit 1:1000 90 
Cds1 
Protein 
expression 
Novusbio; 
H0001040-M01 
Mouse 1:100 55 
COX IV 
Mitochondrial 
marker 
Cell Signalling;  
#4844 
Rabbit 1:1000 
 
17 
Cytochrome C 
Mitochondrial 
marker 
Santa Cruz 
Biotech; (6H2) sc-
13561 
Mouse 1:1000 15 
FLAG-RdgBβ 
(DDK) 
Transfection 
efficiency 
OriGene Tech; 
TA50011 
Mouse 1:1000 50       
GRP75 
Mitochondrial 
marker 
BioLegend; 
#818801 
Mouse 1:1000 75 
Mitofusin 2 
Outer 
mitochondrial 
marker 
Abcam; ab56889 Mouse 1:1000 75 
PITPα 
(674) 
Protein 
expression 
Morgan et al., 
2004 
Rabbit 1:1000 36 
PITPβ 
(1C1) 
Protein 
expression 
Morgan et al., 
2006 
Mouse 1:1000 36 
Cardiac Troponin I Cardiac marker 
Santa Cruz 
Biotech; (H-170) 
sc15368 
Rabbit 1:100 28 
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g. Primary antibody detection 
The primary antibody recognised the target protein in a Western blot however it 
is not directly detectable. Therefore, tagged secondary antibodies were used 
depending upon the species of animal in which the primary antibody was raised. If 
the primary antibody was a mouse monoclonal antibody then the secondary 
antibody used was Anti-mouse IgG, peroxidase-linked whole antibody (from sheep) 
affinity purified general purpose reagent (ECL #NXA 931). All rabbit polyclonal 
antibodies were detected using Anti-Rabbit IgG (whole molecule)-Peroxidase 
produced in goat, affinity isolated antibody adsorbed with human IgG (Sigma-
Aldrich; Catalogue Number A0545). Secondary antibody incubation was done after 
the membrane was washed with PBS-T three times for around 5 minutes each on 
the tube roller once the period of incubation with primary antibody had finished.  
 
 
h. Blot exposure and imaging 
Following secondary antibody incubation, the membrane was washed five times 
with PBS-T for 5 minutes each on the tube roller. For exposure, the membrane was 
placed into a plastic pocket cut to size and a 1:1 mixture of ECL or ECL Advance 
solutions (ECL Western Blotting Detection Reagents, GE Healthcare) was pipetted 
onto each membrane so that it was completely covered. The top leaflet of the plastic 
pocket was placed over the membrane avoiding bubble formation, and the 
membrane incubated in the solution for one to three minutes. Excess liquid was 
then wiped out from the pocket and from the membrane using absorbent paper. The 
chemoluminescence was measured using a LAS-3000 imaging system. Protein 
bands were quantified using AIDA software. 
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i. Stripping of western blots for re-probing 
 PVDF membranes could be stripped of the probed antibody and reused to look 
for other proteins. For re-probing, the western blotted membrane was rinsed with 
PBS-T, then it was heat-sealed into a polythene bag along with 10 mL stripping 
buffer (0.2 M glycine-HCl pH 2.5, 0.05 % tween-20, 100mM β-mercaptoethanol). 
The bag was immersed horizontally in a water bath pre-heated to 80°C for 20 mins. 
After incubation, the membrane was removed from the polythene bag and washed 
several times with PBS-T.  
 
2.6.3: Production of RdgBβ sp1-specific polyclonal antibody 
The custom-made antibodies against RdgBβ already available at the 
laboratory included the rabbit polyclonal antibodies Ab:101 and Ab:218. Ab:101 was 
made against two internal peptides of RdgBβ common to both rodent and human 
splice variants sp1 and sp241 while Ab:218 was made against the full length of the 
protein. Peptide synthesis and immunisations were performed by Eurogentec. In 
addition, the rabbit polyclonal anti-human RdgBβ (Rb59) was a gift from Dr. 
Tavazoie from the Rockefeller University, New York, USA90. 
 
Four additional anti-RdgBβ polyclonal Antibodies were commissioned. 
Antibodies Ab:R1 and Ab:R2 were produced in two rabbits by 4 immunisations one 
every 70 days with the peptide from Hu-RdgBβ sp1 (NCBI ref Q9UKF7.2). Peptide 
synthesis, immunisation and affinity purification was performed by Genosphere 
Biotechnologies. Antibodies Ab:522 and Ab:523 were manufactured by Eurogentec 
on their Rabbit- 3 months program.  
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a. Antibody affinity purification 
The process of affinity purification of the sera Ab:101 and Ab:218 was 
divided into two stages. The first step involved the immobilisation of the antigen (8-
10mg of Recombinant RdgB-sp1) to 2ml of AminoLink coupling gel (Thermo 
Scientific) in a 10ml column. The gel was equilibrated with coupling buffer (0.1M Na 
Phosphate buffer pH7 +0.05%NaN3). A mixture of 5ml of antigen and 1ml of 
reductant buffer (1M NaCNBH3 in 0.01M NaOH) was incubated with the gel on a 
rotating wheel overnight at 4˚C. Later, the aqueous material was separated and the 
gel was quenched with 1M Tris-HCl and reductant buffers.  
 
The second step, affinity purification, started with the equilibration of the 
antigen-coupled gel with PBS/Na3. Then, 5ml of crude antibody serum diluted in 
PBS/Na3 (1:1 ratio) was added to the gel and incubated on a rotating wheel 
overnight at 4˚C. Following incubation, the column was centrifuged at 600rpm for 5 
minutes to pellet the gel. The purified antibody was eluted from the gel twice, first 
with 5ml of 0.1M Glycine (pH 2.5) then with 5ml of 0.1M Triethylamine (TEA; pH 
11.5). Both elutions were concentrated and their buffers exchanged to PIPES buffer 
separately by centrifugation at 3800 rpm for 90min at 4˚C using Centriprep YM-10 
(Millipore) until 500l of each elution was obtained. Finally both elutions were 
mixed together and 50l aliquots were stored at -20˚C. The bicinchoninic acid (BCA) 
assay was used to determine the purified antibodies concentration. Ab:101 at 
1.1mg/ml and Ab:218 at 0.8mg/ml. 
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b. Dot blotting 
Optimisation of RdgBβ antibodies, dilution ratios and blocking buffers for 
immunoblotting was performed by dot blotting. PVDF membranes were activated by 
methanol followed by ddH2O washing and then placed on PBS wet filter paper. Each 
sample (2µl) was dotted on marked squares (1cm x1cm) on the membrane and then 
allowed to air dry. Analyses of different blocking buffers (3% and 5% milk, BSA and 
goat serum in PBS-Tween) and antibody concentrations (1:1000; 1:500; 1:100 and 
1:50), were performed by incubation of membranes in blocking buffer for 1 hour at 
RT, followed by incubation in antibodies prepared in blocking buffer for 3 hours at 
RT. Secondary anti-rabbit antibody incubation followed several washes with PBS-
Tween. Antibody reactivity was analysed by chemiluminescent detection (Figure 
2.6).  The optimal blocking buffer for most antibodies was found to be 5% milk in 
PBS-T.  
 
 
Figure 2.6: Dot blotting testing blocking buffer and antibody dilutions. 
Representative examples of affinity purified antibodies optimisation for 
immunoblotting. 
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2.7: Immunofluorescence microscopy 
 
For visualisation and analysis of cell morphology, H9c2 cells were subjected to 
immunofluorescence microscopy. The cells were grown, treated and fixed directly in 
multi-well plates on coverslips. After washing the coverslip with PBS, the cells were 
fixed with 4%(w/v) paraformaldehyde in PBS for 15 minutes at room temperature.  
 
The fixative mixture was removed followed by three washes with PBS for 5 
minutes each. To permeabilise the cells, PBS- 100mM Glycine buffer (plus 0.2% 
TritonX-100) was applied for 10 min at RT followed by washing with PBS and 
incubation with the fluorescent conjugates DAPI (1:5000) and TRITC labelled 
Phalloidin (1:2000) for 30 minutes at RT in the dar to prevent fluorescence 
bleaching.  
 
Subsequently, coverslips were washed in PBS and finally rinsed in water prior to 
mounting on a microscope slide with mowiol [13% (w/v) in 0.1 M Tris pH 8.5 with 
33% glycerol (w/v)]. Fluorescence was recorded by excitation at 488 nm or 546 nm 
with a light source (Excite 120) using an Olympus IX80 microscope fitted with x20 
and x40 air objectives. Images were acquired using a charge-coupled device 
camera (ORCA) controlled with CellF software (Olympus). 
 
 
2.8: Cds activity assay 
 
CDP diacylglycerol synthase (Cds) activity on isolated tissue and cellular 
samples was determined by measuring the level of incorporation of [3H]-CTP into 
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CDP-DAG using external phosphatidic acid (PA). Assay conditions were assessed 
and optimised based on previous studies29,119.  
 
The isolated samples, source of Cds, were resuspended in CDS lysis buffer 
(50 mM Tris-HCl [pH 8.0]; 50 mM KCl; 0.2 mM EGTA, and 1/100 (v/v) protease 
inhibitor cocktail). If protease inhibitors were added, the buffer was kept at -20°C. All 
other components were diluted in CDS Assay buffer (50mM Tris-HCl [pH 8.0]; 100 
mM KCl; 5.1mM Triton X-100; 2mg/mL BSA and 0.25mM DTT). The total volume 
per assay was 100μL which contained 50μg of the source of the enzyme, 200µM PA 
(Grade 1 Lipid Products Ltd, Table 2.8), 20mM MgCl2 and 2µM CTP which was 
prepared as a mixture with 2.5μCi [3H]-CTP (ARC #ART0343@1mCi/mL; Specific 
activity 20Ci/mmol).  
 
The components of the assay were added in the following order: first the 
sample in triplicate including a sample containing BSA as negative control 
background, then immediately prior to PA addition, the MgCl2 was mixed with the 
PA liposomes and later added to each sample, the reaction was initiated by the 
addition of CTP (radiolabelled +cold) to all samples. The sample mixtures were 
prepared on ice, once the CTP was added the samples were then incubated in a 
water bath at 30°C for 10min.  
 
The reaction was terminated by transferring the samples to ice and adding 
375μL MeOH:CHCl3:HCl (2:1:0.05) followed by the addition of 125µl CHCl3 and 
125µl dH2O which separated the samples into two phases: the chloroform soluble 
(lower) and water soluble (top). The samples were centrifuged at room temperature 
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for 2 min and the lower phase was transferred to a new Eppendorf tube. To remove 
contaminating water-soluble radioactivity, 475µL of synthetic top phase solution 
made of a mixture of MeOH:H2O (5:4.5) was added to the chloroform phase, 
vortexed and centrifuged. The lower chloroform phase was transferred onto 
scintillation vials then left in a fume cabinet for the solvent to evaporate overnight. 
Once the chloroform evaporated, 250µL MeOH was added to each vial, vortexed 
and scintillation fluid was added. Data was measured in disintegrations per minute 
(DPM) in a Packard Tricarb 2500 scintillation counter. Cds activity was expressed 
as an average of the triplicate DPM counts subtracted of the average background 
counts obtained from BSA samples. 
 
2.8.1: Assay characterisation 
 
The addition of 5.1mM (1.7%) Triton X-100 to the assay buffer in order to 
solubilise cellular membranes considerably increased the activity measurement 
(Figure 2.7.A). Furthermore, the requirement for specific species of exogenously 
added PA to the assay was considered (Figure 2.8.B). Egg PA (Lipid Products Ltd; 
Table 2.8) showed significantly higher Cds activity over di-palmitoyl PA in Cos7 cells 
transfected with human myc-Cds1 and Cds2.  
 
In addition, endogenous Cds enzyme in rat heart pure mitochondria, 
obtained as described on Section 2.5.1.b, showed an increase in the level of 
incorporation of 3H over time (0-11.5 minutes; Figure 2.8.A), as well as with 
increasing protein content per assay (0-200μg; Figure 2.8.B). 
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Table 2.8: Fatty acid composition of phosphatidic acid used in the Cds activity 
assay and PA transfer* 
 
Fatty acid 
Name 
 
sn-1 
Notation 
% in Phosphatidic acid 
(PA Grade1; Lipid 
Products) 
Palmitic  16:0 32.1 
Palmitoleic 16:1 2.1 
Stearic 18:0 11.7 
Oleic 18:1 36.2 
Linoleic 18:2 12.5 
Arachidonic 20:4 5.5 
Molecular weight 650 g/mol 
 
(*): As advised by the manufacturer. 
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Figure 2.7: Cds activity assay characterisation – Triton X 100 and Source of 
PA. 
[A.] Triton-X 100 requirement: 100μg of rat heart mitochondria obtained by 
differential centrifugation of rat hearts was incubated in Cds assay buffer ± 5.1mM 
(1.7%) Triton-X 100 for 15 minutes at 30oC. Bars show mean ± SEM from 2 
experiments (N=4).  
[B.] Source of exogenous PA: Cos7 cells were seeded at 1x106 cells/mL in T-75 
flasks and after 16 hours culture, and transfected by electroporation with empty 
vector pcDNA, human Myc-Cds1 or Myc-Cds2 plasmids for 48 hours. Cells were 
harvested and 100μg of lysates were assessed for Cds activity in Cds assay buffer 
with 200μM Di-palmitoyl PA or Egg PA for 10 minutes at 30oC. Bars show mean ± 
SEM from 1 experiment (N=2).  
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Figure 2.8: Cds activity assay characterisation – Time and Protein 
concentration dependency. 
Cds activity of endogenous Rat Heart Pure Mitochondria compared to BSA.  
[A.] Time-dependency: 10μL of sample was removed at 1 minute intervals from the 
incubation. Results from one experiment (n=1).  
[B.] Protein concentration dependency: Assay was performed for 10 minutes at 
30oC. N=2 from one experiment. 
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2.9: PIS activity assay 
 
The assay to determine Phosphatidylinositol Synthase activity on biological 
samples was an adaptation of the Cds activity assay described in Section 2.7. This 
assay measured the turnover of [3H]-PI in cells as a consequence of PIS activity.  
 
The PIS Assay buffer contained 50 mM Tris-HCl (pH 7.4) and 2 mM 
MnCl2.The total volume per assay was 100μL which included 50μg of the source of 
the enzyme plus a mixture of 10µM Myo-Inositol+ 2.5μCi [3H] Myo-Inositol diluted in 
PIS assay buffer.  
 
The assay was then performed exactly as described on Section 2.7 with 
different incubation settings. PIS enzyme reactions were allowed for 15 minutes at 
37°C. 
 
2.10: PLC assay 
 
The Phospholipase C (PLC) assay measured the amount of radiolabelled [3H] 
Inositol phosphates as a result of PLC stimulation of radiolabelled cells as described 
previously27.  The buffer used for the assay, HEPES buffer (137mM NaCl, 2.7mM 
KCl; 20mM HEPES; 2mM MgCl2; 1mM CaCl2; 5.6mM; 1mg/mL; 10mM LiCl; pH 
7.2), was prepared fresh on the day of the experiment and was kept warm at 37°C. 
Cells were equilibrated in the buffer prior to incubation in the stimulant at 37°C for 
one hour. Each condition was set up in duplicate. 
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After stimulation, the cell plates were removed from the incubator and placed on 
ice. The buffer was replaced with 1000µl cold MeOH each well to stop the reaction. 
The cells were then scraped from each well using a cell scraper followed by a final 
wash with 900μl distilled water which was also transferred to the solvent tube. To 
separate the aqueous from the chloroform soluble components of the cells, 1mL 
chloroform was pipetted into each solvent tube following centrifugation at 1200rpm 
for 5mins.  
 
The isolation of Inositol phosphates was achieved using glass Pasteur pipettes 
containing Dowex 1x8 anion exchange resin. After equilibration with 2 mL 2M 
ammonium formate / 0.1M formic acid, the columns were filed with 1.5mL of the 
aqueous top layer from each solvent tube. To elute unbound [3H]-inositol the 
columns were washed with water followed by 5mM sodium tetra borate / 60mM 
sodium formate to elute GPI. These elutions were let to run through. 
 
Finally, to elute total inositol phosphates from the columns, each Dowex was 
transferred to scintillation vials. Elution was achieved by the addition of 1M 
ammonium formate/0.1M formic acid. Ultima FLO scintillation fluid was added to 
each vial to cope with high salt content and radioactivity was counted on the liquid 
scintillation counter. Separately, the chloroform phase from each tube was 
transferred to scintillation vials and counted to obtain total lipid input. For data 
analysis, radioactive counts (dpm) of both top and bottom layers of each solvent 
tube was adjusted accordingly. A mean of the duplicate inositol phosphate values 
was calculated (dpm) and expressed as a proportion of the all the inositol 
phosphates produced in control-transfected cells treated with the same stimulation. 
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2.11. Data presentation and statistical analysis.  
 
All data in this thesis is presented using descriptive statistics as the mean 
value of the measurements ± the standard error. Each figure indicates the sample 
size, the number of experiments and relevant details of calculations. The statistical 
significance of the observations between two samples was evaluated using the 
Student’s t-Test (Paired Two Sample for Means) using Microsoft Excel software. P 
values below 0.05 were considered to be significant and were only included if data 
represented more than two experiments.   
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RESULTS AND DISCUSSION 
 
 
CHAPTER 3: Analysis of the Phosphatidic Acid (PA) transfer activity of 
RdgB proteins. 
 
 
 3.1. Introduction 
 
By studying the structure and biochemical properties of proteins, it is 
possible to find indications of their physiological function. Despite collaborative 
efforts from my research group, there are still no crystal structures available for any 
Class II PITP (RdgB) proteins to date. However, the structures of PITPα and PITPβ, 
with or without their lipid cargo, have been described.96,109,122,129 Since the residues 
directly involved with the phosphate moiety and the inositol headgroup for PI binding 
are conserved in both Class I and RdgB proteins, multiple sequence alignment of 
the PITP domains allowed  me to make predictions and comparisons between them 
(Figure 3.1). In addition, it was recently reported that RdgB proteins differ from 
PITPα and PITPβ in their phospholipid binding properties: Class I bind 
phosphatidylinositol (PI) and phosphatidylcholine (PC) whilst Class II bind PI and 
phosphatidic acid (PA)40. However, the biochemical basis of the PA transfer property 
of RdgB proteins remains to be fully elucidated. 
 
RdgBβ was the first protein to be reported to transfer PA recently using a 
pyrene-labelled phospholipid quenching assay in vitro 40. However, this assay was 
made in collaboration with another group and pyrene-labelled PA is not 
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commercially available. Therefore, I adapted another transfer assay to analyse [3H]-
PA transfer activity of recombinant proteins. The assay used rat liver mitochondria 
as acceptor compartments and [3H]-PA labelled liposomes (PC: PA; 98:2) as donor 
compartments. This Chapter describes initially, an analysis of the PA transfer 
activity of the Wild Type (WT) PITP domains of Class II (RdgB) proteins compared 
to Class I PITPs using the new adapted assay to confirm previous observations with 
PITPα and Hu-RdgBβ; and further characterises the PA transfer activity of PITPβ 
and the PITP domain of RdgBα proteins40. 
 
In addition, a mutational analysis was performed in an attempt to identify the 
residues within the PITP domain that are essential for PA transfer. The recombinant 
mutants of the PITP domain of Dm-RdgBα tested include three of those that are 
unable to bind PI (Point mutations: T59A/E, K61A and N90F; numbers  according to 
the mouse PITPα sequence; Figure 3.1 and Figure 3.2)125; followed by two mutants 
unable to contact the phosphate moiety of the phospholipid (Point mutations: Q22A 
and T97A). An analysis of the mutant that shows defective membrane binding 
(YW203/204AA) is also described, and the Chapter concludes with a discussion of 
the results and offers suggestions for future studies.  
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Figure 3.1: Multiple sequence alignment of PITPs and the PITP domain of 
Drosophila RdgBα.  
The code on the left of each protein is the NCBI sequence reference number. The 
rectangles highlight the residues described in Section 3.3.1; inositol ring binding 
(T59, K61, E86 and N90; mouse PITPα numbering); Section 3.3.2 phosphate moiety 
binding (Q21/22, T97, T113 and K202); and Section 3.3.3 membrane association 
(WW/203 204; YW/210 211). The circle highlights the basic amino acids mentioned 
in Section 3.4. Sequence alignment obtained with Clustal Omega (1.2.1) online tool 
which colours the residues according to their physicochemical properties: Red 
(Small, hydrophobic); Blue (Acidic); Magenta (Basic); Green (Hydroxyl, sulfhydryl, 
amines). * (asterisk, fully conserved residue); : (colon, conservation between groups 
of strongly similar properties); and . (period, conservation between groups of weakly 
similar properties). 
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 Figure 3.2: PITPα structure binding PI 
[A.] Localisation of the residues responsible for the PI (magenta) interaction within 
the PITPα structure. The figure was taken from Cockcroft 2007.19 
[B.] Overall fold structure of PITPα binding PI. Functional regions are lipid-binding 
core (blue), regulatory loop (green), C-terminal region (red), and lipid exchange loop 
(orange). The figure was taken from Tilley et al 2004.109 
 
Table 3.1: List of the recombinant protein mutants analysed in this study.  
Characteristic of the PITP domain PITPα Mutants* Ref. 
Residues in contact with the inositol ring of PI 
K61A 
N90F 
T59A & T59E 
[125] 
Associated with phosphate moiety binding. 
Q21A  
T97A 
N/A 
Assist in membrane docking YW203/204AA [125] 
 
* This study used mutants of the PITP domain of Dm-RdgBα which sequence 
numbers differ from PITPα but they were kept throughout to avoid confusion. 
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3.2. The PA transfer capability is exclusive of Class II PITPs 
 
The ability of binding and transferring phosphatidylinositol (PI) and 
phosphatidylcholine (PC) is a characteristic of Class I PITPs (PITPα and 
PITPβ)97,109. On the other hand, Hu-RdgBβ, a Class II PITP, was recently reported 
to bind and transfer PI and phosphatidic acid (PA). The PA binding property was 
shared by other Class II PITPs including Human and Drosophila melanogaster 
RdgBα.40 To analyse the PA transfer activity of Class II PITPs (Human RdgBα and 
RdgBβ and Drosophila RdgBα), wild type recombinant proteins were tested for PA 
transfer activity at serial dilutions ranging from 1.5 to 200μg/mL using an in vitro 
assay where the radioactivity transferred from di-palmitoyl-[3H]-PA liposomes onto 
rat liver mitochondria was measured.  
 
The results are presented as the % of radiolabelled PA transferred from the 
total input per nmol of PITP. The amount of protein was converted from µg/ml to 
nmol using the molecular weight of each recombinant protein tested (Figure 3.3). 
PITPα, PITPβ and the PITP domain of Hu-RdgBα (residues 1-277) were 36kDa 
(g/mol). The PITP domains of Dm proteins was calculated as 38kDa (g/mol) and Hu-
RgdBβ as 45kDa (g/mol). 
 
Hu-RdgBβ showed increased PA transfer activity according to a rise in 
content from 0.01 nmol of protein transferring 3.4±0.5% to 20±3% achieved by 0.3 
nmol of protein and above. The other RdgB-PITP proteins (Dm-RdgBα and Hu-
RdgBα) demonstrated higher activity than RdgBβ. As little as 4x10-3 nmol of protein 
showed PA transfer activity and saturation was reached by 0.06 nmol of RdgBα. 
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The highest percentage of PA transferred was 24.5±1% of the total input. In clear 
contrast, recombinant Class I proteins, PITPα and PITPβ did not transfer PA at any 
concentration (Figure 3.4.A).  
 
To confirm the activity of the recombinant protein preparations, the PI 
transfer activity of two different batches of PITPα and Hu-RdgBβ was tested using a 
different in vitro essay which uses [3H]-PI from rat liver microsomes as donor 
compartment and PC:PI liposomes as acceptor compartment. The PI transfer 
activity of PITPα was nearly twice the activity showed by Hu-RdgB (Figure 3.4.B). 
These data confirmed that all RdgB proteins can transfer both PI and PA125. 
 
Figure 3.3: Recombinant proteins used in this study 
Human PITPα, PITPβ, RdgBβ, the PITP domains of Human (Hu)-RdgBα (residues 
1-277) and of Drosophila (Dm)-RdgBα  (residues 1-281) including the mutants (Dm)-
RdgBα K61A and N90F were separated by SDS-PAGE and stained with Coomassie 
blue to demonstrate their degree of purity. The red boxes indicate the band at the 
expected molecular weight for each protein. 
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Figure 3.4: Comparison of PA and PI Transfer by Class I and II PITPs.  
 
[A.] PA transfer activity of recombinant wild type (WT) Class I proteins (PITPα and 
PITPβ) compared to the PITP domain of Class II [Human (Hu)-RdgBβ, Hu-RdgBα 
and Drosophila melanogaster (Dm)-RdgBα)] PITP proteins using [3H]PA-labelled 
PC:PA (98:2) liposomes as donors and rat liver mitochondria as acceptors.  
 
[B.] PI transfer of PITPα and RdgBβ. Two separate preparations [(1) and (2)] of 
recombinant proteins using [3H]PI-labelled rat liver microsomes as donor and 
unlabelled PC:PI (98:2) liposomes as acceptors.  
 
The transfer data (%) was calculated from the total input amount of radioactivity 
after substraction of the background radioactivity obtained when no recombinant 
protein was added. Data represents mean±standard errors of a minimum of 3 
experiments for PA transfer and 2 experiments for PI transfer.  
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Figure 3.4: Comparison of PA and PI Transfer by Class I and II PITPs. 
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3.3: PITP domain residues that may affect PA transfer activity of RdgB 
proteins. 
 
The difference in the phospholipid transfer properties of PITP proteins could 
lie within the PITP domain itself as RdgBs are only ~40% identical to the Class I 
PITPs. Based on the crystal structure of PITPα109, some of the residues of the PITP 
domain responsible for binding to the inositol ring of PI, the phosphate group of PI 
and for membrane binding were mutated by site-directed mutagenesis then 
expressed in E.coli and purified, as described in Section 2.3, to determine whether 
they influence PA transfer activity in RdgB proteins.  
 
For this mutational study I used Drosophila melanogaster (Dm) RdgBα 
mutants that were available in the laboratory excluding Dm-RdgBα Q21A and T97A 
which were mutated by Tim Ashlin. Hu-RdgBβ mutants did not purify in the 
quantities and quality seen for Dm-RdgBα mutants. However, the residues studied 
here are conserved in the PITP domain of RdgB protein which suggests that the 
results for Dm-RdgBα would be similar for all RdgB proteins (Figure 3.2.). 
 
3.3.1: PA transfer activity is unaffected in mutants unable of binding PI.   
A conserved property of the PITP domain of both Class I and Class II PITPs 
is the ability to bind and transfer PI in vitro. The crystal structure of PITPα identified 
the amino acid residues within the binding pocket  that are in contact with the 
inositol ring of PI by hydrogen bonds and are essential for both in vitro and in vivo 
activity (T59, K61, E86 and N90; mouse PITPα numbering). 109  The Dm-RdgBα 
single point mutants K61A, N90F and, two versions of T59 (T59A and T59E) were 
analysed for PA transfer activity and compared to the wild type protein using the 
assay described in Section 2.3. As negative control, PITPα was included.  
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The PA transfer of the mutant proteins was unaffected at saturating 
quantities (0.06 nmol and above). However lower levels of the mutant proteins 
K61A, N90F and T59E showed reduced transfer activity. The activity of the T59A 
mutant was unaffected at all concentrations125 (Figure 3.5). These results suggest 
that the residues of the PITP domain responsible for PI binding and transfer are not 
involved in PA transfer.  
 
3.3.2: Effect of mutation in residues of the PITP domain associated with the 
phosphate moiety binding. 
 
 The PITP family of proteins conserve the residues Q21, T97, T113 and K202 
which make contact with the phosphate moiety of phospholipids PI and PC as 
described previously109 Residue Q21 in RdgB proteins occupies position Q22 in 
PITPα and PITPβ (Figure 3.4).  To test whether these amino acids are required for 
PA transfer, two of the residues (Q21A and T97A) were mutated by site-directed 
mutagenesis of wild type Dm-RdgBα. After recombinant expression and purification 
of the proteins, the biochemical properties of these mutants were analysed. PI and 
PA transfer activity were assessed as described in Section 2.3.  
 
The PI transfer of mutant Dm-RdgBα T97A showed reduced activity and its 
PA transfer activity was unaltered compared to wild type Dm-RdgBα at allquantities 
tested (. On the other hand, Dm-RdgBα Q21A affected both PI and PA transfer 
activity. PI transfer was abolished and PA transfer was severely reduced (Figure 
3.5). These results suggest that the amino acid T97 is not involved in PA transfer; 
and Q21 although essential for PI transfer, it is important but not critical for the 
ability of the PITP domain of RdgB proteins to transfer PA in vitro.  
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Figure 3.5: PA Transfer activity of RdgB proteins does not require the 
residues that bind PI.  
 
PA transfer activity of recombinant wild type Drosophila melanogaster (Dm-RdgBα 
WT) PITP domain compared to mutants unable to bind PI (N90F, K61A, T59E and 
T59A) using [3H]PA-labelled PC:PA (98:2) liposomes as donors and rat liver 
mitochondria as acceptors. PITPα WT was used as negative control. Recombinant 
protein preparations were obtained by site directed mutagenesis followed by 
bacterial expression and purification. 
 
The transfer (%) was calculated from the total input amount of radioactivity removed 
from the background values Data represents averages and standard errors of a 
minimum of 3 experiments with different recombinant protein preparations.  
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Figure 3.5: PA Transfer activity of RdgB proteins does not require the 
residues that bind PI. 
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Figure 3.6: PI and PA transfer activity of RdgB protein mutated to bind the 
phosphate moiety. 
 
Phospholipid transfer activity of recombinant wild type Drosophila melanogaster 
(Dm-RdgBα WT) PITP domain compared to mutants unable to interact with the 
phosphate moiety (Q21A and T97A). Mutants obtained by site directed mutagenesis 
followed by bacterial expression and recombinant protein purification 
 
[A.] PA transfer assay using [3H]PA-labelled PC:PA (98:2) liposomes as donors and 
rat liver mitochondria as acceptors.  
 
[B.] PI transfer using [3H]PI-labelled rat liver microsomes as donor and unlabelled 
PC:PI (98:2) liposomes as acceptors.  
 
The graphs show the averages (%) and standard errors of 2 experiments obtained 
from the total input amount of radioactivity following substraction of the background 
radioactivity.  
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Figure 3.6: PI and PA transfer activity of RdgB protein mutated to bind the 
phosphate moiety.  
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3.3.3: Effect of the mutation affecting membrane interaction with the PITP 
domain. 
 
  Class I PITPs have been shown to dock to membranes via two tryptophan 
residues (W203 and W204) which are located at the lipid exchange loop of their 
structure (Figure 3.2). The WW203/204AA mutants failed to associate with the 
membranes and were inactive for PI transfer.98,109 In RdgBα proteins, one of these 
residues is replaced by tyrosine (YW) and, in RdgBβ, by valine (VW). The 
equivalent residues in Dm-RdgBα are at positions 210 and 211 respectively (Figure 
3.1). In this study, the PA transfer activity of Dm-RdgBα (YW/AA) was assessed 
using the assay described in Section 2.3.2 against the activity of the wild type 
protein and, as a negative control, PITPα was included.  
 
The [3H]-PA transfer activity by the YW/AA mutation protein was ~50% of the 
activity obtained with the wild type PITP domain of Dm-RdgBα protein regardless of 
the amount of protein in the assay (Figure 3.7). The results show an involvement of 
residues Y210/W211 in the PA transfer activity of RdgB proteins.   
 
Finally, I compared the outcomes of all recombinant proteins at a specific 
amount (0.03nmol). This quantity of transfer protein was analysed based on the 
saturation of activity that was measured at higher values. It is evident that the 
RdgBα proteins (Hu and Dm) exhibit the highest activity and all mutants a reduced 
activity. This observation suggests that the mutant proteins transfer PA at a slower 
rate. (Table 3.2 and Figure 3.8). 
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Figure 3.7: PA Transfer activity of the mutant YW210A / W211A. 
 
The PA transfer activity of the recombinant Dm-RdgBα PITP domain mutation 
Y210A/W211A was compared to the wild type (WT) domain using [3H]PA-labelled 
PC:PA (98:2) liposomes as donors and rat liver mitochondria as acceptors. PITPα 
WT was used as negative control. The mutant was obtained by site directed 
mutagenesis followed by bacterial expression and recombinant protein purification. 
The data was obtained from 2 experiments and calculated as percentage of the total 
input amount of radioactivity which had the background radioactivity substracted. 
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Table 3.2: PA transfer from total input by 0.03 nmol PITP proteins 
 
Figure 3.8: Comparison of PA transfer by PITP proteins (0.03 nmol) 
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3.4: Summary 
It was demonstrated in this study that Class II proteins, Hu-RdgBβ and the 
PITP domain of Human and Drosophila RdgBα, are capable of transferring 
Phosphatidic acid (PA) in vitro; and this property is not shared with Class I PITPs, 
human PITPα and PITPβ. The PA transfer activity of the RdgB PITP domains 
required much lower quantities compared to Hu-RdgBβ. Moreover the maximal 
activity achieved by RdgBα was greater than that achieved by RdgBβ (Figure 3.4.A). 
In contrast, PI transfer activity was observed for both classes of PITPs, as expected, 
since the residues that are essential for binding the inositol headgroup of PI are 
conserved in all PITPs (Figure 3.4). However, the PI transfer activity of PITPα was 
higher than the activity of Hu-RdgB (Figure 3.4.B) as reported previously40,41.  
On the mutational study of the PITP domain of Dm-RdgBα, I found that all 
the four mutated proteins (Dm-RdgBα T59A, T59E, K61A and N90F) showed PA 
transfer similar to the wild type protein up to saturation quantities. However the 
analysis of all proteins studied in this study at a specific low quantity (0.03nmol) 
showed the PA transfer activity was diminished for all mutants except T59A (Table 
3.2 and Figure 3.8). Furthermore, the mutation of two of the residues studied within 
the PITP domain of Dm-RdgBα that are in contact with the phosphate moiety of PI 
showed that the T97A mutant displayed reduced PI transfer while Q21A showed no 
PI transfer activity (Figure 3.5.B). PA transfer was unaffected by the T97A mutation 
but the Q21A mutation severely reduced transfer activity (Figure 3.6.A). Since in 
PITPα the residues Q22 and T97 are involved in the recognition of both PI and 
PC,109  the decreased PI transfer activity obtained in this study with the mutants was 
anticipated. The reduced PA transfer obtained with the mutant Q21A suggested that 
this residue is involved in PA transfer but not essential. The biochemical analyses of 
the other two residues that are in contact with the phosphate moiety of PI (T113 and 
K202) remain to be analysed. Finally, the PA transfer activity of the Y210A/W211A 
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mutant was compromised compared to the wild type PITP domain (Figure 3.7). This 
result suggested that association with membranes is not essential for PA transfer 
activity from RdgB proteins. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9: Flowchart summarising the results described in Chapter 3. 
Study of the Phosphatidic acid transfer activity of 
the PITP domain.  
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3.5: Discussion. 
 
This study was unable to find the critical amino acids within the PITP domain 
of Dm-RdgBα that participate in PA transfer in vitro. In the literature, there are few 
studies of proteins capable of intracellular PA transfer activity. For instance, Hu-
RdgBβ was the first protein to be described with PA transfer capability in vitro,40 and 
we recently reported that Dm-RdgBα is also a PA transfer protein from the findings 
of this thesis125. Additionally, the complex of Ups1 and Mdm35 was reported to 
transfer PA across mitochondrial membranes in yeast.26 Recently, the crystal 
structure of the Ups1-Mdm35 complex showed that the inner wall of the binding 
pocket  is amphiphilic and consists of several conserved basic amino acids (R25, 
K61 and K155) which were demonstrated to play essential roles in the PA transfer 
activity between liposomes in vitro.117  
 
Although no other proteins have been reported to transfer PA, sequence 
analysis of different PA binding proteins in mammalian cells has shown that they are 
diverse and share no apparent sequence homology but all contain at least one 
polybasic motif.5 Furthermore, the head group of PA was found to be an effective 
docking site for basic amino acids. For instance, PA showed higher affinity for lysine 
(K) residues followed by arginine (R) and histidine (H).66 Following this evidence 
while examining the sequence alignment of the PITP domain (Figure 3.1), I noticed 
that five of the residues in proximity to amino acid Q21 of the Hu-RdgBβ sequence 
are basic amino acids (K18, K28, H29, H31 and R36) and Hu-RdgBα contains three 
(K28, K29 R31). In contrast, positions 28 and 29 of PITPα andβ are occupied by 
glutamic acid (E) and alanine (A) and the only basic amino acid between residues 
18 and 36 is K31 (Figure 3.1). Since the interaction between PA and the PITP 
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domain is specific to Class II PITPs (Figure 3.3.A), it is plausible that one or all of 
the basic residues around Q21 could be essential for PA transfer. I tested this 
argument by analysing the PA transfer activity of the recombinant mutant PITPα 
A29K alongside Dictyostelium discoideum  Dd-PITP, which is homologous to 
PITPα103, with lysine at position 29 (K29). However neither of these proteins was 
positive for PA transfer (Data not shown). Nevertheless, it is still possible that the 
double basic amino acid sequence (K28K29) and surrounding positively charged 
residues of RdgB proteins are crucial for their PA binding and transfer activity. Until 
the crystal structure of any RdgB protein is obtained, the observations into their 
sequence presented here could be taken into consideration for future biochemical 
studies.  
 
.  
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CHAPTER 4: Characterisation of antibodies against RdgBβ in rat heart. 
 
4.1: Introduction 
 
RdgBβ transcripts are strongly expressed in the heart 39,104. However the 
physiological function of RdgBβ in cardiac tissue has not been elucidated. By 
studying the expression pattern of a protein it is possible to identify some clues to 
understand its behaviour and function. Therefore I sought to describe the 
endogenous protein expression of RdgBβ in rat heart by immunoblotting. A previous 
study identified that RdgBβ could be detected in rat heart cytosol using a rabbit 
polyclonal antibody generated in-house named Ab:101 as well as with a commercial 
antibody22. Ab:101 was validated using recombinant RdgBβ and overexpressed 
protein expression in Cos7 cells by Western blot. However, the endogenous protein 
was detected only when rat heart cytosol was subjected to gel filtration to 
concentrate the antigen and both antibodies identified multiple cross-reactive bands. 
I began the investigation by confirming the previous observations of Ab:101 in Cos7 
cells and recombinant RdgBβ followed by an assessment into the possibility of 
outcome improvement by affinity purification.   
 
In addition, this study includes the characterisation of another six non-
commercially available RdgBβ antibodies. Firstly, Ab:Rb59 is a polyclonal antibody 
reported in a recent study which identified RdgBβ as a gene targeted by the 
microRNA miR-126 in human breast cancer cells90. In addition, Ab:218 was another 
in-house made antibody available in the laboratory. Both antibodies (Ab:Rb59 and 
Ab:218) had not been characterised or validated for western blot analysis of rat  
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samples. The characterisation includes comparative evaluation of the sensitivity and 
specificity of antibodies Ab:Rb59,  Ab:218 and Ab:101 detection on recombinant and 
overexpressed RdgBβ using Cos7 cells. The H9c2 cell line which derives from 
embryonic rat ventricles was also assessed for endogenous RdgBβ expression 
alongside rat heart samples. 
 
Additionally, four polyclonal antibodies were further commissioned (Ab:R1, 
Ab:R2, Ab:522 and Ab:523). This Chapter presents a description of the 
characteristics and detection efficiency of these four RdgBβ antibodies. There is a 
summary of all the antibodies characterised in this Chapter in Figure 4.1. 
 
Finally, Chapter 4 concludes with a discussion of the observations and 
highlights the importance of appropriate antibody characterisation and validation in 
biological experimentation. 
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Antibody Name 
Hu-RdgBβ sp1 Sequence target 
(Residue numbers) 
Reference 
101 TKYEDNKGSNDTIFD (111–125)  
ACDETIPERYYK; (140–151) 
Garner et al. 2011. 
Custom-made 
Rb59 DPEKKATLNLPGMHSSDK 
 (308–325) 
Png, et al. 2012 
Custom-made 
218 Full length Custom-made 
R1 and R2 KATLNLPGMHSSDKPC 
 (312-328) 
Custom-made 
522 DPEKKATLNLPGMHSSDK 
(308–325) 
Custom-made 
523 SSIPLLPSSVRSAPS 
(258-273) 
Custom-made 
 
 
Human: Homo sapiens (Q9UKF7.3) 
Rat: Rattus norvegicus (P_002724619.1) 
Length: 332 
Identity:     320/332 (96.4%) 
Similarity:   330/332 (99.4%) 
 
Human    1 MLLKEYRICMPLTVDEYKIGQLYMISKHSHEQSDRGEGVEVVQNEPFEDP  50 
           |||||||||||||||||||||||||||||||||||||||||||||||||| 
Rat      1 MLLKEYRICMPLTVDEYKIGQLYMISKHSHEQSDRGEGVEVVQNEPFEDP  50 
 
Human   51 HHGNGQFTEKRVYLNSKLPSWARAVVPKIFYVTEKAWNYYPYTITEYTCS 100 
           |||||||||||||||||||||||||||||||||||||||||||||||||| 
Rat     51 HHGNGQFTEKRVYLNSKLPSWARAVVPKIFYVTEKAWNYYPYTITEYTCS 100 
 
Human  101 FLPKFSIHIETKYEDNKGSNDTIFDNEAKDVEREVCFIDIACDEIPERYY 150 
           |||||||||||||||||||||:|||:||||:||||||||||||||||||| 
Rat    101 FLPKFSIHIETKYEDNKGSNDSIFDSEAKDLEREVCFIDIACDEIPERYY 150 
 
Human  151 KESEDPKHFKSEKTGRGQLREGWRDSHQPIMCSYKLVTVKFEVWGLQTRV 200 
           |||||||||||||||||||||||||:|||||||||||||||||||||||| 
Rat    151 KESEDPKHFKSEKTGRGQLREGWRDNHQPIMCSYKLVTVKFEVWGLQTRV 200 
 
Human  201 EQFVHKVVRDILLIGHRQAFAWVDEWYDMTMDEVREFERATQEATNKKIG 250 
           |||||||||||||||||||||||||||||||||||||||||||||||||| 
Rat    201 EQFVHKVVRDILLIGHRQAFAWVDEWYDMTMDEVREFERATQEATNKKIG 250 
 
Human  251 IFPPAISISSIPLLPSSVRSAPSSAPSTPLSTDAPEFLSVPKDRPRKKSA 300 
           :||||||||.|.|||||||||||||||||||||||||||:|||||||||| 
Rat    251 VFPPAISISGIALLPSSVRSAPSSAPSTPLSTDAPEFLSIPKDRPRKKSA 300 
 
Human  301 PETLTLPDPEKKATLNLPGMHSSDKPCRPKSE 332 
           |||||||||||||||||||:::|:|||||||| 
Rat    301 PETLTLPDPEKKATLNLPGVYASEKPCRPKSE 332 
 
 
Figure 4.1: Sequence alignment of Human and Rat RdgBβ highlighting the 
targets of the antibodies described in Chapter 4. 
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4.2: Polyclonal antibody Ab:Rb59 compared to Ab:101 and Ab:218.  
 
The RdgBβ-specific rabbit polyclonal antisera Ab:101 was described 
previously as raised using two internal peptides common to both rodent and human 
RdgBβ41 (Figure 4.1). Ab:101 detected recombinant protein of both RdgBβ splice 
variants, sp1 and sp2 as well as a C-terminal-truncated protein of the long splice 
variant (residues 1–263)41. In this thesis, the level of detection of antisera Ab:101 
was analysed by immunoblotting of recombinant RdgBβ alongside Cos7 cells 
transfected with and without FLAG-Hu-RdgBβ (Figure 4.2.A). The sera of antibody 
Ab:101 detected 40ng recombinant Hu-RdgBβ and a strong band when 
overexpressed in Cos-7 cells corresponding to the expected molecular weight for 
RdgBβ. No band was seen in cells transfected with an empty vector (Figure 4.2: A; 
the red arrow indicates the expected molecular weight for RdgBβ). In addition, the 
antibody recognised an endogenous protein present as a double band at ~35 kDa 
and another band of ~70kDa. There was an evident background noise all over the 
PVDF membrane. 
 
A recent study described another custom-made rabbit polyclonal RdgBβ 
antibody (Ab:Rb59) made against a sequence located at the C- terminal tail of the 
long isoform of human RdgBβ (Figure 4.1). Ab:Rb59 was used to show that a type 
of human breast cancer cells (MDA 231 cells) contained RdgBβ by showing a small 
region of the blot without including molecular weight markers or any other 
characterisation (Figure 4.2.C). Therefore, I sought to examine the sensitivity and 
specificity of Ab:Rb59 for RdgBβ protein recognition compared against other 
antibodies made in-house by my research group (Ab:101 and Ab:218).  
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Initially, Ab:Rb59 was assayed under the same conditions as serum Ab:101 
(Figure 4.2: B). The level of detection by immunoblotting of Ab:Rb59 was ∼5ng and 
above of recombinant RdgBβ. In addition, the level of background noise after the 
exposure of the PVDF membranes was significantly lower when probing with serum 
Ab:Rb59 than with Ab:101 and no additional bands were detected. The results also 
showed that transfected Cos-7 cells with an empty vector do not contain detectable 
levels of endogenous RdgBβ.   
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Figure 4.2: Sensitivity test of Ab:Rb59 compared to serum Ab:101  
 
Cos-7 cells were seeded into 60 mm cell culture dishes at a concentration of 2 x105 
cells/mL and transfected 24 hours later by electroporation with an empty vector [-] or 
pcDNA3.1-Flag-RdgBβ-sp1 [+]. Two days after transfection, cells were harvested in 
RIPA buffer. 50μg of each Cos-7 cell lysate alongside 5,10,20 and 40 ng of 
recombinant Hu-RdgBβ were subjected to western blotting using the RdgBβ 
antibodies Ab:101 at a 1:1000 dilution [A.] and Ab:Rb59 at a 1:100 dilution [B.] on 
separate membranes. The red arrow indicates the molecular weight (MW) expected 
for RdgBβ.  
 
[C.] Figure of Western blot analysis presented as supplementary data taken from 
Png, et al 2012 showing RdgBβ detection in MDA 231 cells ± mIR-126 knock down. 
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Figure 4.2: Sensitivity test of Ab:Rb59 compared to serum Ab:101. 
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4.2.1: Affinity purified polyclonal antibodies Ab:101 and Ab:218. 
 
The polyclonal antibody Ab:101 has been used previously to analyse 
endogenous protein expression of RdgBβ on rat heart cytosol. In order to detect 
RdgBβ, it was required to concentrate the antigen by gel filtration and Ab:101 
identified several additional cross-reactive bands.41 Therefore I sought to improve 
antibody specificity by affinity purification of the crude antiserum of Ab:101 using 
recombinant RdgB sp1 covalently immobilised to agarose beads. Alongside 
Ab:101, I affinity purified the serum of polyclonal antibody Ab: 218 which was 
produced in-house against the full length sequence of RdgBβ. 
 
Although both antibodies were raised using the human sequence of RdgBβ, 
the sequence alignment of rat and human showed that the identity of both proteins 
was high (Figure 4.1). Initially, to evaluate whether there was detectable RdgBβ 
protein levels in a heart-derived cell line, I performed western blot analysis of 
different quantities of H9c2 cell lysates. H9c2 cells are derived from embryonic rat 
ventricles53. As controls, I used overexpressed untagged pIRES-RdgBβ in Cos-7 
cells and recombinant Hu-RdgBβ. Neither Ab:101 nor Ab:Rb59 were able to detect 
endogenous RdgBβ in up to 50μg of H9c2 cell lysates (Figure 4.3). This experiment 
also intended to test whether there was an improved immunoblotting outcome after 
affinity purification of Ab:101. Indeed the high background on the membrane was 
eliminated by using purified Ab:101 and the detection level of recombinant protein 
was also improved (Figure 4.3: A.). Purified Ab:101 detected 10ng and above of 
recombinant RdgBβ compared to the 40ng detection of the serum seen before 
(Figures 4.2.A and 4.5.B). However, it still detected cross-reactive bands and the 
band intensity was not as strong as the detected by Ab:Rb59. (Figure 4.3: B.).      
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Figure 4.3: H9c2 cells do not contain detectable levels of endogenous RdgBβ.  
 
Cos-7 cells were seeded into 60mm cell culture dishes at a concentration of 2.0 x 
105 cells/mL and transfected by electroporation one day later with pIRES-RdgBβ. 
Two days after transfection, cells were harvested in RIPA buffer on ice. H9c2 cells 
were seeded into a T-75 culture flask at a concentration of 2x105 cells/mL and 
harvested in RIPA buffer on ice 48 hours later without any treatment. Western blot  
analysis of 50 μg the transfected Cos-7 cell lysate and 12,25 and 50 μg of non-
treated H9c2 cell lysates using as positive controls 5 and 10 ng of recombinant Hu-
RdgBβ. Two separate membranes were probed with the RdgBβ antibodies purified 
Ab:101 at a 1:1000 dilution [A.] and Ab:Rb59 at a 1:100 dilution [B.]   
The red arrow indicates the molecular weight (MW) expected for RdgBβ.  
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Figure 4.3: H9c2 cells do not contain detectable levels of endogenous RdgBβ. 
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4.2.2: Sensitivity test of affinity purified Ab:101 and Ab:218.  
 
The sensitivity of the purified antibodies Ab:101 and Ab:218 was analysed by 
dot blotting. For comparison, the antibody Ab:Rb59 was used (Figure 4.4: A). At a 
dilution of 1:100, Ab:218 detected 5ng and above, Ab:101 detected 2.5ng and 
above and Ab:Rb59 detected 1.25ng and above of recombinant Hu-RdgB sp1 
(Figure 4.4: A). The intensity of the dots obtained by probing with all the antibodies 
increased linearly with the amount of recombinant RdgB (R2 > 93%) (Figure 4.4: 
B). 
 
 
4.2.3: Specificity test of affinity purified Ab:101 and Ab:218.  
 
To test the specificity of the affinity purified antibodies Ab:101 and Ab:218, 
lysates from whole rat hearts, cellular fractions from rat hearts and isolated adult 
cardiomyocytes were analysed by Western blot. Ab:R59 was used for comparison 
(Figure 4.5). Since H9c2 cells did not express detectable quantities of the RdgB 
protein (Figure 4.3), they were used as negative control. As positive controls, H9C2 
cells overexpressing untagged pIRES-RdgBβ were expected to be detected at the 
correct molecular weight. However, pIRES-RdgB expression in cells was not as 
strong as the tagged FLAG-RdgBβ plasmid expression. Therefore, overexpressed 
FLAG-RdgBβ lysates were also included as positive controls. FLAG-RdgB and His-
tagged recombinant RdgB-sp1 were expected to be detected at a higher molecular 
weight due to their tags (Figure 4.5; red arrows indicate the expected molecular 
weight of RdgBβ). 
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The specificity of Ab: 101 and Ab: 218 did not improve with affinity 
purification since several bands were detected when using both purified antibodies 
(Figure 4.5.B. and 4.5.C.). With Ab: 218, there was no a distinguishable band 
corresponding to RdgBβ (Figure 4.5.C). Purified Ab: 101 did detect bands of the 
expected size for the recombinant protein and FLAG- RdgBβ controls. However, 
these bands were not as strong as the cross-reactive bands and pIRES-RdgBβ did 
not show immunoreactivity to Ab: 101 (Figure 4.5.B).  
 
In comparison, antibody Rb59 detected a single band at the expected 
molecular weight for all positive controls, while the whole and cytosolic rat heart 
fractions showed a stronger band at the expected molecular weight and two weak 
lower cross-reactive bands (Figure 4.5.A).  
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Figure 4.4: Sensitivity of affinity purified polyclonal antibodies 101 and 218 
compared to polyclonal antibody Rb59. 
[A.] Dot blotting of 2l of serial dilutions from 40ng to 1.25ng of recombinant Hu-
RdgBβ sp1 probed with polyclonal antibodies Ab:Rb59 (0.8mg/ml) and affinity 
purified antibodies Ab:101 and Ab:218 (1mg/ml). All antibodies diluted at 1:100.  
[B.] The intensity of blotted dots was quantified using AIDA software. A single 
background value was subtracted from the intensity value for each dot. The data 
shown in the graph are the intensity of the dots in arbitrary units and the amount of 
recombinant Hu-RdgB in nanograms. 
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Figure 4.5: Specificity test of affinity purified antibodies Ab:101 and Ab:218 
compared to antibody Ab:Rb59.  
 
H9c2 cells were seeded into 60mm cell culture dishes at a concentration of 2.0 x 106 
cells/mL and transfected 48 hours later with pcDNA3.1-FLAG-RdgBβ-sp1, pIRES-
RdgB or not transfected [Ctrl]. Two days after transfection, cells were harvested in 
RIPA buffer on ice. In addition, two whole rat hearts (P21 days old) were isolated 
from which cytosolic cellular fractions were obtained by differential centrifugation. 
Western blot of 50 μg of each H9c2 cell and rat heart fraction and cell lysate 
alongside 10 or 20 ng of recombinant Hu-RdgBβ were subjected to western blotting 
using the RdgBβ antibodies Ab:Rb59 at a 1:100 dilution [A.] purified Ab:101 [B.] and 
purified Ab:218 at a 1:100 dilution at a dilution of 1:500 on separate PVDF 
membranes. The red arrow indicates the molecular weight expected for RdgBβ.  
 
 
 
 
 
 
Chapter 4: RdgBβ antibodies 
140 
 
 
Figure 4.5: Specificity test of affinity purified antibodies Ab:101 and Ab:218 
compared to antibody Ab:Rb59 
Purified 
Purified 
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4.3: Polyclonal Antibodies R1 and R2  
 
The polyclonal antibody Ab:Rb59 showed better sensitivity and specificity 
when used in immunoblotting assays of rat heart cellular fractions and recombinant 
Hu-RdgB compared to antibodies Ab:101 and Ab:218 before and after affinity 
purification (Figures 4.2; 4.3; 4.4; and 4.5). Following these observations and due to 
the reduced availability of Ab:Rb59,  it was decided to commission additional 
polyclonal RdgBβ antibodies to obtain sufficient antibody with similar effectiveness 
as Ab:Rb59. Antibodies Ab:R1 and Ab:R2 were raised against an amino acid 
sequence within the carboxyl extension of human RdgB sp1, similar to the 
sequence used to produce antibody Ab:Rb59. Antibodies Ab:R1 and Ab:R2 were 
affinity purified by the company who produced them (Eurogentech).  
 
The sensitivity of antibodies Ab:R1 and Ab:R2 was analysed by dot blotting 
titration using recombinant Hu-RdgB (Figure 4.6: A.). Both antibodies Ab:R1 and 
Ab:R2 detected 0,65 ng and above of recombinant RdgB at a dilution of 1:100 as 
seen for Ab:Rb59 at a 1:200 dilution. However, Ab:R2 showed slightly stronger 
immunoreactivity than Ab:R1 as evidenced at a dilution of 1:1000 where Ab:R2 
detected 0,65 ng and above while Ab:R1 detected 1.25 ng and above of 
recombinant Hu-RdgB (Figure 4.6: A.).  
 
The investigation of the specificity of antibodies Ab:R1 and Ab:R2 was 
performed by western blotting Cos-7 cell lysates transfected with an empty vector or 
FLAG-RdgB alongside recombinant RdgB as control (Figure 4.6: B.; red arrows 
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indicate the expected molecular weight for RdgBβ). At a dilution of 1:100, Ab:R1 
detected 10ng and Ab:R2 detected 5ng of recombinant RdgB. Both antibodies 
detected a band corresponding to FLAG-RdgBβ but there were also additional 
bands of slightly lower and higher molecular weights detected in both the 
transfected and the non-transfected cells. None of these bands are likely to be 
endogenous RdgBβ; they are cross-reactive bands. In addition, Ab:R1 and Ab:R2 
showed several other cross-reactive bands of lower and higher molecular weights 
than the expected for RdgB (Figure 4.6: B.). The high cross-reactivity was 
observed in additional experiments with H9c2 cell lysates which makes both RdgBβ 
antibodies (Ab:R1 and Ab:R2) unsuitable for immunoblotting assays. 
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Figure 4.6: Characterisation of polyclonal antibodies Ab:R1 and Ab:R2  
 
[A.] Sensitivity: evaluation by dot blotting of 2l of serial dilutions from 20ng to 
0.65ng of recombinant Hu-RdgBβ sp1 (in duplicate) probed with polyclonal 
antibodies Ab:R1 and Ab:R2.  Ab:Rb59 was used as control. Two antibody dilutions 
were tested simultaneously 1:100 and 1:1000. 
 
[B.] Specificity: Cos-7 cells were seeded into 60 mm cell culture dishes at a 
concentration of 2.0 x 105 cells/mL and 24 hours later transfected by electroporation 
with an empty vector [-] or FLAG-RdgBβ [+]. Two days after transfection, cells were 
harvested in RIPA buffer on ice. Western blot analysis of 50 μg of each Cos-7 cell 
lysate alongside 5 and 10ng of recombinant Hu-RdgBβ as controls. Two separate 
membranes were probed with the RdgBβ antibodies Ab:R1 and Ab:R2 at a 1:100 
dilution. The red arrow indicates the molecular weight (MW) expected for RdgBβ.  
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Figure 4.6: Characterisation of polyclonal antibodies Ab:R1 and Ab:R2  
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4.4: Polyclonal Antibodies Ab:522 and Ab:523 
 
Previously in this chapter, I described Ab:Rb59 as an effective antibody for 
the detection of RdgBβ. However, the amount of Ab:Rb59 available in the laboratory 
was limited. The antibody Ab:101 was proven effective for recombinant and 
overexpressed RdgBβ detection but it was not specific when looking for 
endogenous protein. Moreover, Ab:218, Ab:R1 and Ab:R2 were also unsuitable for 
immunoblotting. The need to find another suitable antibody to study the endogenous 
expression of RdgBβ remained. Therefore two more antibodies were commissioned: 
Polyclonal antibody Ab:522 which was raised against an identical amino acid 
sequence as Ab:Rb59, and antibody Ab:523 made against a different peptide 
sequence to Ab:Rb59 but still within the carboxyl tail of human RdgBβ.   
 
As with all the RdgBβ antibodies described so far, the sensitivity of both 
antibodies Ab:522 and Ab:523 were assessed by dot blotting titration using 
recombinant RdgBβ. For comparison, I used purified Ab:101 (Figure 4.7: A.).  At a 
dilution of 1:500, Ab:101 detected 5ng and above, Ab:522 detected 10ng and above 
and Ab:523 only detected 20ng of the recombinant protein. At a 1:100 dilution, 
Ab:101 detected 2.5 ng and above, Ab:522 detected 2.5 ng and above and Ab:523 
detected 5ng and above of recombinant RdgBβ (Figure 4.7:A).  
 
The specificity for RdgBβ in western blot analysis was tested using Cos-7 
cell lysates transfected with FLAG-RdgBβ alongside recombinant RdgBβ (Figure 
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4.7: B.). Both antibodies detected a strong band at the expected molecular weight 
corresponding to the transfected Cos-7 cells. However they also detected a band at 
the expected molecular weight on the non-transfected cells. Since Ab:522 detected 
only a weak band for the recombinant protein at 20 and 40ng this band is certainly a 
cross-reactive band.   The use of siRNA (small interfering RNA) to silence RdgBβ 
expression in untreated cells confirmed that the protein being detected at  ̴ 45 kDa 
was in fact an unspecific, cross- reactive band. 
 
In addition, Ab:523 detected several other cross-reactive bands of lower and 
higher molecular weights (Figure 4.7: B.). The high cross-reactivity was observed in 
additional experiments with H9c2 cell lysates using Ab:523 (Figure 4.8.A). The 
antibody Ab:523 detected a band at the expected molecular weight for all samples 
regardless of the differentiation state of the cells. This band was not detected by 
Ab:Rb59 or Ab:101 (Figure 4.3). Therefore to test whether the band was indeed 
RdgBβ, undifferentiated H9c2 cells were transfected with rat RdgBβ siRNA for 72 
hours to down-regulate mRNA expression which was confirmed by qPCR (Figure 
4.8.C). The band observed at the molecular weight expected for RdgBβ was not 
affected by siRNA transfection (Figure 4.8.B), consequentially meaning that 
antibody Ab:523 was also not appropriate for detection of the RdgBβ protein using 
Western blotting.  
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Figure 4.7: Characterisation of polyclonal antibodies Ab:522 and Ab:523  
 
[A.] Sensitivity: evaluation by dot blotting of 2l of serial dilutions from 20ng to 
0.65ng of recombinant Hu-RdgBβ sp1 (in duplicate) probed with polyclonal 
antibodies Ab:522 and Ab:523.  Purified Ab:101 was used as control. Two antibody 
dilutions were tested simultaneously (1:100 and 1:500). 
 
[B.] Specificity: Cos-7 cells were seeded into 60 mm cell culture dishes at a 
concentration of 2.0 x 105 cells/mL and 24 hours later transfected by electroporation 
with an empty vector [-] or FLAG-RdgBβ [+]. Two days after transfection, cells were 
harvested in RIPA buffer on ice. Western blot analysis of 50 μg of each Cos-7 cell 
lysate alongside 5, 10, 20 and 40ng of recombinant Hu-RdgBβ as controls. Two 
separate membranes were probed with the RdgBβ antibodies Ab:522 and Ab:523 at 
a 1:100 dilution. The red arrow indicates the molecular weight (MW) expected for 
RdgBβ.  
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Figure 4.7: Characterisation of polyclonal antibodies Ab:522 and Ab:523 
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Figure 4.8: Immunoblotting detection of Ab:523 in H9c2 cells 
 
H9c2 cells were seeded in 10 cm3 cell culture dishes in complete media at a 
concentration of 2x106cells/mL and cultured for 48 hours before replacing the media 
for differentiation media containing 1% FCS in the absence or presence of daily 1μM 
retinoic acid for 8 days. Media was replaced every 48 hours.   
[A.] Western blot analysis of expression levels of RdgBβ in H9C2 whole cell lysates 
(50µg and 75µg), run alongside varying amounts of Hu-RdgBβ recombinant protein 
(1-5ng). Ab:523 at 1:100 dilution and anti- Actin at 1:1000 dilution was used as a 
loading control. 
 
 [B.] H9c2 cells growing in complete media (10%FCS) were transfected with rat -
RdgBβ siRNA (12nM) for 72 hours and harvested in RIPA buffer and RNA lysis 
buffer. The  Image shows immunoblotting of 50μg of lysate run alongside 1,5 and 
10ng of recombinant RdgBβ probed with Ab:523 at a 1:100 dilution. 
 
[C.] qPCR analysis of H9c2 mRNA of cells growing in complete media transfected 
with a negative control siRNA, or rat-RdgBβ siRNA normalised to PGK1. Bars 
represent the average of 3 measurements ± SEM from one experiment. 
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Figure 4.8: Immunoblotting detection of Ab:523 in H9c2 cells 
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4.5: Summary. 
 
 
 
 
 
 
   Polyclonal 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9: Flowchart summarising the results described in Chapter 4.        
* Peptide sequence of Hu-RdgBβ sp1 (NCBI ref Q9UKF7.2). a.a.: amino acids. 
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4.6: Discussion 
 
In this chapter, Ab:Rb59 was characterised and validated for the effective 
detection of RdgBβ by immunoblotting of recombinant and overexpressed protein in 
Cos7 and H9c2 cells, as well as in rat heart cells and tissue samples. Ab:Rb59 
outperformed all other antibodies characterised in this thesis including Ab:101 and 
Ab:218 before and after affinity purification as well as antibodies Ab:R1, Ab:R2, 
Ab:522 and Ab:523 (Figures 4.2.B, 4.3.B, 4.4, 4.5 and 4.6). 
 
Ab:101 was found to be effective at identifying recombinant and over-
expressed RdgBβ, although it also detected additional cross reactive bands (Figure 
4.2.A). These results correlated to the validation of Ab:101 on a previous study. 
Garner et al. (2011) reported that Ab:101 detected RdgBβ when overexpressed in 
Cos-7 cells and also no band corresponding to the expected molecular weight for 
RdgBβ was seen in non-transfected Cos-7 cell lysates. In addition, Ab:101 
recognised an endogenous protein present as a double band at ~35 kDa. This 
doublet was identified as a cross-reactive band since it was not susceptible to RNA 
interference 41. On the other hand, I found that the detection level obtained by 
titration of recombinant RdgBβ was significantly lower than the described before. 
The serum of the antibody Ab:101 was only able to detect 20ng and above of 
recombinant RdgBβ (Figures 4.2.A and 4.5.B) compared to the ∼5 ng and above 
reported previously41. It has been reported that the functionality of antibodies varies 
over a period of time120, it is possible that the antibody Ab:101 lost some detection 
ability with time.  
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The high background noise seen for western blot experiments using the sera 
Ab:101 was reduced with affinity purification and the sensitivity to the recombinant 
protein also improved (Figure 4.3.A). However, the specificity of the antibody Ab:101 
did not improve with affinity purification (Figure 4.5.B), perhaps because it was not 
completely eluted from the purification gel due to high affinity of the antibody for the 
recombinant Hu-RdgBβ-sp1.  
 
In addition, the antisera Ab:101 detected protein expression of RdgBβ in rat 
cytosol concentrated by gel filtration.41 In this study I showed the endogenous 
expression of RdgBβ in rat heart samples using Ab:Rb59 without the need for 
concentrating the antigen (Figure 4.5.A). However, untreated H9c2 cells, which are 
myoblasts derived from embryonic rat heart, did not show detectable levels of the 
protein (Figures 4.3 and 4.5). Since the rat heart fractions used for these 
experiments did not discriminate the type of cells, it is plausible that RdgBβ is 
expressed in cells other than cardiomyocytes such as fibroblasts or endothelial 
cells. There is also the possibility that RdgBβ is expressed at later stages in cardiac 
development. 
 
Antibodies Ab:218, Ab:R1, Ab:R2, Ab:522 and Ab:523 detected recombinant 
RdgBβ but none was specific at western blotting of H9c2 and Cos7 cells or rat 
tissue samples (Figures 4.5.C, 4.6.B , 4.7.B and 4.8). Therefore the need to obtain 
enough quantities of an antibody as effective as Ab:Rb59 still remains. Recently, 
another RdgBβ antibody was used in a study by the same group who provided us 
Ab:Rb59.90 They used a commercial mouse polyclonal antibody raised against a full-
length human RdgBβ (Locus AAH07905) for protein detection in human breast 
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cancer and normal epithelial mammary cells45.  This antibody was not characterised 
with respect to its specificity.   
 
Across the biological research literature, problems with cross-reactivity and 
variability of antibody-based assays have raised difficulties with the reproducibility of 
results. This has repeatedly put into question the use of non-validated antibodies 
with appropriate controls7,120.  In this study, antibodies Ab:R1 and Ab:R2 were raised 
using an identical amino acid sequence in different animals and they showed 
dissimilar levels of detection of RdgBβ (Figure 4.6). The same scenario was seen 
with antibodies Ab:Rb59 and Ab:522 although they were made with the same 
antigen.  
 
The problem of antibody based research reproducibility is compounded by a 
lack of consensus in standards and the extensive steps required for full validation. 
Initiatives such as the Antibody Registry (http://antibodyregistry.org/), intended to 
help with the identification of the antibodies 113 have been overwhelmed with 
commercial antibodies lacking characterisation. Nevertheless, it is my personal 
opinion that scientific journals and reviewers should encourage biological research, 
which relies on the quality of antibodies for their observations, to include a validation 
showing specificity, sensitivity, and reproducibility in the context for which the 
antibody is used or an appropriate citation. A suggested algorithm in Figure 4.10 
offers a framework for antibody validation9. This information, including those 
experiments which failed to validate an antibody, could be gathered on a standard 
online database available to the scientific community. The entries of the database 
should include mandatory criteria of characterisation that could be used as a 
citation.  
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Figure 4.10: Algorithm for antibody validation  
Framework of antibody validation for Western Blot (WB) using cell lines in vitro. 
Tissue microarray (TMA). Adapted from Bordeaux et al. 2010.  
 
 
Considering the results and limitations described above, it was decided to 
use Ab:Rb59 for the expression analysis of RdgBβ in rat heart samples throughout 
this thesis. 
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CHAPTER 5: Study of RdgBβ expression in rat heart. 
 
 
5.1: Introduction 
 
 Describing the expression pattern of RdgBβ in rat heart cells and tissue 
fractions could provide indications of its unknown physiological cardiac function.  
Previously, endogenous protein expression of RdgBβ was found in rat heart cytosol 
that was concentrated by gel filtration41. In addition, the mRNA transcripts of RdgBβ 
were also strongly expressed in heart samples39,104. In Chapter 4, it was described 
how I was able to directly detect endogenous protein expression of RdgBβ in adult 
rat heart fractions by immunoblotting using antibody Ab:Rb59 (Figure 4.5). However, 
it was unclear the type of cells that was expressing RdgBβ or whether protein 
expression was regulated with cell development since I also observed that the rat 
heart embryonic cell line H9c2 did not show detectable levels of RdgBβ protein 
(Figure 4.3). To address these questions and characterise the mRNA and protein 
expression of RdgBβ in rat heart further, I sought to evaluate the ability of H9c2 
myoblast to differentiate into muscle cells or cardiomyocyte-like cells depending 
upon the composition of the culture media. The study also compares adult and 
neonatal rat heart samples and primary cardiomyocytes isolated from neonatal heart 
tissue. 
 
This chapter first describes the endogenous expression of RdgBβ protein 
and mRNA after H9c2 myoblast differentiation to test whether RdgBβ is expressed 
in either skeletal or cardiac muscle and if this expression is regulated during muscle 
development.  In addition, immuno-detection of RdgBβ by Ab:Rb59 was verified by 
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RNA interference transfection of H9c2 cardiomyocyte-like cells. The sub-cellular 
localisation of RdgBβ in differentiated H9c2 cells was also analysed. 
 
Furthermore, RdgBβ expression was compared between neonatal and adult 
rat heart tissue to assess any changes related with cardiac maturity and this chapter 
also includes an analysis of isolated neonatal rat cardiomyocytes as a primary 
system for studying RdgBβ in rat heart.  Finally, the cellular distribution of RdgBβ 
was explored in adult cardiac tissue in comparison to brain and liver cellular 
fractions. The chapter concludes with a discussion of the observations and 
recommendations for future studies.   
 
  
5.2: Analysis of RdgBβ expression in H9c2 cells. 
 
H9c2s cells conserve the ability to differentiate into muscle cells, either 
skeletal or cardiac-like80, which have not been evaluated for endogenous RdgBβ 
protein expression. Proliferating myoblasts were cultured in media supplemented 
with 10% foetal calf serum (FCS). By reducing the FCS content to 1% for a 
minimum of 8 days, H9c2 myoblasts stopped cell cycling and started differentiation 
towards a skeletal muscle phenotype. When the serum reduction to the culture 
media was complemented with daily addition 1μM all-trans retinoic acid (RA) 
treatment, H9c2 cells differentiated into a cardiomyocyte-like cell line as indicated  
by the detection of cardiac troponin I (a cardiac marker) by immunoblotting (Figure 
5.1).   
 
Endogenous RdgBβ protein expression was examined by immunoblotting 
using antibody Ab:Rb59 (Figure 5.1). As expected, there was no band detected at 
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the expected molecular weight for RdgBβ in proliferating H9c2 cells (Figure 5.1; the 
red arrow indicates the expected molecular weight for RdgBβ). Similarly, H9c2 cells 
differentiated with 1% FCS alone showed no detectable protein expression. In 
differentiated H9C2 cells that were treated with retinoic acid, there was a strong 
band corresponding to the molecular weight of RdgBβ by immunoblotting. However 
Ab:Rb59 also identified an endogenous cross reactive band at ~55kDa in all 
samples. The increased expression of RdgBβ following differentiation was highly 
specific for this PITP family member. Class I PITP levels were unaltered by cellular 
differentiation of H9c2 cells (Figure 5.1 lower panel). 
 
In addition, rat RdgBβ mRNA expression was assessed by end point 
polymerase chain reaction (PCR) with the expression of GAPDH used as loading 
control (Figure 5.2.A) followed by quantitative real time PCR (qRT-PCR) where 
RdgBα was used for comparison (Figure 5.2.B). RdgBβ mRNA expression was 
found in undifferentiated H9C2 cells by PCR and qRT-PCR, but RdgBβ mRNA 
analysis showed a stronger band with cellular differentiation detected by PCR and a 
2.4±0.4 fold increase, obtained by qRT-PCR. A stronger band was also seen by 
PCR compared to cells cultured in 10%FCS and 1%FCS alone. Additionally, RdgBβ 
mRNA showed a 3.7±0.3 fold increase compared to proliferating H9c2 cells. In 
comparison, the other PITPs evaluated showed no variation in their expression 
(PITPβ protein and RdgBα mRNA) upon H9c2 differentiation.  
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Figure 5.1: Endogenous RdgBβ protein expression in differentiated H9c2 cells  
H9c2 cells were seeded into T75 culture flasks at a concentration of 2.0 x 106 
cells/mL and cultured for 10 days in culture media supplemented with10% foetal calf 
serum (FCS) and passaged every two days; 1% FCS and the media replaced every 
two days; or 1% FCS media replenished every two days plus daily treatment with 
1μM all-trans retinoic acid (RA). Cell lysates were harvested in RIPA buffer. 50μg of 
lysates were electrophoresed on a 4-12% NuPage gradient acrylamide gel. The 
Western blotting analysis used polyclonal antibody Ab:Rb:59 at a 1:100 dilution, and 
on a separate membrane, polyclonal anti-PITPβ  (Ab:1C1) and anti-cardiac troponin 
I at a 1:1000 dilution were probed. Red arrow indicates the expected molecular 
weight for RdgBβ. MW: molecular weight.  
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Figure 5.2: RdgBβ mRNA expression in differentiated H9c2 cells. 
 
H9c2 cells were cultured for 8 days in culture media supplemented with10% foetal 
calf serum (FCS); 1% FCS, or 1% FCS media plus daily treatment with 1μM all-
trans retinoic acid (RA). RNA was extracted from cell lysates and 1μg RNA was 
used to obtain cDNA by reverse transcription. 
 
[A.] End point PCR of 5μL cDNA using Taq polymerase and the indicated primers. 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as loading 
control.  
[B.] qRT-PCR of 5μL cDNA using SYBR green. Fold change calculated using the 
ΔΔCt formula where Ct values were obtained in triplicate and normalised to the Ct 
values for PGK1.  (*):p=0.002 (n=15 from 5 experiments) (**):  p=1.7x10-9 (n=33 
from 11 experiments). 
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5.2.1: Rat RdgBβ siRNA transfection. 
To confirm that the band observed by Western blot upon H9c2 differentiation 
was indeed RdgBβ (Figure 5.3), the mRNA of RdgBβ was downregulated during the 
last three days of differentiation. The analysis was performed in duplicate by 
western blotting (Figure 5.3.A). The immunodetection experiment showed  the loss 
of the ~44kDa bands corresponding to RdgBβ with rat RdgBβ siRNA transfection 
compared to the bands detected from differentiated cells transfected with a negative 
siRNA control. The rat RdgBβ siRNA transfection efficiency and specificity were 
evaluated by qRT-PCR. The RdgBβ mRNA expression of differentiated cells was 
reduced by 88% compared to the negative siRNA control whilst the mRNA of rat 
RdgBα was not altered (Figure 5.3.B).  
 
 
5.2.2: Expression regulation during cardiomyocyte development. 
Endogenous Rdgbβ was detected after differentiation of H9c2 with reduced 
serum and retinoic acid for 8 and 10 days (Figure 5.1 and Figure 5.2). In order to 
test the expression over time during differentiation, mRNA and protein were 
analysed by qRT-PCR and western blotting at 0, 4, 8, 10 and 12 days differentiation 
(Figure 5.4). Protein expression was not detected until day 8 of RA treatment and it 
increases on day 10 and remains until day 12 of the experiment (Figure 5.4.A). 
mRNA increased overtime from 0 to 8 days (2.7±0.3 fold increase) and remained  at 
the same level until day 12 (Figure 5.4.B). The experiment was repeated three times 
with the same results. The difference of the mRNA and protein expression at day 
four suggest that translation of RdgBβ has not taken place or that the amount of 
RdgBβ was not detected by the antibody. However these observations indicate that 
RdgBβ expression increases with cardiomyocyte maturity. 
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Figure 5.3: Rat RdgBβ siRNA transfection in differentiated H9c2 cells 
  
[A.] Protein expression was analysed by Western blot analysis of 75μg lysate of 
H9c2 cells differentiated in 1% FCS media plus daily treatment with 1μM all-trans 
retinoic acid (RA). On day 8 of culture, cells were transfected for 72 hours with 
12nM Rat RdgBβ siRNA oligonucleotides 2+3 or a negative siRNA. Cell lysates 
were harvested in RIPA buffer and the protein separated using SDS-PAGE. Probing 
of the membrane was performed using polyclonal antibody Ab:Rb:59 at a 1:100 
dilution. The red arrow indicates the expected molecular weight for RdgBβ. MW: 
molecular weight. 
 
[B.] 1μg RNA of differentiated H9c2 cells transfected with rat RdgBβ or a negative 
siRNA was used to obtain cDNA by reverse transcription. qRT-PCR was performed 
using 5μL cDNA using SYBR green and the indicated rat primers (RdgBβ and 
RdgBα). The mRNA fold change expression was calculated using the ΔΔCt formula. 
Ct values were obtained in triplicate and normalised to the Ct values for 
Phosphoglycerate Kinase 1 (PGK1). Bars represent data of 2 separate experiments 
for RdgBβ plus 1 experiment in triplicate for RdgBβ and RdgBα. Error bars indicate 
SEM.  
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Figure 5.3: Rat RdgBβ siRNA transfection in differentiated H9c2 cells. 
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Figure 5.4: RdgBβ expression increases over time of differentiation of H9c2 
cells. H9c2 undifferentiated cells were seeded into 6 well culture dishes at a 
concentration of 2.0 x 106cells/mL and cultured for 2 days in media supplemented 
with 10% FCS which was then replaced for differentiation media and cultured for the 
number of days showing in the figure (0, 4, 8, 10 and 12). Cell lysates were 
harvested in RIPA buffer and RNA lysis buffer. 
 
[A.] The protein content of the H9c2 cell lysates (75µg for RdgBβ and 50μg for 
PITPα) were separated in NuPage gradient gels (4-12%) and analysed by western 
blotting using polyclonal antibody Ab:Rb:59 at a 1:100 dilution, and anti-PITPα  
(Ab:674) at a 1:1000 dilution. Red arrow indicates the expected molecular weight for 
RdgBβ. MW: molecular weight. 
 
[B.] 1μg RNA from cell lysates was used to obtain cDNA by reverse transcription. 
qRT-PCR was performed using 5μL cDNA, SYBR green and 300nM primers. The 
calculation of the change in mRNA expression was achieved using the ΔΔCt formula 
where triplicate Ct values measured from each set of primers were normalised to 
the Ct values for PGK1. Bars show mean ± SEM of Ct measurements from 3 
experiments (**): p<0.001. 
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5.2.3: Subcellular localisation.  
 
Overexpressed tagged RdgBβ was reported to be diffusely present 
throughout the cytoplasm. Human FLAG- RdgBβ in HEK293 cells39 and Cos7 
cells,41 and mouse GFP-RdgBβ in PC12 cells.104 In order to analyse the intracellular 
localisation of endogenous RdgBβ, cardiomyocyte-like H9c2 cell fractions were 
immunoblotted using antibody Ab:Rb59. The cellular fractions were obtained by 
differential centrifugation of cell lysates after 10 days of differentiation (1%FCS + 
1μM RA). Fraction purity was assessed by immunoblotting using a mitochondrial 
marker (GRP75) and, PITPα, a soluble PITP located in the cytosol, was used for 
comparison. Ponceau staining of the membrane before probing was used as loading 
control (Figure 5.5). 
 
 Anti-GRP75 probing showed enrichment in crude mitochondrial fraction and 
no signal from microsomes indicating no mitochondrial contamination. The band 
corresponding to RdgBβ was enriched in the cytosolic fraction compared to whole 
cell extracts whereas very weak bands were seen at microsomes or crude 
mitochondria. In contrast, PITPα probing although it was enriched in the cytosol, it 
detected no bands on microsomes or crude mitochondria. These results localise 
RdgBβ primarily at the cytosolic fraction of differentiated H9c2 cells.  
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Figure 5.5: RdgBβ is a cytosolic protein in differentiated H9c2 cells. H9c2 cells 
were cultured for 10 days in culture media supplemented with 1% FCS media plus 
daily treatment with 1μM all-trans retinoic acid (RA). Cell lysates were harvested in 
SET buffer and subjected to differential centrifugation fractionation. 50μg of each 
lysate was subjected to SDS-PAGE on NuPage 4-12% gradient acrylamide gel. 
PVDF membrane was imaged after Ponceau solution staining as loading control. 
Western blotting was performed using polyclonal Ab:Rb59 at a 1:100 dilution; and 
on a separate membrane using polyclonal antibodies anti-GRP75 (Ab:GRP75) as 
mitochondrial marker and anti-PITPα (Ab:674) at a 1:1000 dilution as comparator. 
Red arrow indicates the expected molecular weight for RdgBβ. MW: molecular 
weight. 
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5.3: Analysis of RdgBβ expression in rat heart. 
 
 The endogenous protein expression of RdgBβ was found in H9c2 cells that 
were differentiated towards a cardiomyocyte-like phenotype (Figure 5.1). In order to 
verify the presence of RdgBβ in primary samples, hearts from the Rattus 
novergicus, strain Sprague-Dawley were analysed for protein and mRNA expression 
of RdgBβ. 
 
 
5.3.1: RdgBβ expression is stronger in adult than in neonatal rat heart. 
 
To analyse whether the protein expression of RdgBβ changes with maturity, 
whole cell lysates from neonatal (1-2 days old) and adult (3 months old) rat hearts 
were obtained as described in Section 2.5; and immunoblotted using antibody 
Ab:Rb59 alongside proliferating H9c2 cells that were transfected with either an 
empty vector or untagged pIRES-RdgBβ as negative and positive controls 
respectively. Lysates were also blotted for 14-3-3 protein as loading control. I was 
able to demonstrate the presence of RdgBβ in both neonatal and adult rat heart 
whole cell lysates. Adult rat heart fractions showed a strong and specific 
immunoreactivity to Ab:Rb59 at the expected size for RdgBβ (Figure 5.6.A.). 
However hearts from neonatal rats (2 days old) showed much lower levels of the 
protein (Figure 5.6.B.). This result indicates that RdgBβ is upregulated upon 
maturation. 
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Figure 5.6: RdgBβ expression is stronger in adult than in neonatal rat heart. 
H9c2 cells cultured in complete media (10% FCS) were transfected for 48 hours 
with either pcDNA3.1-FLAG-RdgBβ-sp1 [+] or an empty vector [-]. Cell lysates were 
harvested in RIPA buffer. In addition, Sprague-Dawley rat hearts were dissected 
and lysed in SET buffer.  [A.] Two hearts from adult (3 months old) rats. [B.] Four 
hearts from neonate pups (2 days old) rats. The figure shows western blotting 
analysis of 50μg of each lysate using polyclonal Ab:Rb59 at a 1:100 dilution; and on 
separate membranes, probed with anti-14-3-3 (Ab:14-3-3) for comparison. Red 
arrows indicate the expected molecular weight for RdgBβ. MW: molecular weight. 
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5.3.2: RdgBβ expression in isolated neonatal rat cardiomyocytes 
 
Cardiac tissue is comprised of cardiomyocytes and other constituent cell 
types including fibroblasts and endothelial cells. RdgBβ was detected in whole cell 
lysates from heart tissue which did not distinguish between cell types (Figure 5.6). 
Therefore whether the presence of RdgBβ in rat heart is due to cardiomyocyte 
content was tested by immunoblotting. Although RdgBβ expression was stronger in 
adult rat heart lysates, neonatal rat cardiomyocytes (NRC) were chosen as the 
primary system to study RdgBβ since their isolation, culture and transfection was 
more suitable to the laboratory set up than adult cells.  
 
Cardiomyocytes were isolated by serial digestion of neonatal rat hearts, cell 
lysates were immunoblotted for a known cardiomyocyte marker (cardiac troponin I).  
There was a positive reaction of whole heart and isolated heart cells to the cardiac 
troponin I antibody. However, isolated heart cells that were cultured for 48 hours in 
maintenance media showed reduced reactivity to the cardiac troponin I antibody.   In 
addition, preparations of freshly isolated neonatal rat cells were positive to Ab:Rb59 
immunoblotting similar to rat heart whole cell extracts (Figure 5.7.A). The mRNA 
expression of RdgBβ was also observed in neonatal rat hearts and isolated cells 
(Figure 5.7.B). Isolated neonatal rat cardiomyocytes showed a similar low intensity 
band as seen in proliferating H9c2 cells. These observations suggest that RdgBβ is 
expressed in cardiomyocytes, and that NRCs are an effective system to study 
RdgBβ. However, after cell culture RdgBβ expression is lost which was not 
investigated further.   
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Figure 5.7: RdgBβ protein expression in isolated and cultured neonatal rat 
heart cells. Six neonatal (2 days old) Sprague-Dawley rat hearts were dissected; 
two of them were lysed in RIPA buffer. The other four hearts were serial digested to 
isolate cardiomyocytes, an aliquot was lysed in RIPA buffer and the rest was plated 
in Primaria 6 well dishes in maintenance media for 48 hours then lysed in RIPA 
buffer. The figure shows Western blot analysis of 50g of lysates alongside 
undifferentiated H9c2 cells as negative control and 10ng recombinant Hu-RdgBβ as 
positive control. Using polyclonal Ab:Rb59 at a 1:100 dilution; and on a separated 
membrane,  probed with anti-cardiac troponin I (Ab:Troponin I)  as a cardiomyocyte 
marker. Red arrows indicate the expected (MW) molecular weight. NRH: Neonatal 
Rat Heart. NRC: Neonatal Rat Cardiomyocytes.  
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5.3.3: Subcellular localisation of RdgBβ in adult rat heart fractions 
 
To study the subcellular expression of RdgBβ in primary cardiac tissue, adult 
rat hearts were fractionated by differential centrifugation and the fractions were 
immunoblotted for Ab:Rb59. RdgBβ was easily detectable in whole cell extracts 
(WCE), and upon fractionation, the protein was stronger in the cytosol compared to 
the other fractions. However, there was also positive immunoreactivity for 
microsomes, and a weak band was detected with mitochondrial associated 
membranes (MAM). Crude mitochondrial fractions showed a faint band, and pure 
mitochondria was negative for RdgBβ; Ab:Rb59 detected other cross-reactive 
proteins of higher and lower molecular weight than the expected band for RdgBβ  
(Figure 5.8).  
 
In addition, the degree of purity of the fractions was examined by 
immunoblotting of the fractions using anti-calnexin antibody as microsomal marker 
and anti-Complex IV (COX IV) antibody as a mitochondrial marker. There was some 
mitochondrial contamination in the microsomes and a small microsomal 
contamination in the mitochondrial fractions whereas cytosolic fractions showed no 
contamination. This experiment was repeated several times with similar results. A 
fraction of RdgBβ seems to be associated with membranes in rat heart. 
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Figure 5.8: Subcellular localisation of RdgBβ protein expression in Adult Rat 
heart fractions.  
 
Two female Sprague-Dawley rats (6 months old) were euthanised and their hearts 
dissected. Homogenised heart tissue was subjected to differential fractionation 
centrifugation and subjected to Western blot analysis.  50μg of each lysate was 
tested for RdgBβ expression using polyclonal Ab:Rb59 at a 1:100 dilution; and on  
separated membranes, probed with polyclonal anti-Complex IV (Ab:COX IV) at a 
1:1000 dilution as a mitochondrial marker and anti-calnexin (Ab:calnexin) as 
microsomal marker at a 1:1000 dilution. 
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a.  Comparison with rat brain and liver samples. 
 
Along with the strong expression of RdgBβ in the heart, transcripts have also 
been found in brain, kidney, liver and testes 39,104. To compare my observations in 
the heart with other tissue samples, immunoblotting of liver and brain tissue 
fractions, obtained in a similar manner to heart fractions, were tested for 
immunoreactivity with Ab:Rb59. Brain fractions showed endogenous RdgB 
expression following the same pattern of localisation as heart fractions. The 
immunoreactivity detected for the crude mitochondrial fractions accounted for the 
microsomal contamination as seen by the anti-calnexin antibody detection. In 
contrast, all liver fractions were negative for Ab:Rb59 (Figure 5.9).   
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Figure 5.9: Subcellular localisation of RdgBβ protein expression in Adult Rat 
Brain [A.] and Liver [B.] fractions. Two female Sprague-Dawley rats (6 months 
old) were euthanised and their brains and livers dissected. Homogenised tissue was 
subjected to differential fractionation centrifugation and immunoblotted using 
polyclonal Ab:Rb59 at a 1:100 dilution for RdgBβ detection, and on separated 
membranes, probed with polyclonal anti-GRP75 (Ab:GRP75) at a 1:1000 dilution as 
a mitochondrial marker and anti-calnexin (Ab:calnexin) as microsomal marker at a 
1:1000 dilution. 
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5.4: Summary and Discussion. 
 
The present chapter describes the endogenous mRNA and protein 
expression of RdgBβ in rat heart tissue, both neonatal and adult, isolated 
cardiomyocytes and the differentiated H9c2 cell line. The findings are summarised 
in the flowchart presented in Figure 5.10.  
 
There are no studies that have directly identified the expression pattern of 
native RdgBβ protein in H9c2 cells or in primary rat cardiomyocytes. The expression 
analysis of RdgBβ showed that protein and mRNA presence was increased over 
time in H9c2 cells differentiated for a minimum of 8 days and up to the 12 days 
evaluated (Figure 5.4). The siRNA transfection data verified that the protein 
detected by Ab:Rb59 was indeed RdgBβ (Figure 5.5). The cellular localisation study 
showed that RdgBβ is mainly cytosolic, but some immunoreactivity was observed in 
rat heart and brain microsomes (Figure 5.8 and Figure 5.9). 
 
In addition, the increase in mRNA expression in muscle-like cells and H9c2 
cells differentiated with RA at 4 days was dissimilar to the protein expression (Figure 
5.1, Figure 5.2 and Figure 5.4), which suggests that RdgBβ translation might be 
regulated distinctly during cardiac cell growth and development. It is possible that 
RdgBβ expression could be detectable at a later stage in skeletal muscle 
differentiation since Northern blot of different human tissues also showed mRNA 
expression in the muscle.39  
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Figure 5.10: Flowchart summarising the results described in Chapter 5. 
WCE: Whole cell extracts; FCS: Foetal calf serum; RA: Retinoic acid; qRT-PCR: 
Real time quantitative polymerase chain reaction.         
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The protein expression of RdgBβ was found to be stronger in the adult 
compared to neonatal rat heart lysates (Figure 5.6) and the RdgBβ signals detected 
by immunoblot on isolated neonatal rat heart cells were severely reduced or lost 
after 48 hours culture in maintenance media. The same samples of cultured 
neonatal rat cells showed a reduction or absence of immunoreactivity for cardiac 
troponin I (Figure 5.7) suggesting that the cultures of isolated neonatal rat cells were 
taken over by cells other than cardiomyocytes; for instance, cardiac fibroblasts. 
These results further support the idea that the expression of RdgBβ is related to 
development and maturity of cardiomyocytes and no other types of cells in the 
heart. This expression pattern has also been described in mouse brain where 
RdgBβ mRNA was mainly expressed in differentiating and mature neurons during 
both pre- and post-natal stages104. 
 
Earlier reports showed the intracellular localisation of RdgBβ throughout the 
cytoplasm of PC12 and HEK293 cell lines transfected with tagged RdgBβ; 39,41,104 
and endogenous protein was previously detected in the cytosol of rat heart41. My 
results correlate with these findings directly in differentiated H9c2 cells and adult rat 
heart cellular fractions obtained by differential centrifugation; RdgBβ is mainly a 
cytosolic protein in rat heart and brain (Figures 5.10 and 5.11.A).  
 
The regulation of protein translation of RdgBβ has not been explained to 
date. However it is known that micro RNAs represent one of several mechanisms of 
translational regulation102 and miRNA 126 has been shown to regulate RdgBβ 
expression in breast cancer cells.90 In the contrary, a recent study reported that  
 
Chapter 5: RdgBβ in the heart 
178 
 
RdgBβ expression was not affected by over expression of mir126 in leukemic cells 
suggesting that miRNAs' function is highly tissue-dependent.2  
 
Additionally a recent report showed that RdgBβ was able to translocate to 
the membranes of transfected Cos7 cells after PMA stimulation in order to bind a 
membrane protein (ATRAP)41; and recently a study revealed that RdgBβ associates 
with Golgi membranes in several cancer cells to bind the phospholipid PI4P and 
recruit another protein (RAB1B)45.  In this thesis I found further evidence of the 
association of RdgBβ with cellular membranes (microsomes and mitochondrial 
associated membranes) in rat heart and brain (Figures 5.5, Figure 5.8 and Figure 
5.9) which offers a good indication that the physiological function of RdgBβ in the 
heart could also be related to its ability to connect membrane protein and lipids .  
 
For instance, considering the PA binding40 and transfer (Figure 3.4) 
properties described for RdgBβ. Cellular PA is present in very small quantities 
mainly due to their rapid conversion into other phospholipids or its involvement in 
cellular signalling including for example the PLD-generated PA regulation in the 
effects of mTOR in several systems, cell types, and cellular phenotypes. (Reviewed 
in Foster, 2007)36 and the increased the level of PA in cardiac sarcolemma as a 
result of inotropic agents stimulation known to stimulate cardiac hypertrophy.31 
However, as a lipid, PA is unable to move freely through the cytoplasm; therefore 
RdgBβ could directly facilitate PA-mediated processes especially in events where 
cells require extensive changes such as in stress conditions. Future studies will 
require a special design to address the physiological association of PA and RdgBβ 
in cardiac cells. 
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CHAPTER 6: Analysis of Cds1 expression in the rat heart. 
 
 
6.1: Introduction. 
 
  RdgBβ protein expression was detected only when H9c2 cells were 
differentiated towards a cardiomyocyte-like phenotype and it was stronger in adult 
compared to neonatal rat hearts (Chapter 5).  These results suggested that RdgBβ 
expression was regulated by development and maturation. Recently, it was reported 
that H9c2 cells differentiated with RA led to an increase in mitochondrial biogenesis 
regulated by the transcriptional coactivator peroxisome proliferator-activated 
receptor –γ coactivator-α (PGC-1α)25.  In mice, PGC-1α deficient hearts showed 
reduced expression of the gene encoding CDP-DAG synthase 1 (Cds1)68. Cds 
enzymes catalyse the reaction between phosphatidic acid (PA) and CTP to form 
CDP-DAG, and RdgBβ is a PA binding protein.  Therefore, I examined whether 
retinoic acid treatment of H9c2 cells also led to increased levels of Cds1. 
  
This chapter starts with a description of the differentiation of H9c2 myoblasts 
by evaluating cell morphology and expression of markers of the cardiomyocyte 
phenotype. The analysis also includes microsomal and mitochondrial markers upon 
differentiation. The study also examines the mRNA and activity content of enzymes 
involved in phospholipid synthesis before and after differentiation.    
 
The Cds1 expression analysis revealed a discrepancy between the mRNA 
and protein data. This prompted an investigation into the efficiency of the antibody 
used to detect Cds1 protein expression. This anti-Cds1 was used in recent 
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publications but it was not characterised42,119. Cds1 is an integral membrane protein 
known to be localised in the microsomal fraction29,71,106,119. Therefore the validation 
study of anti-Cds1 started with an analysis of the cellular localisation of the 55kDa 
band detected by the antibody in differentiated H9c2 cell fractions and adult rat 
heart fractions. The Ab:Cds1 characterisation also included the analysis of 
overexpressed human Cds1 in Cos7 cells and rat Cds1 siRNA transfection of H9c2 
cells. The results found Ab:Cds1 to be unsuitable for the detection of endogenous 
Cds1 which affected the progress of the investigation. The chapter concludes with a 
discussion of the results, reinforcing the argument of chapter 4, regarding the 
damage that uncharacterised commercial antibodies are inflicting on biomedical 
research.  
 
6.2: Characterisation of H9c2 cells differentiation. 
 
6.2.1: Cell morphology comparison.  
 
The cell morphology of H9c2 proliferating myoblasts compared to 
differentiated myocytes was studied visually from images taken by differential 
interference contrast microscopy (DIC) of cells in culture, and immunofluorescence 
microscopy of the nuclei with DAPI and actin filaments with Phalloidin staining of 
fixed H9c2 cells (Figure 6.1.). Proliferating myoblasts were observed as stellate or 
spindle-shaped single mono-nucleated cells. On the other hand, low serum media 
culture promoted cell fusion and elongation into fibres in the presence or absence of 
RA. However, H9c2 cells differentiated with RA showed a degree of multi-nucleation 
not evident in cells differentiated in 1% FCS alone. Morphological changes became 
noticeable after a minimum of 4 days culture in differentiation media.  
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Figure 6.1: Morphological study of H9c2 cells after differentiation.  
H9C2 myoblasts were seeded in 12 well plates with coverslips at 1x106 cells/mL and 
differentiated into myocytes with media containing reduced serum (1%FCS) ± daily 
supplement of all-trans retinoic acid (1μM RA) for eight days. Proliferating cells were 
passaged every two days.  
[A.] Differential interference contrast (DIC) image of H9c2 cells in culture at 20x 
magnification.  
[B.] H9c2 cells were fixed to the coverslips after media removal and washed with 
PBS. Immunofluorescence was achieved by nuclei staining with DAPI (blue) while 
actin filaments were stained with TRITC-Phalloidin (red). Images were taken at 40x 
magnification. 
 
Chapter 6: Cds1 in the heart 
182 
 
 
 
6.2.2: Retinoic acid-induced differentiation increases the expression of 
cardiac-specific markers. 
 
Differentiation of H9c2 cells was achieved by culturing the myoblasts in 1% 
foetal calf serum (FCS) in the presence or absence of all-trans-retinoic acid (RA) for 
a minimum of 8 days. The cardiomyocyte-like phenotype was tested for specific 
cardiac markers by immunoblotting with cardiac troponin I (Figure 6.2.A.), and 
qPCR analysis of the mRNA expression of Atrial natriuretic protein (ANP) and Brain 
natriuretic protein (BNP) (Figure 6.2.B).   
 
Protein expression of cardiac troponin I was only detected in H9c2 cells 
differentiated with RA. Ponceau staining was used as loading control and it showed 
no noticeable differences in the overall protein profiles of proliferating H9c2 
myoblast and differentiated myocytes. Relative mRNA expression of ANP showed a 
small 3.04 ±0.6 fold increase in cells differentiated with low serum alone compared 
to proliferating H9c2s, whilst there was a substantial 39.3±17 fold increase in mRNA 
expression obtained by the addition of RA. In a similar fashion, the relative 
expression of BNP mRNA showed a 4.3±1.2 fold increase in cells cultured in 1% 
FCS only and 26.3±9.3 fold increase obtained from RA differentiated H9c2s 
compared to undifferentiated cells. Increased ANP or BNP mRNA expression also 
indicated cell hypertrophy. These results demonstrate that H9c2 cells differentiated 
with low serum and retinoic acid exhibit characteristics found specifically in 
cardiomyocytes. 
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Figure 6.2: Retinoic acid-induced differentiation increases the expression of 
cardiac-specific markers. 
 
H9c2 cells were seeded into 6 well culture dishes at a concentration of 
2x106cells/mL in complete medium (10% FCS) for 48 hours. Proliferating cells were 
passaged every two days while serum media was reduced to 1%FCS and 
replenished every two days for 10 days in the presence or absence of daily 
treatment with 1μM all-trans retinoic acid (RA). Cell lysates were harvested in RIPA 
buffer and RNA was extracted from cells of which 1μg was used to obtain cDNA by 
reverse transcription. 
 
[A.] SDS-PAGE was performed using 75μg of cell lysates on a gradient 4-12% 
acrylamide gel transferred to a PVDF membrane, stained with Ponceau solution and 
imaged to test transfer efficiency and as a loading control. Membranes were 
subjected to western blotting using polyclonal antibody anti-Troponin I at a 1:100 
dilution. MW: molecular weight. 
 
[B.] qRT-PCR of 5μL cDNA using SYBR green. Fold change calculated using the 
ΔΔCt formula where Ct values were obtained in duplicate or triplicate and 
normalised to the Ct values for the housekeeping gene Phosphoglycerate Kinase 1 
(PGK1). Error bars indicate SEM.  
ANP: Atrial natriuretic protein, 1% only (p=0.05, n=7 from 3 experiments) and RA 
(p=0.02, n=11 from 4 experiments).  
BNP: Brain natriuretic protein, 1% only (p=0.1, n=4 from 2 experiments) 1%+RA 
(p=0.08, n=8 from 3 experiments) 
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Figure 6.2: Retinoic acid-induced differentiation increases the expression of 
cardiac-specific markers. 
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6.2.3: Mitochondrial content increases with H9c2 myoblasts differentiation. 
 
 The expression pattern of representative mitochondrial proteins was 
assessed by immunoblotting to test whether biogenesis of these organelles 
increased with differentiation of H9c2 myoblasts as described previously25. The 
mitochondrial proteins analysed include, 75 kDa glucose-regulated protein (GRP75), 
Complex IV (COX IV) and cytochrome C.  I also studied the protein expression of 
CDP-DAG synthase 1 (Cds1), a protein found to be regulated by transcriptional 
coactivator peroxisome proliferator-activated receptor –γ coactivator-α (PGC-1α) 
which is considered the master regulator of mitochondrial biogenesis68. As a 
comparison, the microsomal protein calnexin as well as the cytosolic protein PITPα 
were evaluated (Figure 6.3.A).  
 
The expression of all three mitochondrial proteins was increased with 
differentiation regardless of the addition of retinoic acid whereas cytosolic PITPα 
was unaltered. The antibodies against these proteins detected a single band at the 
expected molecular weights. A semi-quantitative densitometry analysis of the bands 
obtained in separate experiments showed a significant increase in the protein 
expression of cytochrome C (3.1±0.7 fold increase) and GRP75 (3.93±1.5 fold 
increase) compared to the proliferating cells content (Figure 6.3.B.).  
 
The microsomal content, tested by calnexin protein expression, was 
detected by a single band at the expected molecular weight and showed a slight 
reduction in muscle-like cells (1%FCS) while it was unaltered in cardiomyocyte-like 
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cells (1% FCS + RA). However the results of Cds1 were unclear; the antibody 
detected a band at the expected molecular weight (55kDa, Figure 6.3.A, blue arrow) 
that was stronger with RA differentiation but also several other bands of higher and 
lower molecular weights were observed. The intensity and presence of these bands 
varied in different experiments. 
 
In addition, H9c2s cells were tested for time dependent expression of 
mitochondrial and microsomal proteins following daily treatment with retinoic acid. 
The cell lysates were harvested every 2 days for a total of 12 days (Figure 6.4.). The 
expression of the cardiomyocyte marker cardiac troponin I was detected only after 8 
days of retinoic acid treatment, thus, that was the minimum period of treatment 
required to begin to see the cardiac-like phenotype. In parallel, mitochondrial 
content was increased over time as detected by the protein expression increase of 
GRP75 and cytochrome C. This pattern was also observed for the 55 kDa bands 
detected by the Ab:Cds1 antibody which showed a substantial increase by 10 days 
of treatment (Figure 6.4, blue arrow). In addition, the detection of calnexin and the 
cytosolic protein 14-3-3 remained unaltered during RA differentiation during all of 
the 12 days of experimentation. These results confirmed the increase in 
mitochondrial biogenesis that rises upon differentiation of H9c2 cells.  
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Figure 6.3: Mitochondrial content increases with differentiation of H9c2 cells. 
 
H9c2 cells were cultured in complete media (10% FCS) for 48 hours. Proliferating 
cells were passaged every two days while serum media was reduced to 1%FCS 
and replenished every two days for 10 days in the presence or absence of daily 
treatment with 1μM all-trans retinoic acid (RA). Cell lysates were harvested in RIPA 
buffer every two days. 
 
[A.] 50μg of protein content from cell lysates was separated on a NuPage gradient 
4-12% acrylamide gel. Protein detection was achieved by western blotting using 
monoclonal anti-Cds1 at a 1:100 dilution (blue arrow shows the expected molecular 
weight for Cds1), polyclonal anti-calnexin at a 1:1000 dilution as a microsomal 
marker. GRP75, COX IV and cytochrome c antibodies at a 1:1000 dilution were 
used as mitochondrial markers. The cytosolic marker used was PITPα detected by 
antibody 674 at a 1:1000 dilution. MW: molecular weight. 
 
[B.] Protein expression detected by immunoblotting was imaged and the bands 
obtained were subjected to semi-quantitative 2D densitometry using AIDA software. 
Graphs show the averages of 3 separated experiments and the error bars represent 
SEM. (*): p<0.05. Cytochrome c: p=0.01, n=3. GRP75: p=0.03, n=4. 
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Figure 6.3: Mitochondrial content increases over time with differentiation of 
H9c2 cells. 
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Figure 6.4: Mitochondrial content increases over time with differentiation of 
H9c2 cells. 
 
H9c2 cells were seeded into 6 well culture dishes at a concentration of 
2x106cells/mL in complete media (10% FCS) for 48 hours. All cells were cultured in 
reduced serum media (1%FCS) and replenished every two days for 12 days in the 
presence of daily treatment with 1μM all-trans retinoic acid (RA). Cell lysates were 
harvested in RIPA buffer. 
 
Protein detection was achieved by western blotting using monoclonal anti-Cds1 at a 
1:100 dilution (blue arrow corresponds to the expected molecular weight for Cds1). 
Anti-troponin I at a dilution of 1:100 was the cardiomyocyte marker while the 
polyclonal anti-calnexin at a 1:1000 dilution as a microsomal marker. GRP75 and 
cytochrome c antibodies at a 1:1000 dilution were used as mitochondrial markers 
and Anti-14-3-3 was used to detect the 14-3-3 as a cytosolic marker at a 1:1000 
dilution. MW: molecular weight. 
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Figure 6.4: Mitochondrial content increases over time with differentiation of 
H9c2 cells. 
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6.2.4: Expression of phospholipid biosynthetic enzymes after H9c2 cells 
differentiation.  
 
In order to evaluate whether the mRNA content of Cds1 also increased with 
cell differentiation, as suggested by immunoblotting using the antibody Ab:Cds1 
(Figure 6.3 and Figure 6.4), qPCR analysis of cDNA obtained from H9c2 cells was 
performed in the presence or absence of cellular differentiation. For comparison, the 
mRNA expression of other Cds proteins (Cds2 and Tamm41) alongside 
phosphatidylinositol synthase (PIS) and cardiolipin synthase (CLS) was also 
evaluated (Figure 6.5).   
 
Cds1 mRNA expression was significantly not altered by serum media 
reduction (1% FCS only), and the addition of retinoic acid increased relative mRNA 
expression (1.7±0.1 fold increase) compared to Cds1 mRNA in proliferating cells. 
mRNA expression of other mammalian Cds enzyme (Cds2), showed a reduction in 
mRNA upon H9c2 cells differentiation with low serum (0.65±0.003 fold decrease) 
and modest increase on the cardiomyocyte-like cells (1.56±0.14 fold increase), 
compared to undifferentiated cells. In addition, the mRNA expression of PI synthase 
was unaltered regardless of the differentiation method but cardiolipin synthase 
showed a small increase in mRNA expression in the absence (1.6±0.2 fold) and 
presence (1.4±0.1 fold) of retinoic acid (Figure 6.5.A).  
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To further test the mRNA expression increase observed for the Cds proteins, 
H9c2 cells were cultured in differentiation media containing RA for a total of 12 
days. Cells were harvested every two days and the RNA was extracted for cDNA 
synthesis and qPCR analysis (Figure 6.5.B).  The mRNA expression of all three 
enzymes with CDP-DAG synthesis capability was tested, Cds1, Cds2 and Tamm41. 
Cds1 and Cds2 showed a similar mRNA increase over time whilst Tamm41 mRNA 
was diminished. The strongly increased protein expression seen for the antibody 
Ab:Cds1 does not correlate with the relatively modest yet significant mRNA increase 
seen by qPCR. It is possible that Cds proteins translation is rapidly activated upon 
small increases in mRNA during cardiac differentiation. Alternatively, the sensitivity 
of the antibody is greater than expected or it is detecting a cross reactive band at 
the expected size for Cds1.  
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Figure 6.5: mRNA expression of phospholipid biosynthetic enzymes after 
H9c2 cells differentiation.  
 
H9c2 cells were cultured ± differentiation media supplemented with 1%FCS± 1µM 
retinoic acid (RA). 1μg RNA of each lysate was used to make cDNA by reverse 
transcription. 5μL cDNA were assessed for mRNA expression by qPCR using SYBR 
green and the indicated primers. Bars represent the fold change of mRNA ± SEM 
calculated using the ΔΔCt formula where Ct values were normalised to the Ct 
values for the housekeeping gene Phosphoglycerate Kinase 1 (PGK1).  
  
[A.] CDP-DAG synthases (Cds1 and Cds2), P(T<=t) two-tail analysis p<0.001 (**) 
 Cds1 mRNA 1% +RA: p=0.00009, n=29 from 8 experiments.  
Cds2 mRNA after 1%CS +RA: p=0.0009, n=18 from 6 experiments.  
PI synthase (PIS) no statistically significant (NS) 
Cardiolipin synthase (CLS) after 1%FCS +RA: p=0.0008, n=15 from 5 experiments.  
 
[B.] Cds1, Cds2 and TAMM41mRNA expression of H9c2 cells over 12 days of 
differentiation. Mean from 2 experiments in duplicate (n=4). P(T<=t) two-tail analysis 
p<0.001 (**) 
Cds1: (0-4 days) p=0.005; (0-8) p=0.4; (0-10) p=0.002; (0-12) p=0.02. 
Cds2: (0-4 days) p=0.2; (0-8) p=0.1; (0-10) p=0.02; (0-12) p=0.001. 
TAMM41: (0-4 days) p=0.1; (0-8) p=0.01; (0-10) p=0.001; (0-12) p=3.7x10-4 
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B.  
 
Figure 6.5: mRNA expression of phospholipid biosynthetic enzymes after 
H9c2 cells differentiation.  
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6.2.5: Cds1 and PIS Enzyme activity. 
 
CDP-DAG synthase (Cds) activity of H9c2 cells was assayed to test whether 
the differentiation state of H9c2 cells influences stimulation of phospholipid 
synthesis via Cds catalysis of PA and CTP.  The assay was an adapted 
procedure29,119 which measured the level of incorporation of [3H]-CTP into CDP-DAG 
using external phosphatidic acid in a pH8 buffer on H9c2 cell lysates of 
undifferentiated cells alongside cardiomyocyte-like cells (Figure 6.6.A). The Cds 
activity upon retinoic acid differentiation increased close to 2 fold (1.95±0.02, 
p=0.01, n=6) relative to untreated H9c2 myoblasts (Figure 6.6.A).  
 
In addition, PI synthase (PIS) activity of H9c2 cells differentiation was 
measured by the incorporation of [3H]-myo inositol into phosphatidylinositol (PI) in a 
pH 7.4 buffer containing 2mM MnCl2 (Figure 6.6.B).  The PIS activity increased 
close to 4 fold from 12203±1210 DPM counts in undifferentiated cells to 
46484±1613 DPM counts in cardiomyocyte-like cells. These results suggested that 
phospholipid biosynthesis increases substantially when myoblasts differentiate into 
cardiomyocytes.   
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Figure 6.6:  Cds and PIS activity in H9c2 cells.  
 
 [A.] 50μg of H9c2 cells cultured ± differentiation media for 8 days were used for Cds 
assay in a total volume of 100μL. Triplicate sample mixtures were incubated for 10 
minutes at 30o C. The solvent soluble phase was separated and counted for 
radioactivity. Arbitrary units: The bars represent the average DPM counts subtracted 
from background values from 2 experiments normalised to 1 for proliferating cells ± 
SEM.  
 
[B.] PIS assay of 50μg of H9c2 cell lysates. Triplicate sample mixtures were 
incubated for 15 minutes at 37o C. The bars represent DPM counts of the solvent 
soluble phase separated from the mixtures subtracted from background values ± 
SEM from 1 experiment.  
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6.3: Identification of the protein detected by Ab:Cds1. 
 
 There were conflicting results when studying the expression of Cds1 in H9c2 
cells. The high intensity of the protein band detected by Ab:Cds1 at the expected 
molecular weight (55kDa) for Cds1 did not match the mRNA expression increased 
obtained by qPCR (Figure 6.3, Figure 6.4 and Figure 6.5). Since the use of rat Cds1 
primers was fully validated, a characterisation of Ab:Cds1 was granted.     
 
 Ab:Cds1 (clone 2D10) is a monoclonal antibody raised in mouse using a 
sequence from human Cds1 (amino acids 1-99). To assess the likelihood of 
Ab:Cds1 to detect the rat Cds1, a sequence alignment analysis of the human 
protein compared to rat was performed (Figure 6.7). A comparison of the full length 
of the proteins showed a 95.4% identity and 97.2% similarity. However, the specific 
sequence of amino acids 1-99 showed that rat Cds1 shares 89% of identity with 
Human Cds1 suggesting that specificity for rat Cds1 might be compromised. The 
antibody Ab:Cds1 is available from different providers which have predicted for the 
antibody to work in mouse, rat, pig and orangutan. Antibody Ab:Cds1 has been 
used in the detection of human Cds1 in a recent publication using non-
small cell carcinoma lung cells. 42 
 
Cds1 is an integral membrane protein known to be localised in the 
microsomal fraction.58,71,106,119 Therefore to characterise Ab:Cds1 I first analysed the 
cellular localisation of the 55kDa band in H9c2 differentiated cells and adult rat heart 
cellular fractions, followed by analysis of Cds1 overexpression in Cos7 cells and 
down-regulation by siRNA transfection of differentiated H9c2 cells. 
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Figure 6.7: Ab:Cds1 target in Human and rat Cds1 aligned sequences.  
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6.3.1: Differentiated H9c2 cell fractions 
  
 The expression pattern of the 55 kDa protein detected by Ab:Cds1 was 
analysed by immunoblotting of differentiated H9c2 cell fractions obtained by 
differential centrifugation. To assess the degree of purity of the fractions, specific 
organelle markers were studied. Calnexin was the microsomal marker whilst COX 
IV, GRP75 and cytochrome c were the mitochondrial markers (Figure 6.8.A). 
 
Figure 6.8 shows the results from one experiment which was repeated twice 
with similar results. Ab:Cds1 detected the 55kDa protein enriched in the crude 
mitochondrial fraction and not in the microsomal fraction as expected (Figure 6.8.A, 
blue arrow). The immunoreactivity of the markers indicated a low level of 
contamination. However, crude mitochondrial fractions are known to contain 
associated membranes as detected by the microsomal marker. In addition, the 
highest Cds activity was found in the crude mitochondrial fractions (10262±1127 
DPM), nearly twice the counts measured for the whole cells extract (5880.4±642). In 
contrast, microsomal Cds activity was not enriched in differentiated H9c2 cells as it 
was PIS activity (Figure 6.8.B). 
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Figure 6.8: Differentiated H9c2 cell fractions protein expression, Cds and PIS 
activity.   
 
H9c2 cells were cultured in differentiating media for 8 days in the presence of daily 
1μM all-trans retinoic acid (RA). Cells were harvested, lysed and subjected to 
differential centrifugation 
 
 [A.] Protein expression was analysed by western blotting of 50µg of each cell 
fraction using monoclonal antibodies anti-Cds1 at a 1:100 dilution and anti-
cytochrome c at a 1:1000 dilution as a mitochondrial marker, and on separate 
membranes the polyclonal antibodies (1:1000 dilution) anti-calnexin as a 
microsomal marker, anti-GRP 75 as mitochondrial marker and anti-14-3-3 as a 
cytosolic marker. The blue arrow indicates the expected molecular weight for Cds1. 
MW: molecular weight. 
 
[B.] Cds Activity: 50ug of cell fraction was incubated for 10 min at 30o C in Cds 
activity assay buffer. Bars represent the average of triplicate samples from 2 
experiments ± SEM.  PIS Activity: 50μg of cell fractions was incubated for 15 min at 
37oC in PIS assay buffer. Bars represent the mean± SEM of three samples obtained 
from 1 experiment using the fractions described in A.  
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Figure 6.8: Differentiated H9c2 cell fractions.   
 
Chapter 6: Cds1 in the heart 
202 
 
6.3.2: Adult rat heart fractions 
 The results obtained with Ab:Cds1 together with Cds activity in differentiated 
H9c2 cell fractions showed that Ab:Cds1 was detecting a 55kDa protein enriched in 
crude mitochondria where Cds activity was also the highest compared to the other 
cellular fractions (Figure 6.8.). In order to compare these observations in primary 
tissue, the protein expression and enzyme activity assays were performed using 
cellular fractions from adult rat hearts.  
 
The fractions were obtained by dissection followed by differential 
centrifugation of whole hearts by an adapted protocol from previous studies.77,121 It 
is understood that the heart is a tissue enriched in highly dense mitochondrial 
content and so initially, tissue isolation and homogenisation was performed in the 
presence of the protease subtilisin, which was recommended to increase yield and 
purity of the mitochondria. The fractions were studied by immunoblotting (Figure 
6.9.A). Cds and PIS activity assays were performed as described above (Figure 
6.9.B). Figure 6.9 represents the results from one experiment which represents the 
observations of five other similar experiments. 
 
 The antibody Ab:Cds1 detected a single strong band at 55kDa in the crude 
mitochondrial fraction (Figure 6.9.A., blue arrow). The expression of mitochondrial 
markers (GRP75, COX IV and cytochrome c) was detected strongly in the 
mitochondria. However, although membranes were probed with anti-calnexin to test 
for purity of the microsomal fractions, no bands were detected (data not shown). It 
was noted that in the protein profile obtained by Ponceau staining of the PVDF 
membrane the proteins were only visible in the crude mitochondrial fraction. This 
result suggested that the presence of protease in the isolation buffer had broken 
 
Chapter 6: Cds1 in the heart 
203 
 
down non-mitochondrial proteins. Nevertheless the enzymes Cds and PIS showed 
the same pattern of activity seen in differentiated H9c2 cells. Cds activity was 
stronger in the crude mitochondrial fraction (Figure 6.9.B), while PIS activity was 
concentrated in the microsomes (Figure 6.9.C).    
 
Figure 6.9: Adult rat heart cell fractions obtained in the presence of protease: 
protein expression, Cds and PIS activity.   
 
Two females Sprague-Dawley rats (6 months old) were euthanised, the hearts were 
dissected and homogenised in a pH 7.4 buffer containing subtisilin (0.4 mg/mL) and 
subjected to differential centrifugation. 
 
[A.] 50µg of each rat heart tissue fraction was analysed by western blotting using 
monoclonal antibodies anti-Cds1 at a 1:100 dilution and anti-cytochrome c at a 
1:1000 dilution as a mitochondrial marker and on separate membranes the 
polyclonal antibodies (1:1000 dilution) anti-GRP 75 and anti-complex IV (COX IV) as 
mitochondrial markers. Prior to blotting, the membranes were stained temporarily 
with Ponceau solution and imaged. Blue arrow indicates the expected molecular 
weight for Cds1. MW: molecular weight. 
 
[B.] Cds Activity: 50µg of cell fraction was used for Cds activity analysis for 10 
minutes at 30o C. [C.] PIS Activity: 50μg of fractions was used for PIS assay for 15 
minutes at 37o C. The bars for [B.] and [C.] represent the mean ±SEM of 3 
measurements of radioactivity incorporated into the fractions analysed in [A.] in one 
experiment. Micro: Microsomes. C Mito: crude mitochondria. Cyto: cytosol. 
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Figure 6.9: Adult rat heart cell fractions obtained in the presence of protease: 
protein expression, Cds and PIS activity.   
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a. Pure mitochondria and Mitochondrial Associated Membranes of rat 
hearts. 
 
In order to further analyse the protein detected by Ab:Cds1 in adult rat heart 
crude mitochondrial fractions, crude mitochondria was fractioned into pure 
mitochondria and mitochondrial associated membranes (MAM) by Percol gradient 
centrifugation. No subtisilin was included in the isolation buffer to assess the effect 
of this protease in the results (Figure 6.9.). The purity of the fractions was assessed 
by immunoblotting using calnexin as a microsomal marker and GRP75 and 
mitofusin 2 as mitochondrial markers (Figure 6.10.A). In addition, the activity of Cds 
and PIS was analysed using the assays described above (Figure 6.10.B and Figure 
6.10.C). 
 
By isolating the fractions in the absence of the protease, the protein profiles 
were readily observed by Ponceau staining indicating that in order to compare 
different organelles alongside each other, the use of protease in mitochondrial 
isolation should be avoided. There was an enrichment in crude and pure 
mitochondrial fractions with a low level of mitochondrial contamination in microsomal 
fractions detected by anti-GRP75. A single band was detected by Ab:Cds1 at 55kDa 
by western blotting. Contrary to the observation in fractions isolated with the 
protease, all fractions were positive for Ab:Cds1. However, the band was stronger in 
crude mitochondria and the strongest signal was observed in pure mitochondrial 
fractions, which also showed no level of microsomal contamination. This 
observation indicates that the protein identified by Ab:Cds1 was a mitochondrial 
protein. In addition, the Cds activity measurements reflected the intensity of the 
protein bands obtained with Ab:Cds1 while PIS activity was concentrated in the 
microsomal fractions once more. This observation reinforces the notion that the 
highest Cds activity is found associated with mitochondria in the rat heart.  
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Figure 6.10: Adult rat heart cell fractions: protein expression, Cds and PIS 
activity.   
 
Four females Sprague-Dawley rats ( 6months old) were euthanised, the hearts were 
dissected and homogenised in a pH 7.4 buffer and the lysates were separated by 
differential centrifugation. 
 
 [A.] On a 4-12% gradient acrylamide gel 50μg of adult rat heart fractions were 
subjected to SDS-PAGE. After transfer of protein profiles onto PVDF membranes, 
Ponceau staining was performed and imaged. Protein expression was analysed by 
western blotting using monoclonal antibodies anti-Cds1 at a 1:100 dilution, on 
separate membranes, the polyclonal antibodies (1:1000 dilution) calnexin as 
microsomal marker and anti-GRP 75, anti-mitofusin2  and anti-complex IV (COX IV) 
as mitochondrial markers. Blue arrow indicates the expected molecular weight for 
Cds1. MAM: Mitochondrial Associated Membranes. MW: molecular weight.  
 
[B.] Cds Activity: Three measurements of the same sample mixtures containing 
50µg of each cell fraction were used assay Cds activity during 10 minutes at 30o C.  
[C.] PIS Activity: 50μg of each fraction in triplicate were used to assay PIS activity 
for 15 minutes at 37o C. The bars in [B.] and [C.] represent the mean ± SEM DPM 
counts from one experiment where the background reading was subtracted the 
values obtained from the fractions tested in [A.]. Micro: microsomes. C Mito: crude 
mitochondria. P Mito: pure mitochondria.  
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Figure 6.10: Adult rat heart fractions: protein expression, Cds and PIS activity.   
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6.3.3: Anti-Cds1 recognises overexpressed Cds1 and no Cds2. 
 
To validate Ab:Cds1 for immunoblotting, Cos7 cells were transfected with 
human myc-Cds1. Furthermore, the specificity of the antibody was tested by 
comparing overexpressed myc-tagged human Cds1 and Cds2 by western blotting. 
The plasmids were transfected and analysed on a 7.5% acrylamide gel following the 
methods in the publication from the group that provided us with the plasmids.29 Cos7 
cells transfected with an empty pCDNA plasmid were used as negative control 
(Figure 6.11.). The Cds activity of the overexpressed cell lysates was also analysed 
to evaluate whether the protein expression pattern reflected the activity of the 
enzymes (Figure 6.11.C). 
  
Ab:Cds1 detected a very strong signal at ~80kDa exclusively from Cos7 cell 
lysates transfected with human myc-Cds1, which indicated that the antibody is 
specific for human Cds1. In comparison, the anti-myc antibody detected stronger 
transfection of the human myc-Cds2 over myc-Cds1 in Cos7 cells with a detection 
pattern similar to the one seen with Ab:Cds1 (Figure 6.11.B). On the other hand, the 
analysis of Cds activity on the transfected cells showed a higher activity from the 
Cds1 over the Cds2 overexpressed samples (Figure 6.11.C). 
 
In addition, the single band previously seen at 55kDa from pure 
mitochondrial rat heart (Figure 6.10) was detected at a much lower molecular weight 
compared to overexpressed Cds1 at ~36kDa (Figure 6.11.A) , suggesting that this 
endogenous protein is a mitochondrial protein of unknown identity with possibly 
higher expression in rat samples than Cds1. 
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Figure 6.11: Ab:Cds1 recognises overexpressed human Cds1.  
 
Cos7 cells were transiently transfected with human myc-Cds1, myc-Cds2 or an 
empty pCDNA vector by lipofection for 24 hours and further cultured for 24 hours. 
 
75µg of each Cos7 cell lysates were harvested in PBS and mixed with 2x Laemmili 
buffer and warmed at 60oC for 5 minutes alongside 50µg of pure mitochondrial 
fraction obtained from differential centrifugation of adult rat hearts. SDS-PAGE was 
performed using 7.5% acrylamide gel at 200 volts for 45 minutes. Proteins were 
analysed by western blot using monoclonal antibodies: 
[A.] Anti Cds1, Ab:Cds1 at 1:100 dilution.  
[B.] Anti-myc, Ab:Myc at 1:1000 dilution. 
[C.] 50µg of each Cos7 cell lysates and cellular fractions of cells transfected with 
myc-Cds1 were tested for Cds activity for 10 minutes at 30oC. Samples were 
analysed in triplicate and the bars show mean ± SEM of one experiment.   
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Figure 6.11: Ab:Cds1 recognises overexpressed human Cds1.  
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6.3.4: Transfection of siRNA Cds1 in differentiated H9c2 cells 
 
Although Ab:Cds1 does recognise overexpressed Cds1 and not Cds2, the 
endogenous protein thought to be Cds1 did not co-migrate with the overexpressed 
Cds1 (Figure 6.11). Therefore the identity of the detected 55kDa protein was 
ultimately tested for Cds1 mRNA down-regulation by rat siRNA transfection of 
differentiated H9c2 cells. Due to the length of time required for differentiation (9 
days), siRNA transfection was evaluated at consecutive 3 day intervals using a 
negative siRNA or a combination of two rat Cds1 siRNA oligonucleotides and 
analysed by immunoblotting (Figure 6.12.A). Down-regulation efficiency and 
specificity was tested by qPCR of Cds1 mRNA alongside Cds2 and Tamm41 mRNA 
(Figure 6.12.B). 
  
Cds1 mRNA down-regulation was effective as seen by the 72±0.5% 
reduction in relative mRNA found by qPCR after one round (transfection on day 6) 
and 76±2% reduction after three rounds (transfections on days 0, 3 and 6) of siRNA 
transfection compared to cells transfected with a negative siRNA. This down-
regulation was specific for Cds1 since Cds2 and Tamm41 mRNA was not affected 
by Cds1 siRNA transfection (Figure 6.16.B). However, none of the bands detected 
by Ab:Cds1 were visibly affected by rat Cds1 siRNA after any number of siRNA 
transfections including the signal of the 55kDa protein, which was the band 
presumed to be Cds1. The experiment was repeated several times and although 
some signal reduction was noted in 2 experiments, the majority of results 
determined that antibody Ab:Cds1 recognises another 55kDa protein in rat tissue 
possibly alongside Cds1. Therefore, Ab:Cds1 was not suitable for the study of the 
protein expression of endogenous Cds1 in rat heart by western blotting.  
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Figure 6.12: The 55kDa protein detected by Ab:Cds1 in H9c2 cells is not 
affected by rat Cds1 siRNA 
 
H9c2 cells were cultured in media supplemented with 1% FCS media plus daily all-
trans retinoic acid (1μM RA) for a total of 9 days. On day 0, 3 and/or 6 of 
differentiation, 12nM of two rat Cds1 siRNA oligonucleotides or a negative siRNA 
were introduced into the cells and incubated for 3 days. As control sample, no 
siRNA was transfected (untreated). Cell lysates were harvested in RIPA buffer and 
RNA lysis buffer on day 9 of differentiation.  
 
[A.] 75μg of differentiated H9c2 cell lysates were analysed by western blotting on a 
PVDF membrane stained with Ponceau solution as a loading control. Membranes 
were probed with monoclonal antibody Ab:Cds1 at a 1:100 dilution. 
 
[B.] 1μg RNA was used to obtain cDNA by reverse transcription qRT-PCR of 5μL 
cDNA using SYBR green and the indicated primers. Ct values were obtained in 
triplicate and the ΔΔCt formula was used to normalise to the Ct values from 
Phosphoglycerate Kinase 1 (PGK1). The bars represent average fold change in 
mRNA ± SEM using the samples in [A.]. (*): p<0.05 
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Figure 6.12: The 55kDa protein detected by Ab:Cds1 in H9c2 cells is not 
affected by rat Cds1 siRNA.  
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6.4: Summary and discussion. 
 
 In this chapter I investigated the expression pattern of proteins involved in 
phospholipid biosynthesis in H9c2 cells subjected to differentiation brought about by 
reducing the concentration of FCS from 10% to 1% and by adding all-trans-retinoic 
acid. Differentiated cells exhibited a cardiomyocyte-like phenotype confirmed on the 
basis of changes to morphological features as compared with the parental line 
(Figure 6.1). The changes in cell morphology were found to occur in concomitance 
with the expression of specific cardiac markers including cardiac troponin I, ANP 
and BNP (Figure 6.2), in agreement with previous reports investigating 
cardiomyocyte-like differentiation of H9c2 cells. 25,80,88 
  
During the course of myoblast differentiation there was an increase in the 
expression of the mitochondrial proteins COX IV, GRP75 and cytochrome C, which 
implied an increase in mitochondrial biogenesis (Figure 6.3 and Figure 6.4). Other 
recent studies had also reported up-regulation of proteins related with mitochondrial 
function, including PGC-1, ATP synthase and cytochrome c oxidase. 11,25 PGC-1 is 
known for acting as a master regulator of energy metabolism and mitochondrial 
biogenesis and it has been shown to regulate Cds1 expression in the adult heart by 
a mechanism which involves direct transcriptional activation68. Conversely, other 
mitochondrial enzymes known to assist in CL biosynthesis, such CLS, were not 
regulated by PGC-1.68 Similarly in this study, although the immunoblotting analysis 
of differentiated H9c2 cells determined mitochondrial content increases (Figure 6.3 
and Figure 6.4), the mRNA expression of the enzymes involved in phospholipid 
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synthesis was not up-regulated (Figure 6.5). Nevertheless, Cds and PIS activities 
did increase after differentiation (Figure 6.6) and CLS activity was not investigated.  
 
 
Endogenous Cds1, together with PIS, were recently found restricted to a 
sub-fraction of the calnexin-positive ER fragment after membrane fractionation of 
epidermoid carcinoma human cells.119 Cds1 was also localised exclusively to the ER 
in yeast (Saccharomyces cerevisiae); where the mitochondrial translocator 
assembly and maintenance protein, homolog (Tamm41) was found to be the 
mitochondrial Cds enzyme leading to cardiolipin biosynthesis.68 In this study, when 
differentiated H9c2 cells and adult heart tissue were fractionated, Cds activity was 
constantly higher in the enriched mitochondrial fractions, rather than in microsomes 
or mitochondrial associated membranes as expected (Figure 6.8 and 6.10). 
However the degree of purity of the fractions requires further consideration and, 
established MAM marker antibodies such the sigma1 receptor or ACSL4 were not 
investigated in these experiments. Although mitofusin2 has been reported to be 
present tethering mitochondria to the ER allowing the communication of calcium 
between these two organelles,30 it is considered as a mitochondrial rather than MAM 
marker protein based on its ability to promote mitochondrial fusion. In addition, the 
intention of including Cds activity measurements to cellular fractions was to 
compare activity with protein expression as measured by the Ab:Cds1 and therefore 
no attempt was made to find the statistical significance of those observations. 
Furthermore the Cds activity assay used here was not able to distinguish between 
Cds1, Cds2 or Tamm41 contribution towards the CDP-DAG synthesis measured 
and that could be subject of future studies.  
 
Additionally, immunoblotting analysis showed a stronger content of 
overexpressed human myc-Cds2 than myc-Cds1 in transfected Cos7 cells. Cds 
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activity on the contrary, showed higher activity from Cds1 over Cds2  (Figure 6.11) 
which might be explained by the recent report on the specificity of Cds2 in the fatty 
acid species of the PA used as substrate in the assay. Cds2 preferred 1-stearoyl-2-
arachidonoyl-phosphatidic acid (18:0/20:4) whilst Cds1 showed no particular 
substrate specificity.29 The PA used for the Cds assay in this study contained low 
quantities of arachidonic and stearic acids (Table 2.10).  
 
The study into the protein expression of Cds1 was put into question due to 
the characterisation of the antibody used. The localisation study in conjunction with 
the observation that the endogenous 55kDa protein detected by the antibody 
Ab:Cds1 was not down-regulated by rat Cds1 siRNA in H9c2 cells suggested that 
the band detected a mitochondrial associated protein of unknown identity with 
higher intensity than Cds1(Figure 6.13). However, since this observation relied on 
siRNA data, additional controls other than the negative siRNA and untreated 
transfection controls should have been included in the study for a definite answer. 
The absent controls include an endogenous positive control sample with no siRNA 
where all reagents other than the siRNA should be added to test for any effect from 
the transfection reagents such as cytotoxicity or other non-specific effects.  In 
addition, a ‘mock’ control of a validated siRNA pool or individual siRNA targeting a 
well-characterized housekeeping gene, such as GAPDH which is well-expressed 
but non-essential could have been included to establish cellular viability.  
 
The datasheet of Ab:Cds1, commercially known under catalogue number 
H00001040-M01, shows as positive control a western blot image of a single band 
detected at 55kDa in human liver without any further details. In addition, the 
publication citing the antibody used human lung cells and it did not include an 
antibody characterisation42. The same antibody has been sold by various companies 
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under different codes. For instance, the study reporting that Cds1 activity coincides 
with protein expression of calnexin enriched fractions used antibody MCA5324Z119 
which shows exactly the same details as H00001040-M01. Both studies used 
human cell lines as their model. In addition, the crystal structure of Cds1 showed 
that it forms a homodimer71 and when Cos7 cells were overexpressed with Myc- 
Cds1 demonstrated that Ab:Cds1 does recognise a 80kDa protein which could be 
the dimer form of the protein (Figure 6.11); plus the sequence in rat corresponding 
to the human Cds1 sequence used as immunogen was 89% identical (Figure 6.7). It 
is possible that the antibody exclusively recognises human Cds1 and not rat Cds1. 
Further characterisation to test species specificity will be required. An alternative to 
this problem for future studies in rat heart could be using another antibody, for 
example, anti-Cds rabbit antibody (product No. ab84019, Abcam,). However, this 
antibody has not been characterised appropriately increasing the risk of spending 
time and resources which might end again in invalidation. In chapter 4, I already 
discussed the problems associated with the use of uncharacterised antibodies in 
research.  
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CHAPTER 7: Effects of Arginine Vasopressin stimulation on the 
expression of RdgBβ and Cds1 in H9c2 cells. 
 
7.1. Introduction 
 
This study attempted to describe the endogenous expression of RdgBβ and 
Cds1 in H9c2 cells and rat heart samples in order to identify clues leading to the 
elucidation of their physiological function in the heart. For protein expression of 
RdgBβ, the antibody Ab:Rb59 was validated for immunoblotting experiments 
(Chapter 4), which determined that RdgBβ is a cytosolic protein upregulated by 
differentiation of H9c2 cells, and its protein and mRNA expression increased with 
cardiac maturation (Chapter 5). On the other hand, protein expression of Cds1 was 
limited to mRNA results due to the invalidation of the antibody used for 
immunoblotting on rat samples. Contrary to RdgBβ, Cds1 mRNA was not affected 
by H9c2 differentiation (Chapter 6).  
 
This chapter describes work into an approach that was pursued considering 
the limitations of this thesis. Since H9c2 cells present receptors for vasopressin 
(AVP V1) which are coupled to PLC signalling132 and AVP stimulation was found to 
produce H9c2 cellular hypertrophy and increased protein synthesis,14 the effect of 
AVP receptors stimulation in H9c2 cells was evaluated for possible changes in the 
expression of RdgBβ and Cds1.  
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7.2: Arginine Vasopressin stimulation in H9c2 cells. 
 To evaluate whether the changes observed in H9c2 cells upon differentiation 
resemble the effects of G-coupled receptor-mediated PLC signalling in H9c2 cells, 
the expression pattern of H9c2 cells was studied after chronic stimulation with the 
vasodilator Arginine Vasopressin (AVP). 
    
7.2.1: AVP stimulation of PLC activity in H9c2 cells. 
 
PLC activity was measured by an assay described previoulsly48 which 
quantifies the [3H]-inositol phosphates produced as a result of PIP2 hydrolysis by 
phospholipase C stimulation in H9c2 cells. In brief, 1μM AVP or Ang II were added 
to the cells in culture and incubated for one hour. The addition of 10mM LiCl to the 
incubation buffer inhibited the hydrolysis of inositol phosphates back to inositol 
allowing the inositol phosphates to accumulate. Untreated cells provided the base 
level activity control of the assay (Figure 7.1).  
 
The treatment with arginine vasopressin increased the proportion of labelled 
inositol phosphates from 9.7±4.6% to 43.9±3.5% in proliferating H9c2 cells. 
Similarly, RA differentiated cells showed an increase in PLC activity from 5.9±0.04% 
to 37.3±4.2% of labelled inositol phosphates. On the contrary, Angiotensin II did not 
stimulate PLC-mediated PIP2 hydrolysis in H9c2 cells irrespective of the 
differentiation state, which suggested that AngII receptors are absent or not 
expressed in sufficient quantities to produce a measurable reaction. 
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Figure 7.1:  PLC-mediated PIP2 hydrolysis in H9c2 cells.  
 
H9c2 cells were seeded into 6 well culture dishes and cultured for 2 days 
(Proliferating) or 8 days (Differentiated) before [3H]-Inositol was added for 16 hours. 
Radiolabelled media was removed and replaced by buffer containing LiCl in the 
absence or presence of the agonist in duplicate: 1μM Angiotensin II (Ang II) or 1μM 
Arginine Vasopressin (AVP). Cells were incubated for 1 hour at 37o C with the 
stimulants before harvesting. The samples were separated into aqueous or 
chloroform soluble phases and [3H]-inositol phosphates formed were isolated from 
the aqueous phase using Dowex columns.  For data analysis, the average of 
radioactive counts (dpm) was expressed as a proportion of the total radioactivity 
counted per sample. The bars show average of 2 experiments ± SEM. Proliferating 
(p=0.02), differentiated cells (p=0.003). 
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7.2.2: Arginine Vasopressin stimulation effect in the expression of RdgBβ in 
H9c2 cells. 
 
The effect of AVP stimulation in the expression of RdgBβ in H9c2 cells was 
analysed by immunoblotting and qRT-PCR (Figure 7.2). After 3 days of 0.5μM AVP 
stimulation no change was observed in the protein expression of RdgBβ detected by 
antibody Ab:Rb59 compared to the expression of PITPα regardless of the 
differentiation state (Figure 7.2.A). Similarly treatment with 0.5μM AVP had no 
impact on RdgBβ mRNA expression of differentiated H9c2 cells and showed a non-
significant increase of RdgBα relative mRNA expression. However, proliferating 
cells showed a reduction in RdgBβ mRNA content of around 40% decrease (Figure 
7.2.B).  
 
These results indicated that the expression of RdgBβ is not regulated by 
vasopressin stimulation in H9c2 differentiated cells. Since the experiment with 
proliferating cells was performed only twice, the significance of the decrease in 
RdgBβ mRNA is difficult to interpret.    
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Figure 7.2: Expression of RdgBβ after stimulation of H9c2 cells with AVP. 
 
H9c2 cells were cultured for 2 days (Proliferating) or 8 days (Differentiated) then 0.5 
µM arginine vasopressin (AVP) or no stimulant (Untreated) were added to the media 
for 3 days.  
 
[A.] 75µg of cell lysate was subjected to western blot analysis using polyclonal 
antibodies Ab:Rb59 for RdgBβ detection at a 1:100 dilution and Ab:674 for PITPα 
detection at a 1:1000 dilution.  
 
[B.] 1µg of RNA for each sample was used to produce cDNA which was then used 
for qRT-PCR analysis using the primers indicated in triplicate samples. The bars 
represent the average fold change of relative Ct values normalised to PGK1 
obtained with the ΔΔCt formula ± SEM of 7 experiments for RdgBβ (Differentiated) 
and 2 experiments for RdgBβ (Proliferating) and RdgBα mRNA.   
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7.2.3: AVP stimulation effect in Cds activity and Cds1 mRNA expression in 
H9c2 cells. 
 
The Cds activity and mRNA expression of Cds1 were also analysed after 
chronic stimulation of Arginine Vasopressin of H9c2 cells prior and after 
differentiation (Figure 7.3). The Cds activity upon AVP treatment in proliferating cells 
resembled the activity observed upon retinoic acid differentiation with a close to two 
fold increase. On the other hand, Cds activity of differentiated H9c2 cells was 
minimally increased by AVP stimulation (Figure 7.3.A). These results suggest that 
AVP promotes Cds-mediated CDP-DAG synthesis in proliferating cells but not in 
terminally differentiated H9c2 cells.  
 
Additionally, Cds1 mRNA expression was substantially increased with 
vasopressin stimulation in both myoblasts and differentiated H9c2 cells, although 
the increase in proliferating cells was higher (4.07±0.17 fold increase) than in 
differentiated cells (3.09±0.27 fold increase). In comparison, Cds2 mRNA 
expression was unaffected by AVP stimulation (Figure 7.3.B). The significance of 
the mRNA expression increase of Cds1 mRNA remains to be explored. 
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Figure 7.3:  Cds activity in H9c2 cells.  
H9c2 cells were cultured in complete media (10% FCS) for 16 hours (Proliferating), 
or cultured in serum media reduced to 1%FCS in the presence of daily 1μM all-trans 
retinoic acid. The cells were incubated ±1μM Arginine vasopressin (AVP) for 3 days. 
[A.], 50μg of cell lysates was tested for Cds activity for 10 minutes at 30o C. The 
bars represent dpm counts relative to proliferating untreated cells counts ± SEM. 
(Proliferating: 2.13±0.2, p=0.009, n=6; Differentiated: 2.33±0.006, p=0.005, n=6) 
[B.] 1μg mRNA was used to produce cDNA by reverse transcription. 5μl of cDNA 
was used in qRT-PCR analysis using SYBR-green and the indicated primers in 
triplicates. The bars represent the average of Ct values normalised to PGK1 using 
the ΔΔCt formula relative to the untreated samples. Proliferating Cds1 mRNA: (**) 
p=3.3x10-7 from 7 experiments (n=21). Cds2 mRNA: n=6 from 2 experiments.  
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7.3: Summary and discussion. 
Chapter 7 described work into the effects of chronic AVP stimulation in H9c2 
cells. Firstly it was observed that H9c2 cells responded to AVP but not to AngII 
stimulation (Figure 7.1). This result suggests that proliferating and differentiated 
H9c2 cells do not express Ang II receptors. Alternatively, these receptors might be 
inactive or present in very small quantities in this cell line. Similarly, a previous study 
identified Ang II stimulation on H9c2 cells to be ineffective and found an association 
between vasopressin stimulation of H9c2 myoblast and differentiated cells with the 
development of cardiac hyperthrophy.14   
 
Furthermore, the expression analysis found that RdgBβ is not regulated by 
AVP stimulation (Figure 7.2), indicating that the increase in expression upon cellular 
differentiation observed in this thesis (Chapter 5) is not a result of G-coupled PLCβ 
signalling.  
 
Finally, chronic AVP treatment substantially increased Cds activity in 
proliferating cells while the response in differentiated cells was much smaller (Figure 
7.3.A). A previous study exploring vasopressin stimulation in H9c2 cells 
differentiation also noticed this difference by showing that AVP evoked a large PLC 
signalling-induced Ca2+ release in H9c2 myoblasts, whereas the response in 
differentiated cells was weaker.128 This result was not reflected in the mRNA 
expression analysis where Cds1 was significantly increased upon AVP stimulation 
regardless of the differentiation state of the cells (Figure 7.3.B). Therefore it would 
appear that the increase of Cds1 mRNA upon AVP stimulation might influence the 
Cds activity of H9c2 cells distinctively on the state of differentiation. 
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CHAPTER 8: Effects of RdgBβ and Cds1 silencing by siRNA on cell 
morphology and Cds activity. 
 
8.1: Introduction 
 
In this thesis the endogenous expression of RdgBβ and Cds1 has been 
studied in H9c2 cells. Chapter 7 explored the influence of AVP stimulation on their 
expression and provided a small insight into Cds1 mRNA regulation. However, the 
physiological functions of these proteins remain unclear. This Chapter describes 
briefly two approaches taken to explore the possible contribution of Cds1 and 
RdgBβ towards CDP-DAG formation in the rat heart and shows the observations on 
the effects of rat RdgBβ and Cds1 mRNA downregulation in differentiated H9c2 cell 
morphology. 
 
 
8.2: Potential involvement of Cds1 and RdgBβ in Cds activity in the rat heart. 
 
8.2.1: Cds1 mRNA downregulation effect in total Cds activity. 
 
 The Cds assay used in this study did not distinguish the contribution of each 
Cds protein present in the lysates. Although the characterisation of the Ab:Cds1 
demonstrated that this antibody is not suitable for the study of the protein 
expression of Cds1 in rat heart samples, the mRNA expression was effectively 
downregulated by siRNA transfection (Chapter 6). Therefore, the contribution of 
Cds1 towards total Cds activity in differentiated H9c2 cells was tested by comparing 
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Cds activity in cells transfected with rat Cds1 siRNA against a negative siRNA 
oligonucleotide during cellular differentiation (Figure 8.1).  
 
After one Cds1 siRNA transfection at day 6 of differentiation (72 h), the total 
Cds activity was reduced by 30±4%. Similarly, three consecutive transfections at 
days 0, 3 and 6 of differentiation (72h x 3) showed the activity diminished by 25±6%. 
These results indicated that Cds1 is a minor contributor to the total Cds activity 
during H9c2 cells differentiation using this particular assay. 
 
8.2.2: Effects of RdgBβ on Cds activity. 
 
The most notable characteristic described for RdgBβ to date is its ability to 
transfer Phosphatidic acid (PA) between membranes in vitro,40 and PA is the 
substrate of Cds enzymes which is converted into CDP-DAG. Therefore I tested 
whether RdgBβ influenced Cds activity in the rat heart firstly by comparing Cds 
activity of H9c2 cells where RdgBβ mRNA was downregulated (Figure 8.2.A), 
followed by the addition of recombinant RdgBβ to microsomal and crude 
mitochondrial fractions of adult rat hearts (Figure 8.2.B).  
 
Rat RdgBβ siRNA transfection marginally reduced Cds activity of 
differentiated H9c2 cells, and the addition of recombinant protein did not alter Cds 
activity measurements of microsomes and crude mitochondrial fractions. These 
results indicated that is highly unlikely that RdgBβ directly influences CDP-DAG 
synthesis in the rat heart. 
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Figure 8.1: Cds1 mRNA downregulation effect in Cds activity in differentiated 
H9c2 cells. 
The Cds activity assay was performed using 50µg of cell lysates from differentiated 
H9c2 cells which were transfected with two rat Cds1 siRNA oligonucleotides for the 
duration of the nine days differentiation (72h x 3), or transfected on the last 3 days 
(72h).  
 
The graph shows the average normalised to the values obtained from negative 
siRNA cell lysates. 72h (**): p=0.0004, n=9 from 2 experiments. 72h x 3(*): p=0.03, 
n=9 from 3 experiments. 
 
 
 
 
 
 
Chapter 8: RdgBβ and Cds1 in cell morphology and Cds activity 
229 
 
 
 
Figure 8.2: Effects of RdgBβ in the rat heart Cds activity. 
[A.] Cds activity of 50µg of differentiated H9c2 cells transfected with a negative 
siRNA or two rat RdgBβ siRNA oligonucleotides for the duration of the 9 days 
differentiation (72h x 3). 
 
[B.] 50 µg of microsomal and crude mitochondrial fractions obtained by differential 
centrifugation of adult rat hearts were tested for Cds activity ± 200µg/mL 
recombinant RdgBβ. p=0.002 (n=6 from 2 experiments) 
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8.2.3: Effects of RdgBβ and Cds1 mRNA downregulation in the morphology of 
differentiated H9c2 cells. 
 
During the siRNA experiments described in previous chapters, I noticed that 
the cells in culture differed in their morphology when seen under the microscope 
depending on the type of siRNA oligonucleotides transfected into H9c2 cells. 
Consequently, the changes in cell morphology after rat RdgBβ and Cds1 siRNA 
transfection were analysed by immunofluorescence of the actin filaments by 
phalloidin staining of fixed cells. Untreated proliferating and differentiated cells were 
also analysed for comparison (Figure 8.3). 
 
Differentiated H9c2 cells transfected with a negative siRNA showed the 
same multinucleated fused cells seen in non-transfected cells whilst cells where 
RdgBβ mRNA was downregulated showed a substantial increase in cell volume 
conserving multinucleation and actin filaments. In comparison, transfection of 
RdgBα siRNA was vastly detrimental to the cells whilst PITPβ mRNA 
downregulation did not show any change in cell morphology. This observation 
suggested that unlike other PITPs, RdgBβ may influence H9c2 cells hypertrophy.  
 
In addition, Cds1 siRNA transfection of H9c2 cells showed a distinct 
abnormality in the shape of cells upon Cds1 siRNA transfection; the cells looked 
rounded with a loss of the bright actin filaments compared to cells transfected with 
negative siRNA suggesting that Cds1 is involved in actin filaments formation during 
differentiation of H9c2 cells. 
 
Chapter 8: RdgBβ and Cds1 in cell morphology and Cds activity 
231 
 
 
Figure 8.3: Effects of RdgBβ and Cds1 mRNA downregulation in differentiated 
H9c2s cell morphology. 
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Figure 8.3: Effects of RdgBβ and Cds1 in differentiated H9c2 cells 
morphology. 
 
To study cell morphology, H9c2 cells were seeded at a concentration of 
1x106cells/mL on 12-well plates containing coverslips. Proliferating cells were 
cultured in media supplemented with 10% FCS. Differentiated cells were cultured in 
1% FCS+ daily 1µM retinoic acid for 9 days. Rat siRNA transfection of cells was 
performed on day 0, 3 and 6 during differentiation. After 9 days, cells were fixed with 
4% formaldehyde and analysed by immunofluorescence. Nuclei were stained using 
DAPI at a 1:5000 dilution (blue) and actin filaments were stained with TRITC 
phalloidin at a 1:1000 dilution (red). Images were taken at a 40x magnification. 
RdgBβ and Cds1 images (1) and (2) were taken from separate coverslips in one 
experiment while (3) were taken from a separate experiment.  
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8.3: Summary and discussion 
 
The CDP-DAG synthesis in rat heart samples using the Cds activity assay 
described in this thesis was found not to be affected by RdgBβ (Figure 8.2) and 
Cds1 was a minor contributor (Figure 8.1). The source of PA used for the assay 
might have influenced those results. A recent report showed that the fatty acid 
species of the PA used as substrate in the assay was specific for Cds2 activity 
which preferred 1-stearoyl-2-arachidonoyl-phosphatidic acid (18:0/20:4). Cds1, 
conversely, showed no particular substrate specificity, although di-oleoyl PA 
(18:1/18:1) displayed less activity29. The PA used for the Cds assay in this study 
contained 5.5% of arachidonic acid, 11.7% of stearic acid and 36% of oleic acid 
(Table 2.10).  Although the fatty acid preference of the mitochondrial Cds enzyme 
(Tamm41) has not been studied, these observations suggest that the Cds activity 
measured from H9c2 cells and rat heart fractions could be partly due Tamm41 
catalytic action.  
 
Finally, RdgBβ protein and mRNA expression was found not to be influenced 
by AVP stimulation (Figure 7.2) and it did not affected Cds activity in the rat heart 
(Figure 8.2). Nevertheless the specific upregulation of protein and mRNA 
expression upon H9c2 differentiation (Chapter 5) and the observation that RdgBβ 
mRNA downregulation lead to cellular hypertrophy (Figure 8.3), indicate that the 
cardiac function of RdgBβ is likely associated with physiological hypertrophy due to 
cell growth and development.  
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CHAPTER 9: Conclusions 
 
9.1: Concluding remarks 
 
9.1.1: Phosphatidic Acid (PA) transfer activity is a property exclusive of Class 
II PITP proteins. 
 
Hu-RdgBβ was the first protein to be described with PA transfer capability in 
vitro.40 Using a different assay, this thesis confirmed that PA transfer is a 
characteristic of human RdgBβ and the PITP domain of human and fly (Dm) 
RdgBα.125 This property was not shared with Class I PITPs, PITPα and PITPβ 
(Figure 3.4.A), therefore establishing a clear difference between Class I and Class II 
PITPs. This observation suggested that the RdgB proteins function in vivo may 
facilitate PA metabolism by transferring PA between cellular compartments. Indeed, 
in a recently reported collaboration using  Drosophila phototransduction as a model 
system, RdgB mutants presented a delayed PIP2 resynthesis and an increase on 
PA levels compared to wild-type flies following light-stimulated PLC activity.125 This 
study demonstrated that RdgB is required to facilitate PA metabolism during 
Drosophila phototransduction in vivo, Moreover it has been reported that human 
RdgBα can also bind PA in vitro,40 and murine RdgBα was able to rescue the retinal 
degeneration and altered electrophysiological light response phenotype of RdgB –
null mutant flies.17 
 
In this thesis, there was an attempt to determine the residues within the PITP 
domain of RdgB proteins responsible for PA transfer between membranes in vitro. 
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The mutational analysis of the residues that are in contact with the inositol ring of PI 
showed that they are not involved for PA transfer (Figure 3.5). On the other hand, 
the PA transfer activity of the Y210A/W211A mutant was compromised compared to 
the wild type PITP domain (Figure 3.7) indicating a requirement for membrane 
docking for PA extraction from the membranes. In our recent report, the YW/AA 
mutant was also unable to transfer PI in vitro or to rescue the fly mutant phenotype, 
suggesting that PI transfer is another very important function of RdgB proteins in 
vivo125. 
 
9.1.2: The use of antibodies in biological research requires appropriate 
characterisation. 
 
This study included a characterisation of seven polyclonal antibodies made 
by commission using different sequences of the human RdgBβ as antigens. The 
results showed that only one antibody (Ab:Rb59) was effective for the detection of 
endogenous RdgBβ by western blot (Chapter 4). The process of producing 
antibodies not only requires a considerable amount of time and resources but their 
efficiency and validity is never guaranteed. The raising concern for the misuse of 
antibodies in biological research was discussed in Section 4.6. Most recently, with 
the aim to reach a consensus to standardise antibody validation, the Global 
Biological Standards Institute (GBSI) is organising an event in conjunction 
with the Antibody Society, ‘Antibody Validation: Standards, Policies and 
Practices.’ This initiative brought together academic researchers, antibody 
producers, pharmaceutical companies, funders, and journals 
(https://www.gbsi.org/event/asilomar/#dialogue).  
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 In addition to antibodies made in-house, commercial antibodies have also 
proven to be unreliable. For example, Ab:Cds1 (sold by different companies under 
different catalogue numbers (i.e. MCA5324Z and H00001040-M01), has not been 
characterised using an appropriate negative control by either the manufacturers or 
the research groups that have used it. For instance a recent study using NSCLC cell 
lines chose Ab:Cds1 based only on its availability.42 The mRNA expression analysis 
on this study followed the downregulation of the transcription factor ZEB1 and 
showed a substantial increase in Cds1 expression that did not resemble the 
Western blot data42. Similarly in this thesis using the Ab:Cds1 antibody, I identified 
the same p55 protein whose expression did not correlate with the mRNA results 
(Figures 6.3-5).  
 
Another study using subcellular fractions of the human epidermoid 
carcinoma cell line A431 compared the Cds activity with the expression of the same 
p55 protein detected by Ab:Cds1 in Western blot and immunofluorescence 
experiments to demonstrate the co-localisation of Cds1 with calnexin and the IP3 
receptor in the ER119. Using a similar assay in this study, Cds activity in rat samples 
also correlated with the expression of the p55 protein identified by Ab:Cds1, and the 
immunoreactivity co-localise with ER markers but it was enriched in mitochondrial 
fractions (Figure 6.8 and Figure 6.10). Mitochondrial Cds activity was also increased 
significantly in myocardial tissue with maturity of SHHF rats, while the activity in the 
microsomal fraction remained unaltered.93 However, the characterisation of the 
antibody showed that the p55 protein detected was unlikely to be Cds1 (Section 
6.3.4).  
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9.1.3: Endogenous RdgBβ expression is regulated by development and 
maturity in rat heart. 
 
Previously, RdgBβ transcripts were found expressed in human and mouse 
heart39,104 and protein expression was described in fractionated rat heart cytosol.41 
This thesis described the endogenous mRNA and protein expression of RdgBβ in 
rat heart and H9c2 cells differentiated with media supplemented with 1% FCS and 
1μM retinoic acid for a minimum of 8 days (Figure 5.6), and isolated neonatal rat 
cardiomyocytes (Figure 5.9). In addition, the protein expression of RdgBβ was found 
to be stronger in the adult compared to neonatal rat heart lysates (Figure 5.8). 
Contrary to the ubiquitous presence of PITPα and PITPβ, this particular expression 
of RdgBβ in the heart suggests a specific function related to development and 
maturity of cardiomyocytes. Considering that RdgBβ mRNA downregulation led to 
cellular hypertrophy (Figure 8.3), the cardiac function of RdgBβ is likely associated 
with physiological hypertrophy due to cell growth and development. Therefore the 
null hypothesis was rejected. 
 
H9c2 cells differentiation also showed an increase in mitochondrial 
biogenesis (Figure 6.3 and Figure 6.4). Since the cellular localisation study showed 
that RdgBβ is mainly cytosolic, but some immunoreactivity was also observed in rat 
heart and brain microsomes (Figure 5.10 and Figure 5.11), it is possible that the 
physiological function of RdgBβ is related to its ability to connect membranes and 
lipids. For instance, RdgBβ could facilitate PA transport into the mitochondria in 
tissues such as the heart and the brain which present great quantities of 
mitochondria. In this study RdgBβ was unable to directly influence Cds activity in rat 
heart (Figure 8.2) and it was not affected by AVP stimulation in H9c2 cells (Figure 
7.2).  
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9.1.4: Cds1 expression is regulated by vasopressin stimulation of H9c2 cells. 
 
Previously, the presence of Cds1 in the heart has shown diverse results. 
Northern blot studies have shown no Cds1 expression,75 while another study 
indicated the presence of Cds-1 mRNA in human heart.51  Cds1 was also reported 
as a direct target of the transcriptional factor PGC-1 also suggesting that it plays a 
role in mitochondrial metabolism and membrane structure. That study showed a 
correlation between decreased Cds1 gene expression and reduced CL levels in 
adult rats.110 In this thesis it was shown that Cds1 mRNA expression was unaltered 
by H9c2 cells differentiation (Figure 6.5) and it was possibly a minor contributor to 
the total Cds activity measured in rat heart samples (Figure 8.1). On the other hand, 
this study favours the presence of Cds1 in rat heart by showing a significant 
increase of Cds1 mRNA expression after AVP stimulation of H9c2 cells while Cds2 
remained unaltered (Figure 7.3). It is known that AVP stimulates phospholipase C 
signalling therefore Cds1 might be associated with PIP2 production in the heart. In 
fact there are some studies that have reported the importance of Cds in controlling 
the activity of the PI cycle in signal transduction systems. For instance, 
phototransduction in Drosophila is mediated through PLC signalling, the only 
isoform of Cds (CdsA) plays a regulatory role by providing PIP2 to the system. Flies 
expressing an inactive mutant form of CdsA appeared to be similar to wild type flies 
when grown in the dark, however mutant flies developed retinal degeneration when 
exposed  to light that could be rescued by CdsA expression.124 Similarly the PITP 
domain of RdgB was able to rescue the defective light response of RdgB mutants.125  
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Furthermore, a recent study showed the links between CdsA, PI metabolism, 
and the insulin pathway activity in order to control cell growth and neutral lipid 
storage by diverting PA from PI synthesis to TG synthesis. Interestingly, the role of 
CdsA in fat cell growth was only revealed under conditions in which growth was 
mildly compromised.72 This observation suggested that the CDP-DAG–dependent 
route of phospholipid biosynthesis could be vital only in specific physiological 
scenarios, such as nutrient starvation, mating, or germination as described in 
cycling fission yeast (S. Japonicus).  Cds mutant fission yeast did not stop cell 
growth provided that the mutant cells were supplemented with choline or 
ethanolamine indicating that the cells were able to switch to the Kennedy pathway.49  
 
PIP2 is also the biochemical target for the vascular endothelial growth factor 
A (VEGFA) signalling to generate further messengers, including PIP3, IP3, and 
DAG64. A recent report suggested that the angiogenesis defect observed in Cds-
deficient zebrafish embryos was caused by a failure to fully restore the 
phosphoinositides by VEGFA. In the same study, transfection of Cds1 or Cds2 
siRNAs into HUVECs resulted in significant decreases in endothelial cell invasion.87 
 
Finally, PIP2 signalling regulates actin filament dynamics leading to myocyte 
cell growth.68  Since Cds 1 levels were found to regulate  the  rate  of  the PI cycle75 
and Cds1 siRNA transfection of differentiated H9c2 cells affected their morphology 
(Figure 8.3), it is plausible that the primary function of Cds1 in the heart is to 
regulate and promote actin formation within the cell via PIP2 production.   
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9.2: Study Limitations and future work. 
 
The observations of the PA transfer capability of RdgB proteins and the 
mutational analysis in Chapter 3 relied on the assumption that the PITP domain of 
RdgB proteins resembles the structure of PITPα because there are not crystal 
structures reported for any RdgB proteins to date. In addition, the study was 
performed in Dm-RdgBα recombinants since the attempts to purify RdgBβ mutants 
were ineffective. Future biochemical studies may optimise the purification of RdgBβ 
mutants, complete the analysis of the amino acids that are in contact with the 
phosphate moiety of PI (T113 and K202), or consider the possibility of testing the 
double basic amino acid sequence (K28K29) and surrounding positively charged 
residues of RdgB proteins as described in Section 3.5.. However, deciphering the 
tri-dimensional structure of RdgB proteins binding PA will ultimately allow a more 
comprehensive study into the PA transfer capability of Class I PITPs. 
 
Ab:Rb59 outperformed all other antibodies characterised in this thesis and 
was validated for the effective detection of RdgBβ by immunoblotting of recombinant 
and overexpressed proteins in Cos7 and H9c2 cells, as well as in rat heart cells and 
tissue samples (Chapter 4). Unfortunately, the low availability of Ab:Rb59 limited 
greatly the scope of experiments that can be conducted using this antibody. In 
addition to Ab:Rb59, Ab:101 was found to be effective at identifying recombinant 
and over-expressed RdgBβ, but it also detected additional cross reactive bands 
(Figure 4.2.A). Affinity purification enhanced the sensitivity of the antibody Ab:101 to 
the recombinant protein (Figure 4.3.A), but the specificity to the endogenous protein 
was not improved (Figure 4.5.B). Therefore the need to obtain sufficient quantities of 
an antibody as effective as Ab:Rb59 still remains.  
 
Chapter 9: Conclusions 
241 
 
The dependency on antibodies for protein detection in biomedical research 
raises concern for future studies, which may incur into extensive use of time and 
resources in order to validate the antibody only to discover that the investigation is 
not viable. A novel alternative to the use of polyclonal or monoclonal antibodies is 
the chemiluminescent quantification of protein expression. This method consists in 
inserting the gene of the protein of interest into the multiple cloning site of the 
mammalian expression vector capable of producing a chemiluminescent signal via 
enzyme fragment complementation that can be detected 
by spectrophotometry.32  Another approach is the production of recombinant 
antibodies.10 The production and stable expression of these recombinant antibodies 
has been developed in several hosts, however the procedure also requires 
extensive experimentation.38  
 
Cds activity increased after differentiation (Figure 6.6) and when differentiated H9c2 
cells and adult heart tissue were fractionated, Cds activity was constantly higher in 
the mitochondrial fractions, rather than in microsomes or mitochondrial associated 
membranes as expected (Figure 6.8 and 6.10). However, the antibody mitofusin2 is 
a mitochondrial protein rather than MAM marker protein and antibodies such the 
sigma1 receptor or ACSL4 were not investigated in these experiments. In addition, 
the Cds activity assay used here was not able to distinguish between Cds1, Cds2 or 
Tamm41 contribution towards the CDP-DAG synthesis measured. 
Furthermore, the study into the protein expression of Cds1 was confounded 
by the extensive characterisation of the antibody used. There is still the 
possibility that the antibody used here is species-dependent which was not 
tested. Moreover, additional controls for siRNA experiments such as 
endogenous positive and mock controls were not performed. These 
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experiments will conclude whether Ab:Cds1 is an effective antibody for 
immunoblotting of rat samples. 
 
The observations of this study raise interesting questions which could be 
subject of future studies. For instance, is Tamm41 the mitochondrial Cds protein in 
the mammalian heart? And, what is the identity of this 55kDa protein? The 
characteristics of this unknown protein include its significant upregulation by H9c2 
cells differentiation (Figure 6.3 and Figure 6.4), its enrichment in membrane 
mitochondrial fractions and co-localisation with cellular fractions with high Cds 
activity in human119 and rat samples (Figure 6.8 and Figure 6.10).   Do Cds1 or 
RdgBβ affect phosphoinositide signalling? Another line of enquiry may explore 
whether RdgBβ is somehow required for mitochondrial biogenesis or Cardiolipin 
synthesis during differentiation of H9c2 cells.  
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